var title_f40_54_41824="SEER surv adeno colon";
var content_f40_54_41824=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F81414&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F81414&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 558px\">",
"   <div class=\"ttl\">",
"    Observed survival rates for 28,491 cases with adenocarcinoma of the colon",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 538px; height: 516px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Data from the SEER 1973-2005 Public Use File diagnosed in years 1998-2000. Stage I includes 7417; Stage IIA, 9956; Stage IIB, 997; Stage IIC, 725; Stage IIIA, 868; Stage IIIB, 1492; Stage IIIC, 2000; and Stage IV, 5036.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_54_41824=[""].join("\n");
var outline_f40_54_41824=null;
var title_f40_54_41825="Gastric carcinoid CPC Endosc";
var content_f40_54_41825=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F53130&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F53130&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 537px\">",
"   <div class=\"ttl\">",
"    Gastric carcinoid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 517px; height: 227px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A total of three nodular appearing lesions were seen in the body of the stomach, measuring between 5 by 5 mm to 15 by 5 mm. Two had small ulcerations (arrows), which were presumably the site of bleeding. Image A represents a frontal view and image B is during retroflexion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Andres Gelrud, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_54_41825=[""].join("\n");
var outline_f40_54_41825=null;
var title_f40_54_41826="Patient information: Angiodysplasia of the GI tract (The Basics)";
var content_f40_54_41826=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/17182\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/27/29107\">",
"         Digestive system",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/39/37490\">",
"          Upper endoscopy",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?4/46/4834\">",
"           Colonoscopy",
"          </a>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?18/53/19281\">",
"         Patient information: Anemia caused by low iron (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?41/29/42450\">",
"         Patient information: Bloody stools (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?18/11/18611\">",
"         Patient information: Colonoscopy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?23/60/24515\">",
"         Patient information: GI bleed (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?32/41/33426\">",
"         Patient information: Upper endoscopy (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?29/49/30484\">",
"         Patient information: Anemia caused by low iron (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?17/10/17569\">",
"         Patient information: Blood in the stool (rectal bleeding) in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?10/11/10418\">",
"         Patient information: Bloody stools in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?9/30/9698\">",
"         Patient information: Colonoscopy (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?21/0/21506\">",
"         Patient information: Upper endoscopy (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Angiodysplasia of the GI tract (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/angiodysplasia-of-the-gi-tract-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H18170763\">",
"      <span class=\"h1\">",
"       What is angiodysplasia of the GI tract?",
"      </span>",
"      &nbsp;&mdash;&nbsp;&ldquo;Angiodysplasia&rdquo; is the term doctors use for blood vessels that become abnormal. The &ldquo;GI tract,&rdquo; short for the gastrointestinal tract, includes all the organs in the body that digest food (",
"      <a class=\"graphic graphic_figure graphicRef66110 \" href=\"mobipreview.htm?28/27/29107\">",
"       figure 1",
"      </a>",
"      ). In angiodysplasia of the GI tract, blood vessels along the GI tract become abnormal.",
"     </p>",
"     <p>",
"      This condition can lead to problems. When blood vessels are abnormal, they can bleed very easily and people can have bleeding in their GI tract. The term doctors use for bleeding in the GI tract is a &ldquo;GI bleed.&rdquo;",
"     </p>",
"     <p>",
"      Angiodysplasia of the GI tract happens most often in older adults.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H18170778\">",
"      <span class=\"h1\">",
"       What are the symptoms of angiodysplasia of the GI tract?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Symptoms depend on whether the abnormal blood vessels bleed or not.",
"     </p>",
"     <p>",
"      If the abnormal blood vessels do not bleed, people do not have any symptoms. They find out they have the condition after their doctor does tests for another reason.",
"     </p>",
"     <p>",
"      If the abnormal blood vessels bleed, people might or might not realize they have a GI bleed. When a GI bleed causes symptoms, it can cause bloody or tar-colored bowel movements. But some people with a GI bleed have no symptoms and don&rsquo;t see any blood. People might not see any blood when the bleeding happens very slowly over time.",
"     </p>",
"     <p>",
"      A GI bleed sometimes leads to a condition called &ldquo;anemia,&rdquo; which is when the body has too few red blood cells. Anemia can make people feel tired or weak.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H18170793\">",
"      <span class=\"h1\">",
"       Is there a test for angiodysplasia of the GI tract?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Doctors can do different tests to check for angiodysplasia of the GI tract. The test you have depends on which part of the GI tract your doctor wants to check. The different tests can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        An upper endoscopy &ndash; This procedure lets the doctor look at the lining of your esophagus (the tube from the mouth to the stomach), stomach, and duodenum (the first part of the small intestine). During this test, the doctor puts a thin tube with a camera and light on the end into your mouth and down your esophagus (",
"        <a class=\"graphic graphic_figure graphicRef75392 \" href=\"mobipreview.htm?36/39/37490\">",
"         figure 2",
"        </a>",
"        ).",
"       </li>",
"       <li>",
"        A colonoscopy &ndash; This procedure lets the doctor look at the inside of the large intestine (colon). During this test, the doctor puts a thin tube with a camera and light on the end into your anus and up your rectum and colon (",
"        <a class=\"graphic graphic_figure graphicRef52258 \" href=\"mobipreview.htm?4/46/4834\">",
"         figure 3",
"        </a>",
"        ).",
"       </li>",
"       <li>",
"        A capsule endoscopy &ndash; This test uses a small camera about the size of a pill. You swallow the camera, and it sends pictures of your small intestine to a recording device that you wear on a belt for 8 hours. After the test, the camera leaves your body in a bowel movement.",
"       </li>",
"       <li>",
"        A CT scan &ndash; A CT scan is an imaging test that creates pictures of the inside of the body.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H18170808\">",
"      <span class=\"h1\">",
"       How is angiodysplasia of the GI tract treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment depends on whether the abnormal blood vessels are bleeding, and if you have anemia.",
"     </p>",
"     <p>",
"      In most cases, people only need treatment if the abnormal blood vessels are bleeding or they have anemia. People who do not have bleeding or anemia usually don&rsquo;t need any treatment.",
"     </p>",
"     <p>",
"      When treatment is needed, it usually involves a procedure to stop the bleeding. Your doctor can do this procedure during your colonoscopy or upper endoscopy.",
"     </p>",
"     <p>",
"      If this procedure doesn&rsquo;t stop the bleeding, your doctor will talk with you about other possible treatments to stop the bleeding. These might include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        A procedure called &ldquo;angiography&rdquo; to block the bleeding blood vessel",
"       </li>",
"       <li>",
"        A procedure called &ldquo;enteroscopy&rdquo; &ndash; This is like an upper endoscopy, but the doctor puts the tube further into the small intestine.",
"       </li>",
"       <li>",
"        Surgery &ndash; Most people do not need surgery. But people with a lot of bleeding might need surgery to remove part of their intestine.",
"       </li>",
"       <li>",
"        Other medicines &ndash; Certain medicines might help stop the bleeding. But these medicines don&rsquo;t always work and they can have harmful side effects.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      People with anemia or bleeding might also need treatment with:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Extra iron, which usually comes in pills",
"       </li>",
"       <li>",
"        Blood transfusions &ndash; During a blood transfusion, you will get blood that has been donated by someone else. The donated blood goes into your vein.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H18170823\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/60/24515?source=see_link\">",
"       Patient information: GI bleed (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?41/29/42450?source=see_link\">",
"       Patient information: Bloody stools (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/41/33426?source=see_link\">",
"       Patient information: Upper endoscopy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/11/18611?source=see_link\">",
"       Patient information: Colonoscopy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/53/19281?source=see_link\">",
"       Patient information: Anemia caused by low iron (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/10/17569?source=see_link\">",
"       Patient information: Blood in the stool (rectal bleeding) in adults (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/0/21506?source=see_link\">",
"       Patient information: Upper endoscopy (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/30/9698?source=see_link\">",
"       Patient information: Colonoscopy (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?10/11/10418?source=see_link\">",
"       Patient information: Bloody stools in children (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?29/49/30484?source=see_link\">",
"       Patient information: Anemia caused by low iron (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?40/54/41826?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 17182 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-194.187.108.93-F5F47B5EFB-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_54_41826=[""].join("\n");
var outline_f40_54_41826=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18170763\">",
"      What is angiodysplasia of the GI tract?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18170778\">",
"      What are the symptoms of angiodysplasia of the GI tract?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18170793\">",
"      Is there a test for angiodysplasia of the GI tract?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18170808\">",
"      How is angiodysplasia of the GI tract treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18170823\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/17182\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/27/29107\">",
"      Digestive system",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/39/37490\">",
"       Upper endoscopy",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?4/46/4834\">",
"        Colonoscopy",
"       </a>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?29/49/30484?source=related_link\">",
"      Patient information: Anemia caused by low iron (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/53/19281?source=related_link\">",
"      Patient information: Anemia caused by low iron (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/10/17569?source=related_link\">",
"      Patient information: Blood in the stool (rectal bleeding) in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?41/29/42450?source=related_link\">",
"      Patient information: Bloody stools (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?10/11/10418?source=related_link\">",
"      Patient information: Bloody stools in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/30/9698?source=related_link\">",
"      Patient information: Colonoscopy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/11/18611?source=related_link\">",
"      Patient information: Colonoscopy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/60/24515?source=related_link\">",
"      Patient information: GI bleed (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/0/21506?source=related_link\">",
"      Patient information: Upper endoscopy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/41/33426?source=related_link\">",
"      Patient information: Upper endoscopy (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_54_41827="Methenamine: Pediatric drug information";
var content_f40_54_41827=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Methenamine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?3/57/3989?source=see_link\">",
"    see \"Methenamine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?23/26/23972?source=see_link\">",
"    see \"Methenamine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F194204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Hiprex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F194205\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Dehydral&reg;;",
"     </li>",
"     <li>",
"      Hiprex&reg;;",
"     </li>",
"     <li>",
"      Mandelamine&reg;;",
"     </li>",
"     <li>",
"      Urasal&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1048556\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Miscellaneous",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1048548\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?3/57/3989?source=see_link\">",
"      see \"Methenamine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &gt;2 years to 12 years: Mandelate: 50-75 mg/kg/day divided every 6-8 hours; maximum dose: 4 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children 6-12 years: Hippurate: 0.5-1 g twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &gt;12 years and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hippurate: 1 g twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mandelate: 1 g 4 times/day after meals and at bedtime",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F194182\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hippurate: 1 g",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hiprex&reg;: 1 g [scored; contains tartrazine]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as mandelate: 500 mg, 1 g",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F194166\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1048559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer with food to minimize GI upset; shake suspension well before use; patient should drink plenty of fluids to ensure adequate urine flow; administer with cranberry juice, ascorbic acid, or ammonium chloride to acidify urine; avoid intake of alkalinizing agents (sodium bicarbonate, antacids)",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1048552\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Protect from excessive heat",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1048558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prophylaxis or suppression of recurrent urinary tract infections",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F194234\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Hiprex&reg; may be confused with Mirapex&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Methenamine may be confused with mesalamine, methazolamide, methionine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Urex may be confused with Eurax&reg;, Serax",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Urex: Brand name for methenamine [U.S. (discontinued)], but also the brand name for furosemide [Australia, China, Turkey]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Urex [U.S. (discontinued)] may be confused with Eurax brand name for crotamitin [U.S., Canada, and multiple international markets]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F194232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Dyspepsia, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: ALT increased (reversible; rare), AST increased (reversible; rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Large doses (higher than recommended) have resulted in bladder irritation, frequent/painful micturition, albuminuria, and hematuria.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1048562\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to methenamine or any component; severe dehydration, renal insufficiency (methenamine is ineffective in patients with renal impairment), hepatic insufficiency in patients receiving hippurate salt; concurrent therapy with sulfonamides",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1048547\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with hepatic impairment. Use care to maintain an acidic pH of the urine when treating infections due to urea-splitting organisms such as",
"     <i>",
"      Proteus",
"     </i>",
"     and",
"     <i>",
"      Pseudomonas",
"     </i>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1048546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dosage of 8 g/day for 3-4 weeks has been associated with bladder irritation, albuminuria, and hematuria; Hiprex&reg; tablets contain tartrazine which may cause allergic reactions in susceptible individuals",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F194175\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Methenamine may decrease the serum concentration of Amphetamines. This effect is likely due to an enhanced excretion of amphetamines in the urine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May diminish the therapeutic effect of Methenamine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May diminish the therapeutic effect of Methenamine. Management: Consider avoiding this combination. Monitor for decreased therapeutic effects of methenamine if used concomitant with a carbonic anhydrase inhibitor.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonamide Derivatives: Methenamine may enhance the adverse/toxic effect of Sulfonamide Derivatives. Specifically, the combination may result in the formation of an insoluble precipitate in the urine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1048565\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Foods/diets which alkalinize urine pH &gt;5.5 decrease activity of methenamine; cranberry juice can be used to acidify urine and increase activity of methenamine",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F194178\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (methenamine mandelate) (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F194191\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Methenamine hippurate did not cause adverse fetal effects in animals; animal reproduction studies have not been conducted with methenamine mandelate. Methenamine crosses the placenta and distributes to amniotic fluid. Adverse fetal effects were not observed in two human trials. Methenamine use has been shown to interfere with urine estriol concentrations if measured via acid hydrolysis. Use of enzyme hydrolysis prevents this lab interference.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1048555\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Urinary pH, urinalysis, urine cultures, periodic liver function tests in patients receiving hippurate salt",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1048545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Methenamine is hydrolyzed to formaldehyde and ammonia in acidic urine; formaldehyde has nonspecific bactericidal action",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1048561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Readily from the GI tract; 10% to 30% of the drug will be hydrolyzed by gastric juices unless it is protected by an enteric coating",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Distributes into breast milk; crosses the placenta",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: &sim;10% to 25% in the liver",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 3-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Excretion occurs via glomerular filtration and tubular secretion with &sim;70% to 90% of dose excreted unchanged in urine within 24 hours",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1048563\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should not be used to treat infections outside of the lower urinary tract (ie, pyelonephritis)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Practice Parameter: The Diagnosis, Treatment, and Evaluation of the Initial Urinary Tract Infection in Febrile Infants and Young Children. American Academy of Pediatrics. Committee on Quality Improvement. Subcommittee on Urinary Tract Infection,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1999, 103(4 Pt 1):843-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/54/41827/abstract-text/10103321/pubmed\" id=\"10103321\" target=\"_blank\">",
"        10103321",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12591 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-194.187.108.93-69C8FD1B77-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_54_41827=[""].join("\n");
var outline_f40_54_41827=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194204\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194205\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048556\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048548\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194182\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194166\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048559\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048552\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048558\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194234\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194232\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048562\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048547\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048546\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299683\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194175\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048565\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194178\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194191\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048555\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048545\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048561\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048563\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12591\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12591|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?3/57/3989?source=related_link\">",
"      Methenamine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?23/26/23972?source=related_link\">",
"      Methenamine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_54_41828="Avanafil: Patient drug information";
var content_f40_54_41828=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Avanafil: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/8/44165?source=see_link\">",
"     see \"Avanafil: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F14297554\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F14297556\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691903",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat impotence.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F14297555\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705175",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is not approved for use in women.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3764999",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to avanafil or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703886",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you use drugs called \"poppers\" like amyl nitrite and butyl nitrite.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703715",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been told not to have sex by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F14297560\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697184",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have bleeding problems, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any eye problems, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697280",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease and are on dialysis, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697291",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have low blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697230",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had a stroke within the last 6 months, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697229",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had a stomach ulcer, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug with other drugs used to treat a change in sex ability.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696668",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid grapefruit and grapefruit juice.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your drinking of wine, beer, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697712",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To protect from diseases caused by having sex, use a latex condom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F14297561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698017",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dizziness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698094",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flushing. Wearing layers of clothes or summer clothes and staying in cool places may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nose stuffiness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698350",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sore throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697883",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Back pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3796262",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loss of eyesight. This can be long-lasting.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F14297562\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698997",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Erection that lasts more than 4 hours.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure or a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698616",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in hearing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F14297558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3765018",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take 30 minutes before sex.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F14297559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696575",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is taken on an as needed basis. Do not take more often than every 24 hours unless told to do so by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F14297563\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F14297564\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699681",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Read the package insert for more details.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 85636 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-5CB361C86E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_54_41828=[""].join("\n");
var outline_f40_54_41828=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14297554\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14297556\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14297555\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14297560\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14297561\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14297562\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14297558\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14297559\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14297563\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14297564\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?43/8/44165?source=related_link\">",
"      Avanafil: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_54_41829="Basic case 9";
var content_f40_54_41829=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F64545&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F64545&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1130px;\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Basic case 9",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 80px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal rhythm strip",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 165px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Morton F Arnsdorf, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_54_41829=[""].join("\n");
var outline_f40_54_41829=null;
var title_f40_54_41830="Three-chamber view of classic MVP";
var content_f40_54_41830=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1156px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/83604/Three_chamb_class_MVP_video.mp4?title=Three-chamber+view+of+classic+MVP\" style=\"width:512px;height:368px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Apical three chamber echocardiographic view of classic mitral valve prolapse with bileaflet prolapse",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 343px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Images from a patient with classic Barlow's disease. Note diffusely thickened anterior and posterior leaflets, with massive prolapse mostly of the P2-P3 scallops.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1176px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/83605/3D_SHAX_classic_MVP_video.mp4?title=Three-chamber+view+of+classic+MVP\" style=\"width:512px;height:368px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 544px\">",
"   <div class=\"ttl\">",
"    Three-dimensional short-axis echocardiographic view of classic mitral valve prolapse with bileaflet prolapse",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 524px; height: 344px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Images from a patient with classic Barlow's disease. Note diffusely thickened anterior and posterior leaflets, with massive prolapse mostly of the P2-P3 scallops.",
"    <div class=\"footnotes\">",
"     %: percent.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_54_41830=[""].join("\n");
var outline_f40_54_41830=null;
var title_f40_54_41831="Amlodipine and benazepril: Drug information";
var content_f40_54_41831=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Amlodipine and benazepril: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?27/47/28405?source=see_link\">",
"    see \"Amlodipine and benazepril: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708612\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F134078\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Lotrel&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F134095\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Angiotensin-Converting Enzyme (ACE) Inhibitor;",
"     </li>",
"     <li>",
"      Antianginal Agent;",
"     </li>",
"     <li>",
"      Calcium Channel Blocker;",
"     </li>",
"     <li>",
"      Calcium Channel Blocker, Dihydropyridine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F134081\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Dose is individualized; combination product may be substituted for individual components in patients currently maintained on both agents separately or in patients not adequately controlled with monotherapy (using one of the agents or an agent within same antihypertensive class).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral: 2.5-10 mg (amlodipine) and 10-40 mg (benazepril) once daily; maximum: Amlodipine: 10 mg/day; benazepril: 80 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F134082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Initial dose: 2.5 mg (based on amlodipine component). Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F134083\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;30 mL/minute: Use of combination product is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F134084\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Initial dose: 2.5 mg based on amlodipine component.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F134068\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     2.5/10: Amlodipine 2.5 mg and benazepril hydrochloride 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     5/10: Amlodipine 5 mg and benazepril hydrochloride 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     5/20: Amlodipine 5 mg and benazepril hydrochloride 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     5/40: Amlodipine 5 mg and benazepril hydrochloride 40 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     10/20: Amlodipine 10 mg and benazepril hydrochloride 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     10/40: Amlodipine 10 mg and benazepril hydrochloride 40 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Lotrel&reg; 2.5/10: Amlodipine 2.5 mg and benazepril hydrochloride 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Lotrel&reg; 5/10: Amlodipine 5 mg and benazepril hydrochloride 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Lotrel&reg; 5/20: Amlodipine 5 mg and benazepril hydrochloride 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Lotrel&reg; 5/40: Amlodipine 5 mg and benazepril hydrochloride 40 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Lotrel&reg; 10/20: Amlodipine 10 mg and benazepril hydrochloride 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Lotrel&reg; 10/40: Amlodipine 10 mg and benazepril hydrochloride 40 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F134056\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F134070\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypertension",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F134093\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F134073\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to amlodipine, benazepril, other ACE inhibitors, or any component of the formulation; history of angioedema, with or without previous ACE inhibitor treatment; concomitant use with aliskiren in patients with diabetes mellitus",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F134060\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Angina/MI: Increased angina and/or MI has occurred with initiation or dosage titration of dihydropyridine calcium channel blockers. Reflex tachycardia may occur resulting in angina and/or MI in patients with obstructive coronary disease, especially in the absence of concurrent beta-blockade.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Angioedema: At any time during treatment (especially following first dose) angioedema may occur rarely with ACE inhibitors; it may involve the head and neck (potentially compromising airway) or the intestine (presenting with abdominal pain). African-Americans and patients with idiopathic or hereditary angioedema or previous angioedema associated with ACE inhibitor therapy may be at an increased risk. Prolonged frequent monitoring may be required especially if tongue, glottis, or larynx are involved as they are associated with airway obstruction. Patients with a history of airway surgery may have a higher risk of airway obstruction. Aggressive early and appropriate management is critical. Use is contraindicated in patients with a history of angioedema with or without previous ACE inhibitor treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cholestatic jaundice: A rare toxicity associated with ACE inhibitors includes cholestatic jaundice, which may progress to fulminant hepatic necrosis; discontinue if marked elevation of hepatic transaminases or jaundice occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cough: An ACE inhibitor cough is a dry, hacking, nonproductive one that usually occurs within the first few months of treatment and should generally resolve within 1-4 weeks after discontinuation of the ACE inhibitor. Other causes of cough should be considered (eg, pulmonary congestion in patients with heart failure) and excluded prior to discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperkalemia: May occur with ACE inhibitors; risk factors include renal dysfunction, diabetes mellitus, concomitant use of potassium-sparing diuretics, potassium supplements and/or potassium-containing salts. Use cautiously, if at all, with these agents and monitor potassium closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Anaphylactic/anaphylactoid reactions can occur with ACE inhibitors. Severe anaphylactoid reactions may be seen during hemodialysis (eg, CVVHD) with high-flux dialysis membranes (eg, AN69), and rarely, during low density lipoprotein apheresis with dextran sulfate cellulose. Rare cases of anaphylactoid reactions have been reported in patients undergoing sensitization treatment with hymenoptera (bee, wasp) venom while receiving ACE inhibitors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension/syncope: Symptomatic hypotension with or without syncope can occur with ACE inhibitors (usually with the first several doses); effects are most often observed in volume-depleted patients; correct volume depletion prior to initiation; close monitoring of patient is required especially with initial dosing and dosing increases; blood pressure must be lowered at a rate appropriate for the patient's clinical condition. Although dose reduction may be necessary, hypotension is not a reason for discontinuation of future ACE inhibitor use especially in patients with heart failure where a reduction in systolic blood pressure is a desirable observation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neutropenia/agranulocytosis: Another ACE Inhibitor, captopril, has been associated with rare cases of agranulocytosis, neutropenia, or leukopenia with myeloid hypoplasia. Patients with renal impairment are at high risk of developing neutropenia. Patients with both renal impairment and collagen vascular disease (eg, systemic lupus erythematosus) are at an even higher risk of developing neutropenia. Periodically monitor CBC with differential in these patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peripheral edema: The most common side effect of amlodipine is peripheral edema (dose dependent); occurs within 2-3 weeks of starting therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal function deterioration: May be associated with deterioration of renal function and/or increases in serum creatinine, particularly in patients with low renal blood flow (eg, renal artery stenosis, heart failure) whose glomerular filtration rate (GFR) is dependent on efferent arteriolar vasoconstriction by angiotensin II; deterioration may result in oliguria, acute renal failure, and progressive azotemia. Small increases in serum creatinine may occur following initiation; consider discontinuation only in patients with progressive and/or significant deterioration in renal function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aortic stenosis: Use amlodipine with extreme caution in patients with severe aortic stenosis; may reduce coronary perfusion resulting in ischemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Initiation of therapy in patients with ischemic heart disease or cerebrovascular disease warrants close observation due to the potential consequences posed by falling blood pressure (eg, MI, stroke). Fluid replacement, if needed, may restore blood pressure; therapy may then be resumed. Discontinue therapy in patients whose hypotension recurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Collagen vascular disease: Use benazepril with caution in patients with collagen vascular disease especially with concomitant renal impairment; may be at increased risk for hematologic toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use amlodipine with caution in patients with hepatic impairment; may require lower starting dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertrophic cardiomyopathy (HCM) with outflow tract obstruction: Use amlodipine with caution in patients with HCM and outflow tract obstruction since reduction in afterload may worsen symptoms associated with this condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal artery stenosis: Use benazepril with caution in patients with unstented unilateral/bilateral renal artery stenosis. When unstented bilateral renal artery stenosis is present, use is generally avoided due to the elevated risk of deterioration in renal function unless possible benefits outweigh risks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use benazepril with caution in pre-existing renal insufficiency; dosage adjustment may be needed. Patients with renal impairment may be at increased risk for hematologic toxicity. Avoid rapid dosage escalation which may lead to further renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Angiotensin receptor blockers (ARBs) and renin inhibitors: Concomitant use of an ARB or renin inhibitor (eg, aliskiren) is associated with an increased risk of hypotension, hyperkalemia, and renal dysfunction. Concomitant use with aliskiren should be avoided in patients with GFR &lt;60 mL/minute and is contraindicated in patients with diabetes mellitus (regardless of GFR).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Initiate amlodipine at a lower dose in the elderly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy:",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Used as a replacement for separate dosing of components or combination therapy when response to single agent is suboptimal; the fixed combination is not indicated for initial treatment of hypertension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgery: Use with caution before, during, or immediately after major surgery. Cardiopulmonary bypass, intraoperative blood loss or vasodilating anesthesia increases endogenous renin release. Use of ACE inhibitors perioperatively will blunt angiotensin II formation and may result in hypotension.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F134090\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F134064\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: May enhance the hyperkalemic effect of ACE Inhibitors. Aliskiren may enhance the hypotensive effect of ACE Inhibitors. Aliskiren may enhance the nephrotoxic effect of ACE Inhibitors. Management: Avoid aliskiren use with ACEIs or ARBs in patients with diabetes or estimated glomerular filtration rate below 60 mL/min. In other patients receiving these combinations, monitor serum potassium, serum creatinine, and blood pressure periodically.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: ACE Inhibitors may enhance the potential for allergic or hypersensitivity reactions to Allopurinol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May enhance the hypotensive effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of ACE Inhibitors. Management: Separate fosinopril administration from antacids by at least 2 hours. US and Canadian recommendations for use of other ACE- inhibitors with antacids may vary. Consult appropriate labeling. Monitor for decreased therapeutic effects of ACE-inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May enhance the adverse/toxic effect of Calcium Channel Blockers. Specifically, itraconazole may enhance the negative inotropic effects of verapamil or diltiazem. Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Calcium Channel Blockers. Management: Concurrent use of felodipine or nisoldipine with itraconazole is specifically contraindicated.  Frequent monitoring is warranted with any such combination; calcium channel blocker dose reductions may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprotinin: May diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atosiban: Calcium Channel Blockers may enhance the adverse/toxic effect of Atosiban. Specifically, there may be an increased risk for pulmonary edema and/or dyspnea.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AzaTHIOprine: ACE Inhibitors may enhance the myelosuppressive effect of AzaTHIOprine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May increase the metabolism of Calcium Channel Blockers. Management: Monitor for decreased therapeutic effects of calcium channel blockers with concomitant barbiturate therapy. Calcium channel blocker dose adjustments may be necessary. Nimodipine Canadian labeling contraindicates concomitant use with phenobarbital.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Calcium Channel Blockers (Dihydropyridine) may enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): Calcium Channel Blockers (Dihydropyridine) may enhance the hypotensive effect of Calcium Channel Blockers (Nondihydropyridine). Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: May diminish the therapeutic effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canagliflozin: May enhance the hyperkalemic effect of ACE Inhibitors. Canagliflozin may enhance the hypotensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Calcium Channel Blockers (Dihydropyridine). Management: Consider calcium channel blocker (CCB) dose adjustments or alternative therapy  in patients receiving concomitant carbamazepine. Nimodipine Canadian labeling contraindicates concurrent use with carbamazepine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: Calcium Channel Blockers may diminish the therapeutic effect of Clopidogrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): ACE Inhibitors may enhance the nephrotoxic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May decrease the metabolism of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Substrates: CYP1A2 Inhibitors (Moderate) may decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DPP-IV Inhibitors: May enhance the adverse/toxic effect of ACE Inhibitors. Specifically, the risk of angioedema may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: May enhance the adverse/toxic effect of ACE Inhibitors. Specifically, the risk of angioedema may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ferric Gluconate: ACE Inhibitors may enhance the adverse/toxic effect of Ferric Gluconate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May decrease the metabolism of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Calcium Channel Blockers may increase the serum concentration of Fosphenytoin.  Management: Monitor for phenytoin toxicity with concomitant use of a calcium channel blocker (CCB) or decreased phenytoin effects with CCB discontinuation. Monitor for decreased CCB therapeutic effects. Nimodipine Canadian labeling contraindicates use with phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gold Sodium Thiomalate: ACE Inhibitors may enhance the adverse/toxic effect of Gold Sodium Thiomalate. An increased risk of nitritoid reactions has been appreciated.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May increase the serum concentration of AmLODIPine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hydrochlorothiazide: May enhance the hypotensive effect of Benazepril. Hydrochlorothiazide may enhance the nephrotoxic effect of Benazepril. Benazepril may decrease the serum concentration of Hydrochlorothiazide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Icatibant: May diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Dextran Complex: ACE Inhibitors may enhance the adverse/toxic effect of Iron Dextran Complex. Specifically, patients receiving an ACE inhibitor may be at an increased risk for anaphylactic-type reactions.  Management: Follow iron dextran recommendations closely regarding both having resuscitation equipment and trained personnel on-hand prior to iron dextran administration and the use of a test dose prior to the first therapeutic dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lanthanum: May decrease the serum concentration of ACE Inhibitors. Management: Administer angiotensin-converting enzyme inhibitors at least two hours before or after lanthanum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: ACE Inhibitors may increase the serum concentration of Lithium.  Management: Lithium dosage reductions will likely be needed following the addition of an ACE inhibitor.  Monitor patient response to lithium closely following addition or discontinuation of concurrent ACE inhibitor treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Loop Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Calcium Channel Blockers. Management: Consider using a noninteracting macrolide. Monitor for increased therapeutic effects of calcium channel blockers if an interacting macrolide antibiotic is initiated, or decreased effects if a macrolide is discontinued.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Salts: Calcium Channel Blockers may enhance the adverse/toxic effect of Magnesium Salts. Magnesium Salts may enhance the hypotensive effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Melatonin: May diminish the antihypertensive effect of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nafcillin: May increase the metabolism of Calcium Channel Blockers.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents (Nondepolarizing): Calcium Channel Blockers may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nitroprusside: Calcium Channel Blockers may enhance the hypotensive effect of Nitroprusside.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: ACE Inhibitors may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Calcium Channel Blockers may increase the serum concentration of Phenytoin.  Management: Monitor for phenytoin toxicity with concomitant use of a calcium channel blocker (CCB) or decreased phenytoin effects with CCB discontinuation. Monitor for decreased CCB therapeutic effects. Nimodipine Canadian labeling contraindicates use with phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pirfenidone: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Pirfenidone.  Management: This combination may be used with caution only if the moderate CYP1A2 inhibitor does not significantly inhibit other CYP enzymes and the patient is not taking any other drugs that do significantly inhibit other specific CYP enzymes.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Salts: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May decrease the metabolism of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May increase the serum concentration of Calcium Channel Blockers (Dihydropyridine). Calcium Channel Blockers (Dihydropyridine) may decrease the serum concentration of QuiNIDine. Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers. Management: The labeling for some U.S. and Canadian calcium channel blockers contraindicate use with rifampin however recommendations vary. Consult appropriate labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May diminish the antihypertensive effect of ACE Inhibitors. They may also diminish other beneficial pharmacodynamic effects desired for the treatment of CHF.  The effects are likely dose-related.  100 mg doses aspirin appear to cause no problems, whereas 300 mg doses appear to significantly affect ACE Inhibitor efficacy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: AmLODIPine may increase the serum concentration of Simvastatin.  Management: Avoid the concurrent use of amlodipine with simvastatin when possible.  If used together, avoid doses of simvastatin greater than 20 mg/day (for adults).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: ACE Inhibitors may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with ACEIs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of Tacrolimus (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Temsirolimus: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Thiazide Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TiZANidine: May enhance the hypotensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F11396682\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Grapefruit juice may modestly increase amlodipine levels.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herb/Nutraceutical: St John's wort may decrease amlodipine levels. Avoid herbs with",
"     <i>",
"      hypertensive",
"     </i>",
"     properties (bayberry, blue cohosh, cayenne, ephedra, ginger, ginseng [American], kola, licorice). Avoid herbs with",
"     <i>",
"      hypotensive",
"     </i>",
"     properties (black cohosh, California poppy, coleus, garlic, goldenseal, hawthorn, mistletoe, periwinkle, quinine, shepherd's purse).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F134065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F134076\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"     Also see individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F134086\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Amlodipine: Excretion in breast milk unknown/not recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Benazepril: Enters breast milk",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F134075\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Amlodipine Besy-Benazepril HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5-10 mg (100): $265.45",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-10 mg (100): $270.71",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-20 mg (100): $285.87",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-40 mg (100): $405.32",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-20 mg (100): $332.10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-40 mg (100): $489.65",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Lotrel Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5-10 mg (100): $575.03",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-10 mg (100): $586.42",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-20 mg (100): $619.26",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-40 mg (100): $656.21",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-20 mg (100): $719.46",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-40 mg (100): $792.77",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F6155063\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     BUN, electrolytes, serum creatinine, and blood pressure. In patients with renal impairment and/or collagen vascular disease, monitor CBC with differential periodically.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038524\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Ambix (UY);",
"     </li>",
"     <li>",
"      Amlibon B (VE);",
"     </li>",
"     <li>",
"      Ampliron Plus (PY);",
"     </li>",
"     <li>",
"      Pelmec Duo (AR);",
"     </li>",
"     <li>",
"      Terloc Duo (AR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F134059\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:0em;\">",
"     Amlodipine is a dihydropyridine calcium channel antagonist that inhibits transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle producing relaxation of coronary vascular smooth muscle and coronary vasodilation; amlodipine directly acts on vascular smooth muscle to produce peripheral arterial vasodilation reducing peripheral vascular resistance and blood pressure.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Benazepril lowers blood pressure by suppressing the renin-angiotensin-aldosterone system; benazepril has an antihypertensive effect even in patients with low-renin hypertension.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F134072\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/54/41831/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wynn RL, &ldquo;An Update on Calcium Channel Blocker-Induced Gingival Hyperplasia,&rdquo;",
"      <i>",
"       Gen Dent",
"      </i>",
"      , 1995, 43(3):218-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/54/41831/abstract-text/8940577/pubmed\" id=\"8940577\" target=\"_blank\">",
"        8940577",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wynn RL, &ldquo;Calcium Channel Blockers and Gingival Hyperplasia,&rdquo;",
"      <i>",
"       Gen Dent",
"      </i>",
"      , 1991, 39(4):240-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/54/41831/abstract-text/1916193/pubmed\" id=\"1916193\" target=\"_blank\">",
"        1916193",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8608 Version 48.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-202.43.93.2-481E12C6DB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_54_41831=[""].join("\n");
var outline_f40_54_41831=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708612\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134078\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134095\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134081\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134082\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134083\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134084\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134068\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134056\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134070\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134093\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134073\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134060\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134090\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134064\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11396682\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134065\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134076\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134086\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134075\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6155063\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038524\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134059\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134072\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8608\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8608|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?27/47/28405?source=related_link\">",
"      Amlodipine and benazepril: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_54_41832="Surgical approach to rectal procidentia (rectal prolapse)";
var content_f40_54_41832=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Surgical approach to rectal procidentia (rectal prolapse)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/54/41832/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/54/41832/contributors\">",
"     Madhulika G Varma, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/54/41832/contributors\">",
"     Scott R Steele, MD, FACS, FASCRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/54/41832/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/54/41832/contributors\">",
"     Martin Weiser, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/54/41832/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/54/41832/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/54/41832/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H284496739\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rectal procidentia (rectal prolapse) is a disabling condition that typically affects the elderly, particularly women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41832/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. Surgical repair, either by an intra-abdominal or perineal procedure, is the treatment of choice, with the intra-abdominal procedures offering a lower recurrence rate. However, there is no consensus for the optimal approach (open versus minimally invasive) that provides for a low recurrence rate, a high rate of improvement in bowel function, and a low risk of worsening or creating new-onset bowel dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41832/abstract/4-15\">",
"     4-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will discuss surgical approaches to procidentia. The clinical manifestations, diagnostic evaluation, and medical management of procidentia are reviewed separately.",
"    <strong>",
"    </strong>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/30/7655?source=see_link\">",
"     \"Overview of rectal procidentia (rectal prolapse)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H261085160\">",
"    <span class=\"h1\">",
"     CONTROVERSIES IN SURGICAL APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neither the type of procedure (intra-abdominal versus perineal) nor the approach (open versus minimally invasive) has been identified as optimal.",
"   </p>",
"   <p>",
"    Minimally-invasive (eg, laparoscopic, laparoscopic-assisted, or robotic-assisted) colon and rectal procedures have the advantages of reduced postoperative pain, early return of bowel function, and shortened length of hospital stay [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41832/abstract/16-20\">",
"     16-20",
"    </a>",
"    ]. The disadvantages include longer operating times, required specialized technical skills, costly equipment, higher rate of intra-operative complications (eg, bowel injury), and selective patient eligibility (eg, lack of extensive intra-abdominal adhesions, tolerance of pneumoperitoneum) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41832/abstract/16,21,22\">",
"     16,21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Robotic-assisted pelvic organ prolapse surgical procedures are an emerging technology that combine the advantages of the laparoscopic approach (eg, less postoperative pain, faster recovery) with the advantages of the open approach (eg, high-quality three-dimensional vision, restoration of the eye-hand-target axis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41832/abstract/23-27\">",
"     23-27",
"    </a>",
"    ]. The disadvantages of robotic surgery include high cost, long intra-operative set-up times, and long procedure times [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41832/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data from randomized trials and meta-analyses are inconclusive in identifying the optimal technical approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41832/abstract/21,29-32\">",
"     21,29-32",
"    </a>",
"    ]. While the studies agree that the laparoscopic approach is safe and effective, there is no statistical advantage regarding a decrease in morbidity or mortality rates, recurrence rates, or improvement in bowel function. (See",
"    <a class=\"local\" href=\"#H106270500\">",
"     'Surgical outcomes'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In our opinion, an intra-abdominal approach should be performed for patients who can tolerate an abdominal operation, based upon a risk profile assessment such as the American Society of Anesthesiologists (ASA) physical status scale (",
"    <a class=\"graphic graphic_table graphicRef56098 \" href=\"mobipreview.htm?8/33/8733\">",
"     table 1",
"    </a>",
"    ). Elderly patients and those with serious comorbid illnesses may not be candidates for an intra-abdominal procedure, either open or minimally invasive (laparoscopic or robotic-assisted). For these patients, the perineal approach offers a safe but less effective alternative. (See",
"    <a class=\"local\" href=\"#H106270500\">",
"     'Surgical outcomes'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Additional controversial areas for repair of rectal procidentia include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Suture or mesh rectopexy",
"     </li>",
"     <li>",
"      Anterior or posterior mesh wrap",
"     </li>",
"     <li>",
"      Rectopexy alone or with sigmoid resection",
"     </li>",
"     <li>",
"      Extent of pelvic dissection and division of the lateral ligaments (",
"      <a class=\"graphic graphic_figure graphicRef62931 \" href=\"mobipreview.htm?35/24/36225\">",
"       figure 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Perineal approach in young men to spare risk of pelvic nerve injury",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10292286\">",
"    <span class=\"h1\">",
"     SURGICAL PROCEDURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are multiple operative procedures described, including intra-abdominal operations, which are performed using open or minimally invasive (ie, laparoscopic, or robotic-assisted) approaches, and perineal operations, which avoid an abdominal incision but lack fixation to the presacral fascia in the sacral promontory. The procedures described in this section are the most commonly performed and accepted procedures for repair of rectal procidentia.",
"   </p>",
"   <p>",
"    Repairs of complex pelvic floor defects in women are discussed in separate topics:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/37/43607?source=see_link\">",
"       \"Pelvic organ prolapse in women: Obliterative procedures (colpocleisis)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/23/25976?source=see_link\">",
"       \"Laparoscopic surgery for repair of pelvic floor defects\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/32/1546?source=see_link\">",
"       \"Pelvic organ prolapse and stress urinary incontinence in women: Combined surgical treatment\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10292551\">",
"    <span class=\"h2\">",
"     Intra-abdominal procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;The basic tenets of intra-abdominal repairs include rectal mobilization to the pelvic floor, with or without a sigmoid (anterior) resection, followed by fixation of the rectum to the sacral promontory by mesh or nonabsorbable sutures, depending on the surgeon&rsquo;s preference and expertise (",
"    <a class=\"graphic graphic_figure graphicRef69350 \" href=\"mobipreview.htm?30/15/30962\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41832/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The approach (ie, open or minimally invasive) depends upon the surgeon&rsquo;s skill, preference, and availability of equipment. The use of sutures or mesh to perform the rectopexy is also dependent upon surgeon preference.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10292352\">",
"    <span class=\"h3\">",
"     Rectopexy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rectopexy is based upon the concept that rectal prolapse occurs because the rectum is abnormally straightened from the downward forces of defecation and not due to pelvic floor weakness or an enlarged peritoneal sac. The indication for a rectopexy is rectal procidentia in the",
"    <strong>",
"     absence",
"    </strong>",
"    of concomitant pelvic floor abnormalities.",
"   </p>",
"   <p>",
"    A rectopexy is performed using either sutures or mesh to affix the rectum to the presacral",
"    <span class=\"nowrap\">",
"     fascia/sacral",
"    </span>",
"    periosteum in the sacral promontory. These procedures are performed as either an open or a minimally invasive (laparoscopic or robotic-assisted) approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27760298\">",
"    <span class=\"h4\">",
"     Suture rectopexy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The general principles for performing a suture rectopexy include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mobilize the rectum posteriorly from the pelvic floor to the tip of the coccyx, preserving the lateral attachments. The hypogastric nerves are preserved at the level of the sacral promontory (",
"      <a class=\"graphic graphic_figure graphicRef56679 \" href=\"mobipreview.htm?10/7/10362\">",
"       figure 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In women, mobilize the rectum anteriorly to the level of the mid to upper-third of the vagina. In men, mobilize the rectum anteriorly for a few centimeters to allow for straightening of the rectum and additional scarring. However, the efficacy of the anterior mobilization to prevent relapse or improve functional outcome is unknown.",
"     </li>",
"     <li>",
"      Select a point approximately 1 to 4 cm below the sacral promontory for the inferior-most aspect of suture fixation.",
"     </li>",
"     <li>",
"      Place nonabsorbable sutures in the presacral",
"      <span class=\"nowrap\">",
"       fascia/sacral",
"      </span>",
"      periosteum and rectal mesentery in a horizontal mattress fashion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27760313\">",
"    <span class=\"h4\">",
"     Anterior mesh rectopexy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anterior mesh rectopexy (Ripstein procedure) incorporates an anteriorly based mesh sling for fixation of the rectum into the sacral hollow (",
"    <a class=\"graphic graphic_figure graphicRef50188 \" href=\"mobipreview.htm?15/45/16081\">",
"     figure 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef58833 \" href=\"mobipreview.htm?6/30/6625\">",
"     figure 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The general principles for performing an anterior mesh rectopexy include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41832/abstract/1,33,34\">",
"     1,33,34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mobilize the rectum posteriorly from the pelvic floor to the tip of the coccyx, preserving the lateral attachments. The hypogastric nerves are preserved at the level of the sacral promontory (",
"      <a class=\"graphic graphic_figure graphicRef56679 \" href=\"mobipreview.htm?10/7/10362\">",
"       figure 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In women, mobilize the rectum anteriorly at least to the level of the mid-vagina. In men, mobilize the rectum anteriorly for a few centimeters to allow straightening of the rectum and additional scarring.",
"     </li>",
"     <li>",
"      Select a point approximately 1 to 4 cm below the sacral promontory for the inferior-most aspect of mesh fixation.",
"     </li>",
"     <li>",
"      Suture the 5 cm wide mesh (eg, Marlex, Teflon, Prolene) to the anterior wall of the rectum.",
"     </li>",
"     <li>",
"      Retract the rectum cephalad and posteriorly towards the sacrum to reduce redundancy of the bowel. Suture the mesh in place to the presacral",
"      <span class=\"nowrap\">",
"       fascia/sacral",
"      </span>",
"      periosteum of the sacral promontory. Do not completely encircle the rectum with the mesh wrap, the posterior aspect of the rectum should simply abut the sacrum.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H106269181\">",
"    <span class=\"h4\">",
"     Posterior mesh rectopexy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The posterior mesh rectopexy (Wells procedure) is similar to the anterior mesh rectopexy, however the mesh is secured to the sacrum between the posterior rectum and sacral promontory (",
"    <a class=\"graphic graphic_figure graphicRef82684 \" href=\"mobipreview.htm?0/21/339\">",
"     figure 6",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The general principles for performing a posterior mesh repair include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41832/abstract/13,35\">",
"     13,35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mobilize the rectum posteriorly and anteriorly as described for the anterior mesh rectopexy.",
"     </li>",
"     <li>",
"      Secure the mesh with staples or non-absorbable sutures to the periosteum of the sacral promontory.",
"     </li>",
"     <li>",
"      Retract the rectum cephalad and posteriorly towards the sacral hollow to reduce redundancy of the bowel. Wrap the sling from the posterior to anterior surface of the rectum, and suture the mesh in place to the serosal surface of the rectum. Do not completely encircle the rectum with the mesh wrap, leave an anterior gap of approximately 1 cm (",
"      <a class=\"graphic graphic_figure graphicRef64515 \" href=\"mobipreview.htm?22/26/22948\">",
"       figure 7",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef77068 \" href=\"mobipreview.htm?33/42/34469\">",
"       figure 8",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Sufficient tension is applied to the mesh sling to prevent a recurrence of the prolapse but not enough to result in an obstruction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6676255\">",
"    <span class=\"h3\">",
"     Sigmoid resection with rectopexy",
"    </span>",
"    &nbsp;&mdash;&nbsp;If redundant sigmoid colon is present in a patient with preoperative constipation and a rectal prolapse, a sigmoid resection is included with the rectopexy (",
"    <a class=\"graphic graphic_figure graphicRef71661 \" href=\"mobipreview.htm?35/62/36847\">",
"     figure 9",
"    </a>",
"    ). This procedure is performed as either an open, laparoscopic, or robotic-assisted approach.",
"   </p>",
"   <p>",
"    The general principles for the repair of rectal procidentia with colon resection include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mobilization of the rectum is performed as previously described. (See",
"      <a class=\"local\" href=\"#H10292352\">",
"       'Rectopexy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The distal transection is at the level of the splayed taeniae coli, distal to the transition to the intraperitoneal rectum. The superior rectal artery may be sacrificed or preserved, depending upon transection level (",
"      <a class=\"graphic graphic_figure graphicRef73756 \" href=\"mobipreview.htm?40/32/41479\">",
"       figure 10",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The proximal transection level is identified by selecting the location where there is no tension on the anastomosis and no residual redundant",
"      <span class=\"nowrap\">",
"       descending/sigmoid",
"      </span>",
"      colon (",
"      <a class=\"graphic graphic_figure graphicRef71661 \" href=\"mobipreview.htm?35/62/36847\">",
"       figure 9",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      A rectopexy is performed after the sigmoid colon resection using suture fixation; scarring assists in adherence of the rectum and mesorectum to the presacral fascia (",
"      <a class=\"graphic graphic_figure graphicRef51730 \" href=\"mobipreview.htm?37/59/38833\">",
"       figure 11",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef64515 \" href=\"mobipreview.htm?22/26/22948\">",
"       figure 7",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10292302\">",
"    <span class=\"h2\">",
"     Perineal procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;The advantages of the perineal approach (eg, sparing pelvic nerves, no abdominal incisions) must be weighed against the disadvantages (eg, removal of rectal reservoir) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41832/abstract/36\">",
"     36",
"    </a>",
"    ]. The perineal procedures are generally reserved for the most elderly and frail, particularly those who are not candidates for either an open or laparoscopic approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41832/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other candidates considered for the perineal approach include the following clinical settings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41832/abstract/38\">",
"     38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Comorbid illnesses that preclude an intra-abdominal procedure",
"     </li>",
"     <li>",
"      Failed previous intra-abdominal rectal procidentia repair procedure",
"     </li>",
"     <li>",
"      Prior pelvic surgery",
"     </li>",
"     <li>",
"      Prior pelvic radiation therapy",
"     </li>",
"     <li>",
"      Young males, in order to minimize the risk of erectile dysfunction. There is little, if any, risk of damage to the hypogastric nerves with the perineal procedures.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The two most common perineal approaches are the perineal rectosigmoidectomy (Altemeier procedure) and the Delorme procedure (mucosal stripping and muscle plication).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10292435\">",
"    <span class=\"h3\">",
"     Altemeier perineal rectosigmoidectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Altemeier perineal rectosigmoidectomy is the most frequently performed perineal procedure in North America (",
"    <a class=\"graphic graphic_figure graphicRef77068 \" href=\"mobipreview.htm?33/42/34469\">",
"     figure 8",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41832/abstract/15,39,40\">",
"     15,39,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The principle components of this procedure include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The redundant rectum is prolapsed through the anal canal using Allis clamps.",
"     </li>",
"     <li>",
"      The dentate line is identified and epinephrine-based solution is injected into the submucosa to aid in hemostasis.",
"     </li>",
"     <li>",
"      A full thickness circumferential incision is performed in the rectum, approximately 1 to 2 cm proximal to the dentate line.",
"     </li>",
"     <li>",
"      The dissection continues proximally along the rectum, detaching the rectum from the mesorectum and surrounding ligamentous attachments, typically until the peritoneal cavity is entered.",
"     </li>",
"     <li>",
"      The redundant bowel is transected at the level of the rectosigmoid junction or on the sigmoid colon, selecting a site where there will be no tension on the anastomosis and no further redundancy of the rectum.",
"     </li>",
"     <li>",
"      A hand-sewn colo-anal anastomosis is performed in a single layer with non-absorbable suture.",
"     </li>",
"     <li>",
"      A levatorplasty is performed anteriorly by suturing the levator muscles together to lengthen the anal canal and provide additional support.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients with a rectal prolapse shorter than 3 to 4 cm, a perineal rectosigmoidectomy is technically difficult and the optimal approach is a modification of the Delorme procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41832/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14876073\">",
"    <span class=\"h3\">",
"     Delorme procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to the perineal rectosigmoidectomy, the Delorme procedure, which is more commonly performed in Europe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41832/abstract/15\">",
"     15",
"    </a>",
"    ], is performed by dissecting within the submucosal layer (",
"    <a class=\"graphic graphic_figure graphicRef57165 \" href=\"mobipreview.htm?15/3/15416\">",
"     figure 12",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41832/abstract/14,39,41,42\">",
"     14,39,41,42",
"    </a>",
"    ]. The principle components of this procedure include: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The redundant rectum is prolapsed through the anal canal using Allis clamps.",
"     </li>",
"     <li>",
"      The dentate line is identified and epinephrine-based solution is injected into the submucosa to aid in hemostasis.",
"     </li>",
"     <li>",
"      The mucosa is incised circumferentially to the submucosal layer, approximately 1 to 2 cm proximal to the dentate line. A sleeve resection of the mucosa is continued proximally until the tube of redundant mucosa is resected.",
"     </li>",
"     <li>",
"      The exposed muscularis propria is plicated using a series of interrupted non-absorbable sutures.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A hand-sewn anastomosis is performed in a single layer with absorbable suture between the proximal mucosa at the level of transection and the anal canal proximal to the dentate line.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H284497230\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The typical postoperative course includes early ambulation and initiation of enteral feeding. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/3/25656?source=see_link\">",
"     \"Fast-track protocols in colorectal surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with a history of constipation, an aggressive bowel regimen is maintained for the first one to two weeks following surgery to avoid constipation and excessive straining that may lead to recurrence. Most patients undergoing rectal prolapse repair will be able to return to normal activities, including work, within four to six weeks after surgery. Heavy lifting and straining the abdominal and perineal muscles are to be avoided until fully healed in approximately a few months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H106270477\">",
"    <span class=\"h1\">",
"     MORTALITY AND MORBIDITY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H106271000\">",
"    <span class=\"h2\">",
"     Intra-abdominal procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients undergoing an intra-abdominal procedure (open or laparoscopic), the mortality rates range from 0 to 7 percent and morbidity rates range from 0 to 52 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41832/abstract/9,36,42-48\">",
"     9,36,42-48",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    The most common major complications following intra-abdominal procedures include pelvic sepsis, hematomas, fistulas, stenosis, and obstructed defecation. Sigmoid colon resections are associated with anastomotic leaks, and when performed with a mesh repair, slightly higher rates of surgical site infections and fistulas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41832/abstract/42\">",
"     42",
"    </a>",
"    ]. Rectopexy by sutures alone avoids the complications associated with mesh repair (eg, infections, fistulas, stenosis), but otherwise has comparable morbidity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41832/abstract/42,46\">",
"     42,46",
"    </a>",
"    ]. Rates of reoperation and 30-day readmission were comparable for open and laparoscopic procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41832/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H106271008\">",
"    <span class=\"h2\">",
"     Perineal procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;The advantage of perineal procedures is that they avoid the operative risks and complications associated with intra-abdominal procedures. Most series report low mortality (0 to 4 percent) and low morbidity rates (typically less than 20 percent) for bleeding, pelvic sepsis, pelvic nerve injury, and fecal leakage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41832/abstract/36,42,44\">",
"     36,42,44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H106270500\">",
"    <span class=\"h1\">",
"     SURGICAL OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients undergoing an intra-abdominal procedure have better outcomes (ie, fewer recurrences and improved bowel functional results) compared with patients undergoing a perineal procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41832/abstract/42,49\">",
"     42,49",
"    </a>",
"    ]. Outcomes are similar for intra-abdominal procedures performed as an open or minimally invasive (laparoscopic or robotic-assisted) technique.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H100798135\">",
"    <span class=\"h2\">",
"     Recurrence rates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon prospective studies and retrospective reviews, the intra-abdominal procedures have generally lower recurrence rates compared with perineal procedures (range 0 to 27 percent versus 4 to 38 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41832/abstract/7,8,36,42,45-48,50-52\">",
"     7,8,36,42,45-48,50-52",
"    </a>",
"    ]. Most recurrences present within three years of surgery, with mean time to recurrence ranging from 7 to 33 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41832/abstract/53-56\">",
"     53-56",
"    </a>",
"    ]. Recurrence rates are comparable for suture and mesh rectopexy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41832/abstract/42\">",
"     42",
"    </a>",
"    ], open and laparoscopic approaches [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41832/abstract/42,47\">",
"     42,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rectopexy (presacral fixation) is the mainstay of the surgical repair to reduce the risk of recurrence (see",
"    <a class=\"local\" href=\"#H10292352\">",
"     'Rectopexy'",
"    </a>",
"    above). In a randomized, multicenter trial that included 252 patients with rectal procidentia, patients undergoing a rectal mobilization procedure with rectopexy had a significantly lower five-year recurrence rate compared with patients undergoing rectal mobilization without a rectopexy (1.5 versus 8.6 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41832/abstract/9\">",
"     9",
"    </a>",
"    ]. However, the rectopexy technique was not standardized. As a comparison, the higher recurrence rate following perineal procedures is due to the lack of a rectopexy component of the operation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41832/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recurrence rates are approximately three times higher in men who undergo an intra-abdominal procedure compared with women, secondary to the technical challenges of a narrow pelvis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41832/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H100802859\">",
"    <span class=\"h2\">",
"     Bowel function",
"    </span>",
"    &nbsp;&mdash;&nbsp;The surgeon should counsel patients preoperatively regarding realistic changes in bowel habits after repair. Fecal incontinence and constipation generally improve for most patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41832/abstract/7,42,45-47\">",
"     7,42,45-47",
"    </a>",
"    ], with the exception of those undergoing a pelvic dissection with division of lateral ligaments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41832/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Persistence of some symptoms may exist secondary to prolonged preoperative anal sphincter trauma and the negative effects on colon motility from long-term constipation. While postoperative satisfaction with the procidentia repair was rated as excellent or good in 72 to 80 percent of patients, incontinence and persistent constipation were the most common reasons for dissatisfaction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41832/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two randomized trials identified no significant difference in anorectal physiologic studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41832/abstract/12\">",
"     12",
"    </a>",
"    ] or colonic transit times [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41832/abstract/13\">",
"     13",
"    </a>",
"    ] for patients undergoing an intra-abdominal rectopexy with or without a sigmoid (anterior) resection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H100797576\">",
"    <span class=\"h3\">",
"     Fecal incontinence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Improvement in fecal incontinence symptoms depends, in part, on the operative procedure (eg, rectopexy, anterior resection) and approach (intra-abdominal or perineal).",
"   </p>",
"   <p>",
"    There is a wide range of results, based on small series, retrospective reviews, and prospective studies as illustrated by the following examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Simple suture rectopexy alone improves incontinence in 15 to 82 percent of patients, with most studies demonstrating over 50 percent success rates [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/54/41832/abstract/48,57-61\">",
"       48,57-61",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Rectopexy with a mesh sling improves incontinence in 3 to 92 percent, with a mean improvement of 20 to 60 percent of patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/54/41832/abstract/35,62,63\">",
"       35,62,63",
"      </a>",
"      ]. Incontinence is improved in 15 to 80 percent of patients undergoing an anterior rectopexy (Ripstein repair) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/54/41832/abstract/64\">",
"       64",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A sigmoid resection improves incontinence in 11 to 90 percent of patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/54/41832/abstract/11,48,50\">",
"       11,48,50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Perineal procedures (ie, Altemeier and Delorme) resulted in a complete resolution of fecal incontinence in 20 to 50 percent of patients, with varying improvements identified in 20 to 90 percent of patients and worsening of symptoms in 22 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/54/41832/abstract/42,44,50,65-67\">",
"       42,44,50,65-67",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H100797583\">",
"    <span class=\"h3\">",
"     Constipation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most series report improvement in constipation for most patients (range 14 to 83 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41832/abstract/7,9,10,45,48\">",
"     7,9,10,45,48",
"    </a>",
"    ], but new-onset or worsening constipation occurred in 14 to 50 of patients, especially after intra-abdominal procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41832/abstract/35,45,57,63\">",
"     35,45,57,63",
"    </a>",
"    ]. Possible etiologies include neuropathy from division of the lateral ligaments, or redundant sigmoid colon kinking at the proximal rectum resulting in increased outlet resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41832/abstract/5,12\">",
"     5,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients undergoing perineal repair procedures have also shown an improvement in constipation following surgery (range 13 to 100 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41832/abstract/36,68-70\">",
"     36,68-70",
"    </a>",
"    ], as well as a very low rate of new-onset of constipation (1 to 15 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41832/abstract/38\">",
"     38",
"    </a>",
"    ]. The low rate of new onset of constipation may be a result of loss of capacitance of the rectum, and relief of the intussusception and functional obstruction following rectal resection.",
"   </p>",
"   <p>",
"    There is a wide range of results, based on small series, retrospective reviews, and prospective studies, as illustrated by the following examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a prospective study that included 72 patients undergoing a laparoscopic suture rectopexy, constipation was improved or completely resolved in 76 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/54/41832/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a series of 77 patients undergoing laparoscopic posterior sling procedure (modified Wells procedure), constipation was improved in 36 percent but developed as a new symptom in 18 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/54/41832/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A retrospective review found no difference in functional improvement (constipation or incontinence) for 183 patients undergoing a perineal rectosigmoidectomy compared with 161 patients treated with an anterior resection and rectopexy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/54/41832/abstract/36\">",
"       36",
"      </a>",
"      ]. Patients undergoing perineal rectosigmoidectomy were significantly more likely to have associated medical problems compared with patients undergoing abdominal rectopexy (61 versus 30 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H284497966\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF RECURRENT RECTAL PROLAPSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management is guided by symptoms and patient operative risk profile when recurrences develop. Surgical options for recurrent rectal procidentia are the same as for primary prolapse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41832/abstract/71\">",
"     71",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10292286\">",
"     'Surgical procedures'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For patients with small full-thickness recurrences or mucosal protrusion, management includes observation and bowel regimen. Longitudinal multiple rubber band ligation of the prolapsing mucosa alone has been described for patients with mucosal prolapse with 14 of 17 patients experiencing complete remission of symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41832/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no prospective data to determine the optimal surgical management for recurrent rectal procidentia. Retrospective studies show that reoperation can be safely performed with similar complication rates to a primary repair, but varying recurrence rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41832/abstract/10,53-56,73,74\">",
"     10,53-56,73,74",
"    </a>",
"    ]. In a retrospective review of 136 patients undergoing a perineal rectosigmoidoscopy, patients (n = 23) undergoing the procedure for recurrent prolapse had a significantly higher rate of recurrence compared with patients undergoing a primary repair (39 versus 18 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41832/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following retrospective studies illustrate the high rates of second recurrence for patients undergoing a repair of a recurrent rectal procidentia:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The rate of second recurrence was significantly higher in patients undergoing a perineal procedure compared with patients undergoing an intra-abdominal procedure (19 of 51 patients [37 percent] versus 4 of 27 patients [15 percent]) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/54/41832/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The rate of a recurrence following a laparoscopic repair was higher for patients who had a previous perineal repair procedure (and recurred) compared with those undergoing a laparoscopic procedure for a primary repair (7 of 13 patients [54 percent] versus 3 of 77 patients [4 percent]) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/54/41832/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H284498109\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rectal procidentia is a disabling condition that typically affects the elderly, particularly women. Surgical management is the treatment of choice for most patients who are operative candidates.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is no consensus on the optimal procedure or approach for repair of rectal procidentia. We suggest an intra-abdominal approach rather than a perineal approach for patients with rectal prolapse who are candidates for an abdominal procedure (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H10292551\">",
"       'Intra-abdominal procedures'",
"      </a>",
"      above). Recurrence rates are generally lower for patients undergoing an intra-abdominal procedure compared with perineal procedures. (See",
"      <a class=\"local\" href=\"#H100798135\">",
"       'Recurrence rates'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with comorbid illnesses that would preclude an intra-abdominal approach, we perform a perineal procedure for repair of rectal procidentia. (See",
"      <a class=\"local\" href=\"#H10292302\">",
"       'Perineal procedures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with rectal prolapse shorter than 3 to 4 cm, we suggest the Delorme procedure rather than the perineal rectosigmoidectomy (Altemeier procedure) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ) based on the technical challenges of the rectosigmoidectomy. (See",
"      <a class=\"local\" href=\"#H14876073\">",
"       'Delorme procedure'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10292435\">",
"       'Altemeier perineal rectosigmoidectomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most patients with rectal procidentia without constipation, we perform a suture rectopexy without a sigmoid colon resection. (See",
"      <a class=\"local\" href=\"#H10292352\">",
"       'Rectopexy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The use of a suture or mesh rectopexy is dependent upon surgeon&rsquo;s preference. Mesh repairs have the potential for more complications, including infection, fistulas, or stenosis. (See",
"      <a class=\"local\" href=\"#H106270500\">",
"       'Surgical outcomes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with constipation and rectal procidentia, we suggest a sigmoid resection be included with the rectopexy to improve postoperative bowel function (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). The procedure can be performed either as an open or laparoscopic approach. (See",
"      <a class=\"local\" href=\"#H6676255\">",
"       'Sigmoid resection with rectopexy'",
"      </a>",
"      above.) Robotic-assisted procedures should be performed only by those qualified and certified to perform those procedures.",
"     </li>",
"     <li>",
"      Surgical repair of a recurrent rectal procidentia includes the same procedures available for a primary repair. (See",
"      <a class=\"local\" href=\"#H284497966\">",
"       'Management of recurrent rectal prolapse'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41832/abstract/1\">",
"      Felt-Bersma RJ, Tiersma ES, Stella MT, Cuesta MA. Rectal prolapse, rectal intussusception, rectocele, solitary rectal ulcer syndrome, and enterocele. Gastroenterol Clin North Am 2008; 37:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41832/abstract/2\">",
"      Kairaluoma MV, Kellokumpu IH. Epidemiologic aspects of complete rectal prolapse. Scand J Surg 2005; 94:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41832/abstract/3\">",
"      Stein EA, Stein DE. Rectal procidentia: diagnosis and management. Gastrointest Endosc Clin N Am 2006; 16:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41832/abstract/4\">",
"      Tou S, Brown SR, Malik AI, Nelson RL. Surgery for complete rectal prolapse in adults. Cochrane Database Syst Rev 2008; :CD001758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41832/abstract/5\">",
"      Speakman CT, Madden MV, Nicholls RJ, Kamm MA. Lateral ligament division during rectopexy causes constipation but prevents recurrence: results of a prospective randomized study. Br J Surg 1991; 78:1431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41832/abstract/6\">",
"      Scaglia M, Fasth S, Hallgren T, et al. Abdominal rectopexy for rectal prolapse. Influence of surgical technique on functional outcome. Dis Colon Rectum 1994; 37:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41832/abstract/7\">",
"      Portier G, Iovino F, Lazorthes F. Surgery for rectal prolapse: Orr-Loygue ventral rectopexy with limited dissection prevents postoperative-induced constipation without increasing recurrence. Dis Colon Rectum 2006; 49:1136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41832/abstract/8\">",
"      Raftopoulos Y, Senagore AJ, Di Giuro G, et al. Recurrence rates after abdominal surgery for complete rectal prolapse: a multicenter pooled analysis of 643 individual patient data. Dis Colon Rectum 2005; 48:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41832/abstract/9\">",
"      Karas JR, Uranues S, Altomare DF, et al. No rectopexy versus rectopexy following rectal mobilization for full-thickness rectal prolapse: a randomized controlled trial. Dis Colon Rectum 2011; 54:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41832/abstract/10\">",
"      Laubert T, Kleemann M, Schorcht A, et al. Laparoscopic resection rectopexy for rectal prolapse: a single-center study during 16 years. Surg Endosc 2010; 24:2401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41832/abstract/11\">",
"      Johnson E, Stangeland A, Johannessen HO, Carlsen E. Resection rectopexy for external rectal prolapse reduces constipation and anal incontinence. Scand J Surg 2007; 96:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41832/abstract/12\">",
"      McKee RF, Lauder JC, Poon FW, et al. A prospective randomized study of abdominal rectopexy with and without sigmoidectomy in rectal prolapse. Surg Gynecol Obstet 1992; 174:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41832/abstract/13\">",
"      Luukkonen P, Mikkonen U, J&auml;rvinen H. Abdominal rectopexy with sigmoidectomy vs. rectopexy alone for rectal prolapse: a prospective, randomized study. Int J Colorectal Dis 1992; 7:219.",
"     </a>",
"    </li>",
"    <li>",
"     Hamel CT, Wexner SD. Rectal prolapse. In: Surgical treatment: Evidence-based and problem oriented., Holzheimer RG, Mannick JA.  (Eds), Zuckshwerdt, 2001.",
"PMID: 21028753.NBK6929.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41832/abstract/15\">",
"      Lindsey I. Commentary: Best practice in rectal prolapse. Colorectal Dis 2010; 12:512.",
"     </a>",
"    </li>",
"    <li>",
"     Schwenk W, Haase O, Neudecker J, Muller JM. Short term benefits for laparoscopic colorectal resection. Cochrane Database Syst Rev 2005; :CD003145.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41832/abstract/17\">",
"      Lourenco T, Murray A, Grant A, et al. Laparoscopic surgery for colorectal cancer: safe and effective? - A systematic review. Surg Endosc 2008; 22:1146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41832/abstract/18\">",
"      Novitsky YW, Litwin DE, Callery MP. The net immunologic advantage of laparoscopic surgery. Surg Endosc 2004; 18:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41832/abstract/19\">",
"      MacKay G, Ihedioha U, McConnachie A, et al. Laparoscopic colonic resection in fast-track patients does not enhance short-term recovery after elective surgery. Colorectal Dis 2007; 9:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41832/abstract/20\">",
"      King PM, Blazeby JM, Ewings P, et al. Randomized clinical trial comparing laparoscopic and open surgery for colorectal cancer within an enhanced recovery programme. Br J Surg 2006; 93:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41832/abstract/21\">",
"      Purkayastha S, Tekkis P, Athanasiou T, et al. A comparison of open vs. laparoscopic abdominal rectopexy for full-thickness rectal prolapse: a meta-analysis. Dis Colon Rectum 2005; 48:1930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41832/abstract/22\">",
"      Sammour T, Kahokehr A, Srinivasa S, et al. Laparoscopic colorectal surgery is associated with a higher intraoperative complication rate than open surgery. Ann Surg 2011; 253:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41832/abstract/23\">",
"      Ayav A, Bresler L, Hubert J, et al. Robotic-assisted pelvic organ prolapse surgery. Surg Endosc 2005; 19:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41832/abstract/24\">",
"      Munz Y, Moorthy K, Kudchadkar R, et al. Robotic assisted rectopexy. Am J Surg 2004; 187:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41832/abstract/25\">",
"      Heemskerk J, Zandbergen R, Maessen JG, et al. Advantages of advanced laparoscopic systems. Surg Endosc 2006; 20:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41832/abstract/26\">",
"      Heemskerk J, de Hoog DE, van Gemert WG, et al. Robot-assisted vs. conventional laparoscopic rectopexy for rectal prolapse: a comparative study on costs and time. Dis Colon Rectum 2007; 50:1825.",
"     </a>",
"    </li>",
"    <li>",
"     De Hoog DE, Heemskerk J, Nieman FH, et al. Recurrence and functional results after open versus conventional laparoscopic versus robot-assisted laparoscopic rectopexy for rectal prolapse: a case-control study. Int J Colorectal Dis 2009; 24:1201.",
"    </li>",
"    <li>",
"     Heemskerk J, de Hoog DE, van Gemert WG, et al. Robot-assisted vs. conventional laparoscopic rectopexy for rectal prolapse: a comparative study on costs and time. Dis Colon Rectum 2007; 40:1825.",
"    </li>",
"    <li>",
"     Tou S, Brown SR, Malik AI, Nelson RL. Surgery for complete rectal prolapse in adults. Cochrane Database Syst Rev 2008; :CD001758.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41832/abstract/30\">",
"      Sajid MS, Siddiqui MR, Baig MK. Open vs laparoscopic repair of full-thickness rectal prolapse: a re-meta-analysis. Colorectal Dis 2010; 12:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41832/abstract/31\">",
"      Bachoo P, Brazzelli M, Grant A. Surgery for complete rectal prolapse in adults. Cochrane Database Syst Rev 2000; :CD001758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41832/abstract/32\">",
"      Deen KI, Grant E, Billingham C, Keighley MR. Abdominal resection rectopexy with pelvic floor repair versus perineal rectosigmoidectomy and pelvic floor repair for full-thickness rectal prolapse. Br J Surg 1994; 81:302.",
"     </a>",
"    </li>",
"    <li>",
"     Mills S. Chapter 33: Rectal prolapse. In: The ASCRS textbook of colon nad rectal surgery, Second, Beck DE, Roberts PL, Saclarides TJ, et al.  (Eds), Springer, New York City 2011. p.549.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41832/abstract/34\">",
"      Boons P, Collinson R, Cunningham C, Lindsey I. Laparoscopic ventral rectopexy for external rectal prolapse improves constipation and avoids de novo constipation. Colorectal Dis 2010; 12:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41832/abstract/35\">",
"      Sayfan J, Pinho M, Alexander-Williams J, Keighley MR. Sutured posterior abdominal rectopexy with sigmoidectomy compared with Marlex rectopexy for rectal prolapse. Br J Surg 1990; 77:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41832/abstract/36\">",
"      Kim DS, Tsang CB, Wong WD, et al. Complete rectal prolapse: evolution of management and results. Dis Colon Rectum 1999; 42:460.",
"     </a>",
"    </li>",
"    <li>",
"     Clark CE, Jupiter DC, Thomas JS, Papaconstantinou. Rectal Prolapse in the Elderly: Trends in Surgical Management and Outcomes from the American College of Surgeons National Surgical Quality Improvement Program Database. JACS 2012;215:709.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41832/abstract/38\">",
"      Kling KM, Rongione AJ, Evans B, McFadden DW. The Delorme procedure: a useful operation for complicated rectal prolapse in the elderly. Am Surg 1996; 62:857.",
"     </a>",
"    </li>",
"    <li>",
"     Marcello PW, Roberts PL. Chapter 17 Surgery for rectal prolapse. In: Complications of Colon &amp; Rectal Surgery, Hicks TC, Beck DE, Opelka FG, Timmcke AE.  (Eds), Williams &amp; Wilkins, Baltimore 1996. p.237.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41832/abstract/40\">",
"      Altemeier WA, Culbertson WR, Schowengerdt C, Hunt J. Nineteen years' experience with the one-stage perineal repair of rectal prolapse. Ann Surg 1971; 173:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41832/abstract/41\">",
"      Penninckx F, D'Hoore A, Sohier S, Kerremans R. Abdominal resection rectopexy versus Delorme's procedure for rectal prolapse: a predictable outcome. Int J Colorectal Dis 1997; 12:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41832/abstract/42\">",
"      Madiba TE, Baig MK, Wexner SD. Surgical management of rectal prolapse. Arch Surg 2005; 140:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41832/abstract/43\">",
"      Roberts PL, Schoetz DJ Jr, Coller JA, Veidenheimer MC. Ripstein procedure. Lahey Clinic experience: 1963-1985. Arch Surg 1988; 123:554.",
"     </a>",
"    </li>",
"    <li>",
"     Agachan F, Pfeifer J, Joo JS, et al. Results of perineal procedures for the treatment of rectal prolapse. Am Surg 1997; 53:9.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41832/abstract/45\">",
"      Dulucq JL, Wintringer P, Mahajna A. Clinical and functional outcome of laparoscopic posterior rectopexy (Wells) for full-thickness rectal prolapse. A prospective study. Surg Endosc 2007; 21:2226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41832/abstract/46\">",
"      Benoist S, Taffinder N, Gould S, et al. Functional results two years after laparoscopic rectopexy. Am J Surg 2001; 182:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41832/abstract/47\">",
"      Kariv Y, Delaney CP, Casillas S, et al. Long-term outcome after laparoscopic and open surgery for rectal prolapse: a case-control study. Surg Endosc 2006; 20:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41832/abstract/48\">",
"      Bruch HP, Herold A, Schiedeck T, Schwandner O. Laparoscopic surgery for rectal prolapse and outlet obstruction. Dis Colon Rectum 1999; 42:1189.",
"     </a>",
"    </li>",
"    <li>",
"     Jan S, Gross L, Hills RK, et al. Persistent benefits in bowel function and quality of life following rectal prolapse surgery&mdash;the ACPGBI PROSPER trial. Available at file://www.prosper.bham.ac.uk/index.shtml Accessed March 2011.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41832/abstract/50\">",
"      Watts JD, Rothenberger DA, Buls JG, et al. The management of procidentia. 30 years' experience. Dis Colon Rectum 1985; 28:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41832/abstract/51\">",
"      DiGiuro G, Ignjatovic D, Brogger J, et al. How accurate are published recurrence rates after rectal prolapse surgery? A meta-analysis of individual patient data. Am J Surg 2006; 191:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41832/abstract/52\">",
"      Faucheron JL, Voirin D, Riboud R, et al. Laparoscopic anterior rectopexy to the promontory for full-thickness rectal prolapse in 175 consecutive patients: short- and long-term follow-up. Dis Colon Rectum 2012; 55:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41832/abstract/53\">",
"      Steele SR, Goetz LH, Minami S, et al. Management of recurrent rectal prolapse: surgical approach influences outcome. Dis Colon Rectum 2006; 49:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41832/abstract/54\">",
"      Fengler SA, Pearl RK, Prasad ML, et al. Management of recurrent rectal prolapse. Dis Colon Rectum 1997; 40:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41832/abstract/55\">",
"      Hool GR, Hull TL, Fazio VW. Surgical treatment of recurrent complete rectal prolapse: a thirty-year experience. Dis Colon Rectum 1997; 40:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41832/abstract/56\">",
"      Pikarsky AJ, Joo JS, Wexner SD, et al. Recurrent rectal prolapse: what is the next good option? Dis Colon Rectum 2000; 43:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41832/abstract/57\">",
"      Graf W, Karlbom U, P&aring;hlman L, et al. Functional results after abdominal suture rectopexy for rectal prolapse or intussusception. Eur J Surg 1996; 162:905.",
"     </a>",
"    </li>",
"    <li>",
"     Khanna AK, Misra MK, Kumar K. Simplified sutured sacral rectopexy for complete rectal prolapse in adults. Eur J Surg 1996; 162;143.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41832/abstract/59\">",
"      Briel JW, Schouten WR, Boerma MO. Long-term results of suture rectopexy in patients with fecal incontinence associated with incomplete rectal prolapse. Dis Colon Rectum 1997; 40:1228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41832/abstract/60\">",
"      Kellokumpu IH, Vironen J, Scheinin T. Laparoscopic repair of rectal prolapse: a prospective study evaluating surgical outcome and changes in symptoms and bowel function. Surg Endosc 2000; 14:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41832/abstract/61\">",
"      Heah SM, Hartley JE, Hurley J, et al. Laparoscopic suture rectopexy without resection is effective treatment for full-thickness rectal prolapse. Dis Colon Rectum 2000; 43:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41832/abstract/62\">",
"      Aitola PT, Hiltunen KM, Matikainen MJ. Functional results of operative treatment of rectal prolapse over an 11-year period: emphasis on transabdominal approach. Dis Colon Rectum 1999; 42:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41832/abstract/63\">",
"      Himpens J, Cadi&egrave;re GB, Bruyns J, Vertruyen M. Laparoscopic rectopexy according to Wells. Surg Endosc 1999; 13:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41832/abstract/64\">",
"      Schultz I, Mellgren A, Dolk A, et al. Continence is improved after the Ripstein rectopexy. Different mechanizms in rectal prolapse and rectal intussusception? Dis Colon Rectum 1996; 39:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41832/abstract/65\">",
"      Williams JG, Rothenberger DA, Madoff RD, Goldberg SM. Treatment of rectal prolapse in the elderly by perineal rectosigmoidectomy. Dis Colon Rectum 1992; 35:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41832/abstract/66\">",
"      Liberman H, Hughes C, Dippolito A. Evaluation and outcome of the delorme procedure in the treatment of rectal outlet obstruction. Dis Colon Rectum 2000; 43:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41832/abstract/67\">",
"      Tobin SA, Scott IH. Delorme operation for rectal prolapse. Br J Surg 1994; 81:1681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41832/abstract/68\">",
"      Tsunoda A, Yasuda N, Yokoyama N, et al. Delorme's procedure for rectal prolapse: clinical and physiological analysis. Dis Colon Rectum 2003; 46:1260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41832/abstract/69\">",
"      Marchal F, Bresler L, Ayav A, et al. Long-term results of Delorme's procedure and Orr-Loygue rectopexy to treat complete rectal prolapse. Dis Colon Rectum 2005; 48:1785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41832/abstract/70\">",
"      Whitlow CB, Beck DE, Opelka FG, et al. Perineal repair of rectal prolapse. J La State Med Soc 1997; 149:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41832/abstract/71\">",
"      Tsugawa K, Sue K, Koyanagi N, et al. Laparoscopic rectopexy for recurrent rectal prolapse: a safe and simple procedure without a mesh prosthesis. Hepatogastroenterology 2002; 49:1549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41832/abstract/72\">",
"      Klein&uuml;bing H Jr, Pinho MS, Ferreira LC. Longitudinal multiple rubber band ligation: an alternative method to treat mucosal prolapse of the anterior rectal wall. Dis Colon Rectum 2006; 49:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41832/abstract/73\">",
"      Watts AM, Thompson MR. Evaluation of Delorme's procedure as a treatment for full-thickness rectal prolapse. Br J Surg 2000; 87:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41832/abstract/74\">",
"      Ding JH, Canedo J, Lee SH, et al. Perineal rectosigmoidectomy for primary and recurrent rectal prolapse: are the results comparable the second time? Dis Colon Rectum 2012; 55:666.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16920 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-528937E1C1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_54_41832=[""].join("\n");
var outline_f40_54_41832=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H284498109\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H284496739\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H261085160\">",
"      CONTROVERSIES IN SURGICAL APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10292286\">",
"      SURGICAL PROCEDURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10292551\">",
"      Intra-abdominal procedures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10292352\">",
"      - Rectopexy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H27760298\">",
"      Suture rectopexy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H27760313\">",
"      Anterior mesh rectopexy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H106269181\">",
"      Posterior mesh rectopexy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6676255\">",
"      - Sigmoid resection with rectopexy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10292302\">",
"      Perineal procedures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10292435\">",
"      - Altemeier perineal rectosigmoidectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14876073\">",
"      - Delorme procedure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H284497230\">",
"      POSTOPERATIVE MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H106270477\">",
"      MORTALITY AND MORBIDITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H106271000\">",
"      Intra-abdominal procedures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H106271008\">",
"      Perineal procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H106270500\">",
"      SURGICAL OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H100798135\">",
"      Recurrence rates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H100802859\">",
"      Bowel function",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H100797576\">",
"      - Fecal incontinence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H100797583\">",
"      - Constipation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H284497966\">",
"      MANAGEMENT OF RECURRENT RECTAL PROLAPSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H284498109\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/16920\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/16920|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?35/24/36225\" title=\"figure 1\">",
"      Lateral ligament of the rectum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?30/15/30962\" title=\"figure 2\">",
"      Retrorectal avascular space",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?10/7/10362\" title=\"figure 3\">",
"      Pelvic nerve plexus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?15/45/16081\" title=\"figure 4\">",
"      Ripstein anterior rectopexy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?6/30/6625\" title=\"figure 5\">",
"      Modified Ripstein rectopexy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?0/21/339\" title=\"figure 6\">",
"      Posterior rectopexy with mesh sling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?22/26/22948\" title=\"figure 7\">",
"      Transection of redundant sigmoid colon sagittal view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?33/42/34469\" title=\"figure 8\">",
"      Perineal proctosigmoidectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?35/62/36847\" title=\"figure 9\">",
"      Redundant sigmoid colon",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?40/32/41479\" title=\"figure 10\">",
"      Blood supply to the colon and rectum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?37/59/38833\" title=\"figure 11\">",
"      Transection of redundant sigmoid colon AP view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?15/3/15416\" title=\"figure 12\">",
"      Delorme procedure for rectal procidentia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/16920|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/33/8733\" title=\"table 1\">",
"      American Society of Anesthesiologists physical status scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/3/25656?source=related_link\">",
"      Fast-track protocols in colorectal surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/23/25976?source=related_link\">",
"      Laparoscopic surgery for repair of pelvic floor defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/30/7655?source=related_link\">",
"      Overview of rectal procidentia (rectal prolapse)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/32/1546?source=related_link\">",
"      Pelvic organ prolapse and stress urinary incontinence in women: Combined surgical treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/37/43607?source=related_link\">",
"      Pelvic organ prolapse in women: Obliterative procedures (colpocleisis)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_54_41833="Idiopathic intracranial hypertension (pseudotumor cerebri): Prognosis and treatment";
var content_f40_54_41833=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Idiopathic intracranial hypertension (pseudotumor cerebri): Prognosis and treatment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/54/41833/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/54/41833/contributors\">",
"     Andrew G Lee, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/54/41833/contributors\">",
"     Michael Wall, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/54/41833/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/54/41833/contributors\">",
"     Paul W Brazis, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/54/41833/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/54/41833/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/54/41833/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Idiopathic intracranial hypertension (IIH) is also commonly called pseudotumor cerebri. It is a disorder defined by clinical criteria that include symptoms and signs isolated to those produced by increased intracranial pressure (eg, headache, papilledema, vision loss), elevated intracranial pressure with normal cerebrospinal fluid composition, and no other cause of intracranial hypertension evident on neuroimaging or other evaluations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41833/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While once called benign intracranial hypertension, to distinguish it from secondary intracranial hypertension produced by a neoplastic malignancy, it is not a benign disorder. Many patients suffer from intractable, disabling headaches, and there is a risk of severe, permanent vision loss.",
"   </p>",
"   <p>",
"    Recommendations for the treatment of IIH are limited by the absence of randomized controlled trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41833/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Moreover, the natural history of untreated IIH is unknown.",
"   </p>",
"   <p>",
"    This topic will discuss the prognosis and treatment of IIH. The epidemiology, pathogenesis, clinical features and diagnosis of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/25/15769?source=see_link\">",
"     \"Idiopathic intracranial hypertension (pseudotumor cerebri): Epidemiology and pathogenesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/0/17417?source=see_link\">",
"     \"Idiopathic intracranial hypertension (pseudotumor cerebri): Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;No prospective series describe the natural history of idiopathic intracranial hypertension (IIH). A protracted course lasting months to years appears to be common [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41833/abstract/4-7\">",
"     4-7",
"    </a>",
"    ]. Generally, symptoms worsen slowly, but a subset has a more fulminant course. With treatment, there is usually gradual improvement",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    stabilization, but not necessarily recovery; many patients have persistent papilledema, elevated intracranial pressure as documented on lumbar puncture, and residual visual field deficits.",
"   </p>",
"   <p>",
"    Permanent vision loss is the major morbidity associated with IIH. An early, hospital-based study that followed 57 patients for 5 to 41 years found that 24 percent developed blindness or severe visual impairment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41833/abstract/8\">",
"     8",
"    </a>",
"    ]. Community and clinic-based studies have found a lower rate of severe visual loss of 6 to 14 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41833/abstract/9-11\">",
"     9-11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies have attempted to identify patients at risk of severe permanent vision loss. Significant vision loss at presentation suggests a higher risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41833/abstract/5,9\">",
"     5,9",
"    </a>",
"    ]. Other risk factors more variably identified in studies include male gender, systemic hypertension, anemia, black race, younger age or onset in puberty, more severe obesity or recent weight gain, higher opening pressure on lumbar puncture, and severe papilledema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41833/abstract/5,8,11-15\">",
"     5,8,11-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A recurrence of symptoms may occur in 8 to 38 percent of patients after recovery from an episode of IIH or after a prolonged period of stability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41833/abstract/8,16-18\">",
"     8,16-18",
"    </a>",
"    ]. Weight gain is a common but not universal antecedent to recurrent IIH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41833/abstract/16,19\">",
"     16,19",
"    </a>",
"    ]. The time interval may be as long as several years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41833/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Fulminant IIH",
"    </span>",
"    &nbsp;&mdash;&nbsp;A subset of individuals with IIH have a more malignant or fulminant course with rapid development of vision loss within a few weeks of symptom onset [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41833/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. This is generally apparent at presentation. To limit the severity of permanent vision loss, more aggressive surgical treatment measures are considered at the outset, often with temporizing measures (eg. serial lumbar punctures, lumbar drain,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    corticosteroids) employed until surgery can be performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     GENERAL TREATMENT AND FOLLOW-UP CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of IIH has two major goals: the alleviation of symptoms (usually headache) and the preservation of vision.",
"   </p>",
"   <p>",
"    Patients require regular follow-up visits until they stabilize. Follow-up visit intervals are individualized based on the severity, duration, and response to treatment of the clinical manifestations, but initially should be at least monthly. Each office visit should include a best corrected visual acuity, formal visual field testing, and dilated fundus examination with optic disc photographs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41833/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some patients with normal vision and minimal symptoms require no treatment other than monitoring.",
"   </p>",
"   <p>",
"    Any potential agents that might cause or worsen IIH (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    derivatives) should be discontinued. However, this intervention alone may not be sufficient to manage IIH. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/25/15769?source=see_link&amp;anchor=H5#H5\">",
"     \"Idiopathic intracranial hypertension (pseudotumor cerebri): Epidemiology and pathogenesis\", section on 'Medications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similarly, patients should be questioned regarding symptoms of sleep apnea; diagnostic polysomnography and treatment of sleep apnea should follow where appropriate. The association of sleep apnea and IIH is uncertain, but treatment of sleep apnea has other benefits. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/13/6359?source=see_link\">",
"     \"Overview of obstructive sleep apnea in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     WEIGHT LOSS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A low-sodium weight reduction program is recommended for all obese patients with IIH and appears to alleviate symptoms and signs in many but not all patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41833/abstract/3\">",
"     3",
"    </a>",
"    ]. However, studies documenting benefit are limited to observations in patients who generally receive treatment with other interventions for IIH.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a prospective cohort of 25 obese women with IIH, a low-calorie diet (425",
"      <span class=\"nowrap\">",
"       kcal/day)",
"      </span>",
"      for three months produced significant reductions in weight (mean 15.7 kg), intracranial pressure (mean decline 8.0 cm H",
"      <sub>",
"       2",
"      </sub>",
"      O), and symptom prevalence [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/54/41833/abstract/23\">",
"       23",
"      </a>",
"      ]. Vision outcomes were not reported.",
"     </li>",
"     <li>",
"      One report describes nine patients placed on a salt-restricted, rapid weight reduction rice diet whose mean weight decreased from 261 to 187 pounds [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/54/41833/abstract/24\">",
"       24",
"      </a>",
"      ]. Papilledema improved in all patients, but visual function was not reported.",
"     </li>",
"     <li>",
"      Another retrospective review compared outcomes in 38 women with IIH who had some lost weight (at least 2.5kg) to 20 women with no weight loss [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/54/41833/abstract/25\">",
"       25",
"      </a>",
"      ]. Final outcomes of visual acuity and visual field deficits were similar between groups; however, visual fields and papilledema improved more quickly in the weight loss group.",
"     </li>",
"     <li>",
"      In another case series of 15 patients, a six percent weight loss over 24 weeks was associated with resolution of papilledema in obese IIH patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/54/41833/abstract/26\">",
"       26",
"      </a>",
"      ]. In this series, weight loss, rather than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5752?source=see_link\">",
"       acetazolamide",
"      </a>",
"      treatment, appeared to be temporally associated with improvement.",
"     </li>",
"     <li>",
"      Finally, in a study of nine obese women with IIH and polycystic ovary syndrome, a low calorie, low carbohydrate, high protein diet achieved a median weight loss of 3 percent and improved papilledema in all but one patient [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/54/41833/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Medically supervised weight loss programs or surgically induced weight reduction (eg, gastric banding or gastric bypass procedures) may be necessary in morbidly obese patients. Case series of IIH patients undergoing gastric surgery report improvement of IIH symptoms and signs including papilledema, headache, tinnitus, and cerebrospinal fluid (CSF) pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41833/abstract/28-31\">",
"     28-31",
"    </a>",
"    ]. These findings were observed over one to three years after surgery and were associated with mean weight loss of 45 to 58 kg. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/31/33274?source=see_link\">",
"     \"Surgical management of severe obesity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These uncontrolled observations provide limited support for weight loss as a treatment for IIH. Because weight loss takes some time to achieve, other treatments for IIH are generally required at the same time.",
"   </p>",
"   <p>",
"    Weight gain may be a risk factor for recurrence of IIH. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Prognosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Weight loss also has other health benefits. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/45/13016?source=see_link&amp;anchor=H12#H12\">",
"     \"Overview of therapy for obesity in adults\", section on 'Benefits of weight loss'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     MEDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medical treatments include carbonic anhydrase inhibitors, loop diuretics, and corticosteroids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Carbonic anhydrase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carbonic anhydrase inhibitors are believed to reduce the rate of cerebrospinal fluid production [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41833/abstract/32\">",
"     32",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5752?source=see_link\">",
"     Acetazolamide",
"    </a>",
"    is the usual first line treatment for IIH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41833/abstract/3\">",
"     3",
"    </a>",
"    ]. However, evidence supporting its efficacy is mostly observational. Lowering of CSF pressure with acetazolamide has been documented in IIH patients who underwent continuous ICP recordings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41833/abstract/33\">",
"     33",
"    </a>",
"    ]. Case series suggest that in patients who can tolerate it, acetazolamide is successful in managing symptoms and stabilizing vision in 47 to 67 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41833/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. In addition, in a long-term follow-up study of 54 patients, the average treatment duration for acetazolamide was 14 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41833/abstract/18\">",
"     18",
"    </a>",
"    ]. While recurrent episodes of IIH occurred in 38 percent over a mean 6.2 years of follow-up, no recurrences occurred in the setting of ongoing acetazolamide treatment.",
"   </p>",
"   <p>",
"    In adult patients, we usually start with 500 mg twice per day and advance the dose as required and tolerated by the patient. Although doses of up to 2 to 4 g per day can be administered, many patients develop dose limiting side effects at higher levels. In young children, the recommended starting dose is 25",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day with a maximum dose of 100",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    or 2 g per day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41833/abstract/34\">",
"     34",
"    </a>",
"    ]. The sustained release formulation (Diamox sequels) may be better tolerated by patients who are intolerant of generic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5752?source=see_link\">",
"     acetazolamide",
"    </a>",
"    , but are substantially more expensive.",
"   </p>",
"   <p>",
"    Although a sulfa allergy is reported to be a relative contraindication to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5752?source=see_link\">",
"     acetazolamide",
"    </a>",
"    use, there is little clinical or pharmacologic basis for this recommendation. A true cross-reaction between sulfonamide antimicrobials and the sulfa moiety in acetazolamide and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    is unlikely [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41833/abstract/37\">",
"     37",
"    </a>",
"    ]. Before prescribing acetazolamide to patients who report a sulfa allergy, we discuss the risks and benefits of treatment considering the nature of the adverse reaction comprising the reported sulfa allergy. For patients who have had major adverse reactions (eg, Stevens-Johnson syndrome, anaphylaxis), we usually consider that the risk precludes the use of acetazolamide. Allergy consultation or other desensitization protocols may be considered in these patients, but we have not employed these. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/2/23594?source=see_link\">",
"     \"Sulfonamide allergy in non HIV-infected patients\"",
"    </a>",
"    .) However, if the previous sulfa-related reaction was minor, we usually proceed with acetazolamide treatment. We treated 27 patients who had a reported sulfa allergy (excluding those that reported a severe adverse reaction) with acetazolamide; only two patients suffered urticaria, and there were no severe allergic cross-reactions to sulfa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41833/abstract/37\">",
"     37",
"    </a>",
"    ]. Another case series documents uneventful administration of acetazolamide to three patients with reported sulfa allergy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41833/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other medication side effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5752?source=see_link\">",
"     acetazolamide",
"    </a>",
"    include digital and oral paresthesias, anorexia, malaise, metallic taste, fatigue, nausea, vomiting, electrolyte changes, mild metabolic acidosis, and kidney stones. These are usually dose-related. Monitoring of electrolytes is suggested during acetazolamide treatment.",
"   </p>",
"   <p>",
"    Pregnancy, particularly the first 20 weeks, is often considered a relative contraindication to the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5752?source=see_link\">",
"     acetazolamide",
"    </a>",
"    , which is classified by the FDA as category C for pregnancy risk (",
"    <a class=\"graphic graphic_table graphicRef50021 \" href=\"mobipreview.htm?16/42/17068\">",
"     table 1",
"    </a>",
"    ). Teratogenic effects have been reported with high doses in animals and a single case of a teratoma was seen in humans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41833/abstract/6,39\">",
"     6,39",
"    </a>",
"    ]. If we consider that the benefit of acetazolamide use outweighs potential risks, we do use it in pregnant women after discussion with the patient and the obstetrician and obtaining informed consent. Treatment options are somewhat limited in pregnancy as caloric restriction and the use of other diuretics are also relatively contraindicated during pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41833/abstract/40-42\">",
"     40-42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"     Topiramate",
"    </a>",
"    is an antiepileptic drug that inhibits carbonic anhydrase activity. Its efficacy in the treatment of migraine headaches and its association with weight loss are features that make it an attractive potential therapeutic option in IIH. Case reports and one small unblinded study suggest that topiramate appears to have a similar efficacy to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5752?source=see_link\">",
"     acetazolamide",
"    </a>",
"    with regard to visual field improvement and symptom relief [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41833/abstract/43-47\">",
"     43-47",
"    </a>",
"    ]. However, further study is needed before this can be considered a first-line treatment for IIH.",
"   </p>",
"   <p>",
"    Other carbonic anhydrase inhibitors, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/43/41652?source=see_link\">",
"     methazolamide",
"    </a>",
"    (Neptazane), can also be used in",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5752?source=see_link\">",
"     acetazolamide",
"    </a>",
"    -intolerant patients. We occasionally have had apparent success with these agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Loop diuretics",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/52/28488?source=see_link\">",
"     Furosemide",
"    </a>",
"    (20 to 40 mg per day for adults and 1 to 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in children) may be a useful adjunctive therapy to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5752?source=see_link\">",
"     acetazolamide",
"    </a>",
"    in IIH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41833/abstract/34\">",
"     34",
"    </a>",
"    ]. In one report of eight children treated with combined therapy of acetazolamide and furosemide, all had a rapid clinical response with resolution of papilledema, reduction in the mean CSF pressure after the first week of treatment, and normalization of CSF pressure within six weeks of starting therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41833/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The same considerations discussed above regarding sulfa allergy and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5752?source=see_link\">",
"     acetazolamide",
"    </a>",
"    also apply to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    . We, after discussion of risk and benefits with patients, use furosemide in patients whose prior reactions have not included Stevens Johnson syndrome, anaphylaxis, or other severe reactions. Among 21 such patients treated with furosemide, no allergic reactions were noted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41833/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Corticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although corticosteroids (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ) have been recommended in the past for IIH, we avoid the use of corticosteroids in IIH for the following reasons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41833/abstract/49\">",
"     49",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Corticosteroids can cause weight gain that might worsen IIH.",
"     </li>",
"     <li>",
"      Steroid withdrawal can cause severe rebound intracranial hypertension associated with marked visual loss.",
"     </li>",
"     <li>",
"      There are significant systemic side effects from chronic corticosteroids. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=see_link\">",
"       \"Major side effects of systemic glucocorticoids\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the setting of acute visual loss, a short course of intravenous corticosteroids may be useful as a temporizing measure prior to surgical intervention in IIH. One case series describes successful use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    (250 mg four times a day for five days followed by an oral taper) in conjunction with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5752?source=see_link\">",
"     acetazolamide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/56/42888?source=see_link\">",
"     ranitidine",
"    </a>",
"    in four patients with IIH and severe, acute visual loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41833/abstract/21\">",
"     21",
"    </a>",
"    ]. We and others suggest not using corticosteroids for long-term management of IIH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41833/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Other treatments",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some reports suggest that",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/50/36649?source=see_link\">",
"       indomethacin",
"      </a>",
"      may have efficacy in the treatment of secondary intracranial hypertension (eg, traumatic brain injury, hepatic encephalopathy) presumably by causing cerebral vasoconstriction and reducing cerebral blood flow [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/54/41833/abstract/51\">",
"       51",
"      </a>",
"      ]. In one report of seven patients with IIH, intravenous administration of 50 mg indomethacin was associated with prompt reduction in CSF pressure, and long-term treatment with 75 mg daily produced symptom relief, and improvement in visual fields and papilledema grade [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/54/41833/abstract/52\">",
"       52",
"      </a>",
"      ]. Further study of this treatment is needed before it can be recommended for use in IIH.",
"     </li>",
"     <li>",
"      Iron supplementation in IIH patients with iron deficiency anemia appeared to be efficacious in a case series of six patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/54/41833/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Headache prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with IIH can continue to have headaches despite improvement in papilledema and visual function. Medications used in the prophylactic treatment of migraine headaches are often used for headache management in IIH, if other treatments described above are not effective in this regard [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41833/abstract/54\">",
"     54",
"    </a>",
"    ]. The choice of agent is influenced by the propensity of some of these medications (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    , tricyclic antidepressants) to produce weight gain. If these medications are employed, careful monitoring of weight is recommended. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/56/42889?source=see_link\">",
"     \"Preventive treatment of migraine in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Analgesic overuse or rebound headaches may be common in patients with IIH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41833/abstract/54-56\">",
"     54-56",
"    </a>",
"    ]. Efforts should be made to avoid and treat this condition. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/34/3624?source=see_link&amp;anchor=H8#H8\">",
"     \"Headache syndromes other than migraine\", section on 'Medication overuse headache'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SERIAL LUMBAR PUNCTURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although serial lumbar punctures have been advocated for the treatment of IIH, we do not generally recommend this treatment for the following reasons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41833/abstract/57\">",
"     57",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CSF reforms within six hours unless there is a CSF leak, making any treatment benefit of short-term duration only.",
"     </li>",
"     <li>",
"      Lumbar punctures are uncomfortable for most patients and painful for many.",
"     </li>",
"     <li>",
"      Lumbar punctures can produce complications (eg, low pressure headaches, CSF leak, CSF infection, intraspinal epidermoid tumors).",
"     </li>",
"     <li>",
"      In obese patients, lumbar punctures are often technically difficult.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, serial lumbar punctures can be a useful temporizing measure as a prelude to surgery or in patients who are pregnant who wish to avoid medical therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41833/abstract/41,42,58\">",
"     41,42,58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with IIH who fail, are intolerant to, or are non-compliant with maximum medical therapy and have intractable headache or progressive visual loss appear to benefit from surgical intervention. Potential indications for surgical therapy include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41833/abstract/49\">",
"     49",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Worsening visual field defect despite medical therapy.",
"     </li>",
"     <li>",
"      Presence of visual acuity loss attributed to papilledema (ie, not due to serous detachment, macular edema, hemorrhage, or choroidal folds).",
"     </li>",
"     <li>",
"      Intractable headache.",
"     </li>",
"     <li>",
"      Anticipated hypotension (blood pressure treatment, renal dialysis). In theory, these might precipitate ischemic optic neuropathy in a disc that is swollen. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/61/20442?source=see_link\">",
"       \"Nonarteritic anterior ischemic optic neuropathy: Epidemiology, pathogenesis, and etiologies\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients unable to participate in follow-up examinations (eg, noncompliance, impaired cognition, itinerant lifestyle).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While deteriorating vision (as suggested by an abnormal visual acuity or worsening visual field deficits) is a universally accepted indication for surgical intervention, other potential considerations need to be balanced against the inherent risks of the surgical procedures and the uncertainties regarding their efficacy.",
"   </p>",
"   <p>",
"    The two main surgical procedures in IIH are CSF shunting procedures and optic nerve sheath fenestration. While not a surgical procedure per se, venous stenting will also be discussed in this section as an invasive treatment option for IIH. These treatments have not been compared in a single population. Indirect comparisons of their efficacy in case series are challenged by different indications considered for intervention and different outcome measures used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Shunting",
"    </span>",
"    &nbsp;&mdash;&nbsp;CSF shunting procedures include ventriculoperitoneal (VPS) or lumboperitoneal shunt (LPS). Uncontrolled observations report that these can relieve headache, diplopia, papilledema, and visual loss in patients with IIH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41833/abstract/3,59-64\">",
"     3,59-64",
"    </a>",
"    ]. However, reported outcomes are mixed, some report that 95 to 100 percent achieve stabilization or remission of visual problems [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41833/abstract/59-62,65\">",
"     59-62,65",
"    </a>",
"    ], while others note that vision continued to worsen in up to 32 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41833/abstract/63\">",
"     63",
"    </a>",
"    ]. While headache relief appeared to occur in almost all patients soon after shunting, in one case series, the benefit was not universally sustained, with nearly half of patients having recurrent severe headaches within three years of surgery, despite a working shunt [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41833/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, the rate of complications from shunting is high. Shunt failure requiring revision is the most common complication of lumboperitoneal shunts and occurs in 48 to 86 percent of patients, with a few patients requiring multiple (10 to 38) shunt revisions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41833/abstract/59-63,66\">",
"     59-63,66",
"    </a>",
"    ]. In rare cases, shunt failure is accompanied by visual loss that can be rapid and severe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41833/abstract/67\">",
"     67",
"    </a>",
"    ]. Other common complications include shunt infection, abdominal pain, back pain, radicular pain, operative complications, and cerebrospinal fluid leak with low pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41833/abstract/59-63,68,69\">",
"     59-63,68,69",
"    </a>",
"    ]. Rare complications include cerebellar tonsillar herniation and syringomyelia, subdural and subarachnoid hemorrhage, and bowel perforation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41833/abstract/68,70,71\">",
"     68,70,71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    More recently developed technologies using advanced imaging as well as endoscopic operative techniques have improved the ability of surgeons to place catheters in the ventricles of patients with IIH who do not have ventricular enlargement. Case series suggested that ventriculoperitoneal catheters may be less prone to shunt obstruction than lumboperitoneal shunts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41833/abstract/66,72-74\">",
"     66,72-74",
"    </a>",
"    ]. However, the risks for low pressure, infections, and other complications were similar to lumboperitoneal shunts and requirements for shunt revision remained substantial at 40 to 60 percent.",
"   </p>",
"   <p>",
"    We consider shunting with caution in IIH. However, it remains an option for patients who have failed other treatment approaches. Some patients who don't respond to optic nerve fenestration have been reported to have a clinical response to shunting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41833/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Optic nerve sheath fenestration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optic nerve sheath fenestration (ONSF) can stabilize or improve visual loss due to papilledema in IIH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41833/abstract/3,76-87\">",
"     3,76-87",
"    </a>",
"    ]. There is more extensive documentation of the benefit on visual function for ONSF as compared to shunting and venous stenting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41833/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one of the largest published case series summarizing 158 operations in 86 patients, visual acuity stabilized or improved in 94 percent, while visual fields stabilized or improved in 88 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41833/abstract/87\">",
"     87",
"    </a>",
"    ]. These results are consistent with aggregated data from other smaller case series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41833/abstract/65,76-80,83-86\">",
"     65,76-80,83-86",
"    </a>",
"    ]. Patients with a less severe and a shorter duration of visual abnormality have better visual outcomes after ONSF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41833/abstract/88,89\">",
"     88,89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Preservation of vision is the primary goal of ONSF. While some patients experience headache relief after ONSF, many do not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41833/abstract/76,87\">",
"     76,87",
"    </a>",
"    ]. ONSF has been associated with improvement in patients with deteriorating vision loss despite a working shunt [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41833/abstract/81,83,87\">",
"     81,83,87",
"    </a>",
"    ]. ONSF also appears to be safe and effective in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41833/abstract/82,90\">",
"     82,90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Complications of ONSF occur in as many as 40 to 45 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41833/abstract/85,87,91,92\">",
"     85,87,91,92",
"    </a>",
"    ]. Most, but not all, of these are transient and nondisabling. The more common complications include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Temporary diplopia (due to extraocular muscle injury or to their nerve or blood supply) in 29 to 35 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/54/41833/abstract/77,85,87\">",
"       77,85,87",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pupillary dysfunction in up to 11 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/54/41833/abstract/77,85,87,89\">",
"       77,85,87,89",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Vision loss in up to 11 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/54/41833/abstract/85\">",
"       85",
"      </a>",
"      ]. This is usually transient, but can be catastrophic and permanent in 1.5 to 2.6 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/54/41833/abstract/83,85\">",
"       83,85",
"      </a>",
"      ]. Vision loss can result from vascular complications (central retinal or branch artery occlusion, choroidal infarction), trauma (eg, operative traction), infectious optic neuritis, orbital hematoma, hemorrhage into the optic nerve sheath causing compressive hematoma, and other operative events [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/54/41833/abstract/75,80,87,89,91,92\">",
"       75,80,87,89,91,92",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    ONSF may fail after initial benefit, requiring repeat surgery in 7 to 32 percent of eyes, depending in part on the duration of follow-up; failure may occur within months or after several years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41833/abstract/79,84,87\">",
"     79,84,87",
"    </a>",
"    ]. Repeat surgery appears to have a similar benefit to the original [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41833/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ONSF appears to be an effective procedure in patients who fail medical therapy and in our experience is preferable to CSF shunting for patients experiencing progressive vision loss.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Venous stenting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Venous stenting is a new and somewhat controversial treatment option for IIH. Its use results from the observation that many patients with IIH have apparent stenoses of the transverse venous sinus or other cerebral veins; although whether this is a primary or secondary phenomenon is uncertain. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/25/15769?source=see_link&amp;anchor=H8#H8\">",
"     \"Idiopathic intracranial hypertension (pseudotumor cerebri): Epidemiology and pathogenesis\", section on 'Intracranial venous hypertension'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Three case series describe three centers' experience with venous stenting in patients with IIH who had apparent venous sinus obstruction on cerebral venography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41833/abstract/93-95\">",
"     93-95",
"    </a>",
"    ]. The effects on vision were not consistently documented and follow-up was often limited. Some patients had had prior ONSF",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    shunting. The benefit was described as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among four patients treated with venous stent in the transverse sinus, all had immediate and sustained relief of headache and normalization of CSF pressures [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/54/41833/abstract/93\">",
"       93",
"      </a>",
"      ]. Vision reportedly improved or remained normal in three and remained poor in one.",
"     </li>",
"     <li>",
"      Among 12 treated patients, five were cured of their headache, two substantially relieved, and five had no improvement after 2 to 26 months of follow-up [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/54/41833/abstract/94\">",
"       94",
"      </a>",
"      ]. Papilledema did not universally resolve.",
"     </li>",
"     <li>",
"      Among 10 treated patients, six were cured of their headache, two improved, and two were unchanged after 6 to 36 months of follow-up [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/54/41833/abstract/95\">",
"       95",
"      </a>",
"      ]. In all 10 patients, CSF pressure normalized and papilledema disappeared. Visual acuity improved in seven patients, remained normal in two patients, and remained abnormal and unchanged in one.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There were no significant complications in any of these patients, although transient post procedure symptoms (headache lateralized to treated side, partial hearing loss, unsteadiness) were common. Also, two patients were treated with thrombolytic therapy when an intraluminal thrombus was noted to develop postoperatively, despite anticoagulation treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41833/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We and others feel that further documentation of clinical benefit from venous stenting is required before this becomes a routine part of IIH treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/54/41833/abstract/3,96\">",
"     3,96",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?37/51/38706?source=see_link\">",
"       \"Patient information: Idiopathic intracranial hypertension (pseudotumor cerebri) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major morbidity associated with IIH is loss of vision, although persistent headaches are also a source of disability and lost quality of life. Treatment recommendations for IIH are based on uncontrolled observations. There are no clinical trials that have documented the effects of treatments in IIH.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      While the natural history of IIH is not known, as many as 25 percent of individuals may be at risk of severe, permanent vision loss. Symptoms usually wax and wane for several weeks, months, and even years; however, a more fulminant course with rapid vision loss is described in a minority. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients require regular follow-up visits with serial examinations including visual acuity, formal visual field testing and a dilated fundus examination with optic disc photographs until they stabilize. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'General treatment and follow-up considerations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Potential agents that might cause or worsen IIH (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"       tetracycline",
"      </a>",
"      derivatives) should be discontinued, and treatment provided for comorbid sleep apnea and anemia if present. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'General treatment and follow-up considerations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Other treatments'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend counseling",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      treatment for weight loss in all obese patients with IIH. While the reported benefit for IIH is anecdotal, weight loss is associated with other health benefits. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Weight loss'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/45/13016?source=see_link\">",
"       \"Overview of therapy for obesity in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest the use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5752?source=see_link\">",
"       acetazolamide",
"      </a>",
"      as the initial treatment of patients with IIH (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). While there is little documented efficacy of acetazolamide in IIH, it has a long history of use in patients with IIH, as well as a documented CSF-pressure lowering effect, and little serious toxicity in patients without a history of significant sulfa allergy.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"       Topiramate",
"      </a>",
"      and other carbonic anhydrase inhibitors are alternatives to acetazolamide; experience with these agents is more limited. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Carbonic anhydrase inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/52/28488?source=see_link\">",
"       Furosemide",
"      </a>",
"      or other diuretics may provide an additional benefit to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5752?source=see_link\">",
"       acetazolamide",
"      </a>",
"      in patients who experience continuing symptoms on acetazolamide. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Loop diuretics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Traditional headache therapies can be employed in symptomatic IIH patients. Analgesic rebound headache in particular is a common complication in IIH and should be prevented and treated as appropriate. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Headache prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend against prolonged corticosteroid treatment for treatment of IIH (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We also suggest not using serial lumbar punctures as a primary treatment modality for IIH (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). However, both short-term use of corticosteroids and serial lumbar punctures have been successfully used as short term temporizing measures in patients with rapidly progressive symptoms who are waiting more definitive surgical therapy. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Corticosteroids'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Serial lumbar punctures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with progressing visual loss, we recommend surgical intervention with optic nerve sheath fenestration (ONSF)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a CSF shunting procedure (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). The choice of surgical procedure is individualized based upon available expertise and patient preference. We prefer ONSF rather than shunting for most patients because of better documentation of efficacy and a lower rate of severe side effects. However, headache response may be superior with shunting. Patients who do not respond to one treatment, may respond to the other. Neither intervention is a panacea; serious complications may occur, and failure rates and symptom recurrence are common, requiring long-term follow-up of all patients. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/1\">",
"      Friedman DI, Jacobson DM. Diagnostic criteria for idiopathic intracranial hypertension. Neurology 2002; 59:1492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/2\">",
"      Lueck C, McIlwaine G. Interventions for idiopathic intracranial hypertension. Cochrane Database Syst Rev 2005; :CD003434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/3\">",
"      Biousse V, Bruce BB, Newman NJ. Update on the pathophysiology and management of idiopathic intracranial hypertension. J Neurol Neurosurg Psychiatry 2012; 83:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/4\">",
"      Celebisoy N, Se&ccedil;il Y, Aky&uuml;rekli O. Pseudotumor cerebri: etiological factors, presenting features and prognosis in the western part of Turkey. Acta Neurol Scand 2002; 106:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/5\">",
"      Wall M. Sensory visual testing in idiopathic intracranial hypertension: measures sensitive to change. Neurology 1990; 40:1859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/6\">",
"      Acheson JF. Idiopathic intracranial hypertension and visual function. Br Med Bull 2006; 79-80:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/7\">",
"      Salman MS, Kirkham FJ, MacGregor DL. Idiopathic \"benign\" intracranial hypertension: case series and review. J Child Neurol 2001; 16:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/8\">",
"      Corbett JJ, Savino PJ, Thompson HS, et al. Visual loss in pseudotumor cerebri. Follow-up of 57 patients from five to 41 years and a profile of 14 patients with permanent severe visual loss. Arch Neurol 1982; 39:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/9\">",
"      Rowe FJ, Sarkies NJ. Visual outcome in a prospective study of idiopathic intracranial hypertension. Arch Ophthalmol 1999; 117:1571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/10\">",
"      Radhakrishnan K, Ahlskog JE, Cross SA, et al. Idiopathic intracranial hypertension (pseudotumor cerebri). Descriptive epidemiology in Rochester, Minn, 1976 to 1990. Arch Neurol 1993; 50:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/11\">",
"      Bruce BB, Preechawat P, Newman NJ, et al. Racial differences in idiopathic intracranial hypertension. Neurology 2008; 70:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/12\">",
"      Wall M, George D. Idiopathic intracranial hypertension. A prospective study of 50 patients. Brain 1991; 114 ( Pt 1A):155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/13\">",
"      Stiebel-Kalish H, Kalish Y, Lusky M, et al. Puberty as a risk factor for less favorable visual outcome in idiopathic intracranial hypertension. Am J Ophthalmol 2006; 142:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/14\">",
"      Bruce BB, Kedar S, Van Stavern GP, et al. Idiopathic intracranial hypertension in men. Neurology 2009; 72:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/15\">",
"      Bruce BB, Kedar S, Van Stavern GP, et al. Atypical idiopathic intracranial hypertension: normal BMI and older patients. Neurology 2010; 74:1827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/16\">",
"      Taktakishvili O, Shah VA, Shahbaz R, Lee AG. Recurrent idiopathic intracranial hypertension. Ophthalmology 2008; 115:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/17\">",
"      Shah VA, Kardon RH, Lee AG, et al. Long-term follow-up of idiopathic intracranial hypertension: the Iowa experience. Neurology 2008; 70:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/18\">",
"      Kesler A, Hadayer A, Goldhammer Y, et al. Idiopathic intracranial hypertension: risk of recurrences. Neurology 2004; 63:1737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/19\">",
"      Ko MW, Chang SC, Ridha MA, et al. Weight gain and recurrence in idiopathic intracranial hypertension: a case-control study. Neurology 2011; 76:1564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/20\">",
"      Thambisetty M, Lavin PJ, Newman NJ, Biousse V. Fulminant idiopathic intracranial hypertension. Neurology 2007; 68:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/21\">",
"      Liu GT, Glaser JS, Schatz NJ. High-dose methylprednisolone and acetazolamide for visual loss in pseudotumor cerebri. Am J Ophthalmol 1994; 118:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/22\">",
"      Kidron D, Pomeranz S. Malignant pseudotumor cerebri. Report of two cases. J Neurosurg 1989; 71:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/23\">",
"      Sinclair AJ, Burdon MA, Nightingale PG, et al. Low energy diet and intracranial pressure in women with idiopathic intracranial hypertension: prospective cohort study. BMJ 2010; 341:c2701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/24\">",
"      Newborg B. Pseudotumor cerebri treated by rice reduction diet. Arch Intern Med 1974; 133:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/25\">",
"      Kupersmith MJ, Gamell L, Turbin R, et al. Effects of weight loss on the course of idiopathic intracranial hypertension in women. Neurology 1998; 50:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/26\">",
"      Johnson LN, Krohel GB, Madsen RW, March GA Jr. The role of weight loss and acetazolamide in the treatment of idiopathic intracranial hypertension (pseudotumor cerebri). Ophthalmology 1998; 105:2313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/27\">",
"      Glueck CJ, Golnik KC, Aregawi D, et al. Changes in weight, papilledema, headache, visual field, and life status in response to diet and metformin in women with idiopathic intracranial hypertension with and without concurrent polycystic ovary syndrome or hyperinsulinemia. Transl Res 2006; 148:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/28\">",
"      Sugerman HJ, Felton WL 3rd, Salvant JB Jr, et al. Effects of surgically induced weight loss on idiopathic intracranial hypertension in morbid obesity. Neurology 1995; 45:1655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/29\">",
"      Sugerman HJ, Felton WL 3rd, Sismanis A, et al. Gastric surgery for pseudotumor cerebri associated with severe obesity. Ann Surg 1999; 229:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/30\">",
"      Chandra V, Dutta S, Albanese CT, et al. Clinical resolution of severely symptomatic pseudotumor cerebri after gastric bypass in an adolescent. Surg Obes Relat Dis 2007; 3:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/31\">",
"      Nadkarni T, Rekate HL, Wallace D. Resolution of pseudotumor cerebri after bariatric surgery for related obesity. Case report. J Neurosurg 2004; 101:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/32\">",
"      McCarthy KD, Reed DJ. The effect of acetazolamide and furosemide on cerebrospinal fluid production and choroid plexus carbonic anhydrase activity. J Pharmacol Exp Ther 1974; 189:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/33\">",
"      G&uuml;cer G, Viernstein L. Long-term intracranial pressure recording in the management of pseudotumor cerebri. J Neurosurg 1978; 49:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/34\">",
"      Matthews YY. Drugs used in childhood idiopathic or benign intracranial hypertension. Arch Dis Child Educ Pract Ed 2008; 93:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/35\">",
"      Youroukos S, Psychou F, Fryssiras S, et al. Idiopathic intracranial hypertension in children. J Child Neurol 2000; 15:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/36\">",
"      Warman R. Management of pseudotumor cerebri in children. Int Pediatr 2000; 15:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/37\">",
"      Lee AG, Anderson R, Kardon RH, Wall M. Presumed \"sulfa allergy\" in patients with intracranial hypertension treated with acetazolamide or furosemide: cross-reactivity, myth or reality? Am J Ophthalmol 2004; 138:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/38\">",
"      Platt D, Griggs RC. Use of acetazolamide in sulfonamide-allergic patients with neurologic channelopathies. Arch Neurol 2012; 69:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/39\">",
"      Lee AG, Pless M, Falardeau J, et al. The use of acetazolamide in idiopathic intracranial hypertension during pregnancy. Am J Ophthalmol 2005; 139:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/40\">",
"      Digre KB, Corbett JJ. Pseudotumor cerebri in men. Arch Neurol 1988; 45:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/41\">",
"      Huna-Baron R, Kupersmith MJ. Idiopathic intracranial hypertension in pregnancy. J Neurol 2002; 249:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/42\">",
"      Digre KB, Varner MW, Corbett JJ. Pseudotumor cerebri and pregnancy. Neurology 1984; 34:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/43\">",
"      Celebisoy N, G&ouml;k&ccedil;ay F, Sirin H, Aky&uuml;rekli O. Treatment of idiopathic intracranial hypertension: topiramate vs acetazolamide, an open-label study. Acta Neurol Scand 2007; 116:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/44\">",
"      Pagan FL, Restrepo L, Balish M, et al. A new drug for an old condition? Headache 2002; 42:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/45\">",
"      Shah VA, Fung S, Shahbaz R, et al. Idiopathic intracranial hypertension. Ophthalmology 2007; 114:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/46\">",
"      Friedman, DI, Eller, PF. Topiramate for the treatment of idiopathic intracranial hypertension. Headache 2003; 43:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/47\">",
"      Finsterer J, F&ouml;ldy D, Fertl E. Topiramate resolves headache from pseudotumor cerebri. J Pain Symptom Manage 2006; 32:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/48\">",
"      Schoeman JF. Childhood pseudotumor cerebri: clinical and intracranial pressure response to acetazolamide and furosemide treatment in a case series. J Child Neurol 1994; 9:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/49\">",
"      Corbett JJ, Thompson HS. The rational management of idiopathic intracranial hypertension. Arch Neurol 1989; 46:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/50\">",
"      Friedman DI, Jacobson DM. Idiopathic intracranial hypertension. J Neuroophthalmol 2004; 24:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/51\">",
"      Rasmussen M. Treatment of elevated intracranial pressure with indomethacin: friend or foe? Acta Anaesthesiol Scand 2005; 49:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/52\">",
"      F&ouml;rderreuther S, Straube A. Indomethacin reduces CSF pressure in intracranial hypertension. Neurology 2000; 55:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/53\">",
"      Biousse V, Rucker JC, Vignal C, et al. Anemia and papilledema. Am J Ophthalmol 2003; 135:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/54\">",
"      Friedman DI, Rausch EA. Headache diagnoses in patients with treated idiopathic intracranial hypertension. Neurology 2002; 58:1551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/55\">",
"      Wang SJ, Silberstein SD, Patterson S, Young WB. Idiopathic intracranial hypertension without papilledema: a case-control study in a headache center. Neurology 1998; 51:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/56\">",
"      Mathew NT, Ravishankar K, Sanin LC. Coexistence of migraine and idiopathic intracranial hypertension without papilledema. Neurology 1996; 46:1226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/57\">",
"      Corbett JJ, Mehta MP. Cerebrospinal fluid pressure in normal obese subjects and patients with pseudotumor cerebri. Neurology 1983; 33:1386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/58\">",
"      Evans RW, Friedman DI. Expert opinion: the management of pseudotumor cerebri during pregnancy. Headache 2000; 40:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/59\">",
"      Burgett RA, Purvin VA, Kawasaki A. Lumboperitoneal shunting for pseudotumor cerebri. Neurology 1997; 49:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/60\">",
"      Eggenberger ER, Miller NR, Vitale S. Lumboperitoneal shunt for the treatment of pseudotumor cerebri. Neurology 1996; 46:1524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/61\">",
"      Johnston I, Besser M, Morgan MK. Cerebrospinal fluid diversion in the treatment of benign intracranial hypertension. J Neurosurg 1988; 69:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/62\">",
"      Chumas PD, Kulkarni AV, Drake JM, et al. Lumboperitoneal shunting: a retrospective study in the pediatric population. Neurosurgery 1993; 32:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/63\">",
"      Rosenberg ML, Corbett JJ, Smith C, et al. Cerebrospinal fluid diversion procedures in pseudotumor cerebri. Neurology 1993; 43:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/64\">",
"      Lundar T, Nornes H. Pseudotumour cerebri-neurosurgical considerations. Acta Neurochir Suppl (Wien) 1990; 51:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/65\">",
"      Feldon SE. Visual outcomes comparing surgical techniques for management of severe idiopathic intracranial hypertension. Neurosurg Focus 2007; 23:E6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/66\">",
"      McGirt MJ, Woodworth G, Thomas G, et al. Cerebrospinal fluid shunt placement for pseudotumor cerebri-associated intractable headache: predictors of treatment response and an analysis of long-term outcomes. J Neurosurg 2004; 101:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/67\">",
"      Liu GT, Volpe NJ, Schatz NJ, et al. Severe sudden visual loss caused by pseudotumor cerebri and lumboperitoneal shunt failure. Am J Ophthalmol 1996; 122:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/68\">",
"      Chumas PD, Armstrong DC, Drake JM, et al. Tonsillar herniation: the rule rather than the exception after lumboperitoneal shunting in the pediatric population. J Neurosurg 1993; 78:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/69\">",
"      Sell JJ, Rupp FW, Orrison WW Jr. Iatrogenically induced intracranial hypotension syndrome. AJR Am J Roentgenol 1995; 165:1513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/70\">",
"      Padmanabhan R, Crompton D, Burn D, Birchall D. Acquired Chiari 1 malformation and syringomyelia following lumboperitoneal shunting for pseudotumour cerebri. J Neurol Neurosurg Psychiatry 2005; 76:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/71\">",
"      Suri A, Pandey P, Mehta VS. Subarachnoid hemorrhage and intracereebral hematoma following lumboperitoneal shunt for pseudotumor cerebri: a rare complication. Neurol India 2002; 50:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/72\">",
"      Bynke G, Zemack G, Bynke H, Romner B. Ventriculoperitoneal shunting for idiopathic intracranial hypertension. Neurology 2004; 63:1314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/73\">",
"      Maher CO, Garrity JA, Meyer FB. Refractory idiopathic intracranial hypertension treated with stereotactically planned ventriculoperitoneal shunt placement. Neurosurg Focus 2001; 10:E1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/74\">",
"      Woodworth GF, McGirt MJ, Elfert P, et al. Frameless stereotactic ventricular shunt placement for idiopathic intracranial hypertension. Stereotact Funct Neurosurg 2005; 83:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/75\">",
"      Mauriello JA Jr, Shaderowfsky P, Gizzi M, Frohman L. Management of visual loss after optic nerve sheath decompression in patients with pseudotumor cerebri. Ophthalmology 1995; 102:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/76\">",
"      Acheson JF, Green WT, Sanders MD. Optic nerve sheath decompression for the treatment of visual failure in chronic raised intracranial pressure. J Neurol Neurosurg Psychiatry 1994; 57:1426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/77\">",
"      Brourman ND, Spoor TC, Ramocki JM. Optic nerve sheath decompression for pseudotumor cerebri. Arch Ophthalmol 1988; 106:1378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/78\">",
"      Corbett JJ, Nerad JA, Tse DT, Anderson RL. Results of optic nerve sheath fenestration for pseudotumor cerebri. The lateral orbitotomy approach. Arch Ophthalmol 1988; 106:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/79\">",
"      Goh KY, Schatz NJ, Glaser JS. Optic nerve sheath fenestration for pseudotumor cerebri. J Neuroophthalmol 1997; 17:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/80\">",
"      Kelman SE, Heaps R, Wolf A, Elman MJ. Optic nerve decompression surgery improves visual function in patients with pseudotumor cerebri. Neurosurgery 1992; 30:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/81\">",
"      Kelman SE, Sergott RC, Cioffi GA, et al. Modified optic nerve decompression in patients with functioning lumboperitoneal shunts and progressive visual loss. Ophthalmology 1991; 98:1449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/82\">",
"      Lee AG, Patrinely JR, Edmond JC. Optic nerve sheath decompression in pediatric pseudotumor cerebri. Ophthalmic Surg Lasers 1998; 29:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/83\">",
"      Sergott RC, Savino PJ, Bosley TM. Modified optic nerve sheath decompression provides long-term visual improvement for pseudotumor cerebri. Arch Ophthalmol 1988; 106:1384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/84\">",
"      Spoor TC, McHenry JG. Long-term effectiveness of optic nerve sheath decompression for pseudotumor cerebri. Arch Ophthalmol 1993; 111:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/85\">",
"      Plotnik JL, Kosmorsky GS. Operative complications of optic nerve sheath decompression. Ophthalmology 1993; 100:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/86\">",
"      Hupp SL, Glaser JS, Frazier-Byrne S. Optic nerve sheath decompression. Review of 17 cases. Arch Ophthalmol 1987; 105:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/87\">",
"      Banta JT, Farris BK. Pseudotumor cerebri and optic nerve sheath decompression. Ophthalmology 2000; 107:1907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/88\">",
"      Spoor TC, Ramocki JM, Madion MP, Wilkinson MJ. Treatment of pseudotumor cerebri by primary and secondary optic nerve sheath decompression. Am J Ophthalmol 1991; 112:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/89\">",
"      Chandrasekaran S, McCluskey P, Minassian D, Assaad N. Visual outcomes for optic nerve sheath fenestration in pseudotumour cerebri and related conditions. Clin Experiment Ophthalmol 2006; 34:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/90\">",
"      Thuente DD, Buckley EG. Pediatric optic nerve sheath decompression. Ophthalmology 2005; 112:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/91\">",
"      Brodsky MC, Rettele GA. Protracted postsurgical blindness with visual recovery following optic nerve sheath fenestration. Arch Ophthalmol 1997; 115:1473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/92\">",
"      Rizzo JF 3rd, Lessell S. Choroidal infarction after optic nerve sheath fenestration. Ophthalmology 1994; 101:1622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/93\">",
"      Owler BK, Parker G, Halmagyi GM, et al. Pseudotumor cerebri syndrome: venous sinus obstruction and its treatment with stent placement. J Neurosurg 2003; 98:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/94\">",
"      Higgins JN, Cousins C, Owler BK, et al. Idiopathic intracranial hypertension: 12 cases treated by venous sinus stenting. J Neurol Neurosurg Psychiatry 2003; 74:1662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/95\">",
"      Donnet A, Metellus P, Levrier O, et al. Endovascular treatment of idiopathic intracranial hypertension: clinical and radiologic outcome of 10 consecutive patients. Neurology 2008; 70:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/54/41833/abstract/96\">",
"      Friedman DI. Cerebral venous pressure, intra-abdominal pressure, and dural venous sinus stenting in idiopathic intracranial hypertension. J Neuroophthalmol 2006; 26:61.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5253 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-2ED33AB258-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_54_41833=[""].join("\n");
var outline_f40_54_41833=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Fulminant IIH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      GENERAL TREATMENT AND FOLLOW-UP CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      WEIGHT LOSS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      MEDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Carbonic anhydrase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Loop diuretics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Other treatments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Headache prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SERIAL LUMBAR PUNCTURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SURGERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Shunting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Optic nerve sheath fenestration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Venous stenting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5253\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5253|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\" title=\"table 1\">",
"      Drug ratings in pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/34/3624?source=related_link\">",
"      Headache syndromes other than migraine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/0/17417?source=related_link\">",
"      Idiopathic intracranial hypertension (pseudotumor cerebri): Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/25/15769?source=related_link\">",
"      Idiopathic intracranial hypertension (pseudotumor cerebri): Epidemiology and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/61/20442?source=related_link\">",
"      Nonarteritic anterior ischemic optic neuropathy: Epidemiology, pathogenesis, and etiologies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/13/6359?source=related_link\">",
"      Overview of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/45/13016?source=related_link\">",
"      Overview of therapy for obesity in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?37/51/38706?source=related_link\">",
"      Patient information: Idiopathic intracranial hypertension (pseudotumor cerebri) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/56/42889?source=related_link\">",
"      Preventive treatment of migraine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/2/23594?source=related_link\">",
"      Sulfonamide allergy in non HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/31/33274?source=related_link\">",
"      Surgical management of severe obesity",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_54_41834="Pulmonary histiocytosis X Low";
var content_f40_54_41834=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F52774%7EPULM%2F71884%7EPULM%2F51661&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F52774%7EPULM%2F71884%7EPULM%2F51661&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pulmonary Langerhans cell histiocytosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 411px; height: 273px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power photomicrograph shows both nodular (long arrow) and stellate (short arrow) lesions.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Colby, TV, Koss, MN, Travis, WD. Tumors of the Lower Respiratory Tract. Armed Forces Institute of Pathology, Washington, DC.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pulmonary Langerhans cell histiocytosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 404px; height: 263px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEHAZQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6figSJ5WjBHmPvbnIzgDgdulcZq3h621TVkuLM2kwhdJQqxo7FV3K8ZJPIJPf0PTFal1fa2dTiie0sU0qWVoWk8x2fuAGwAEJOOeeoqzZW7/2TcWqwKlzbI0EXlnacAZTDfTHPTOeK6Ytw1uRHmhqcHq51rw/fxWdijQC4eSZIIn3wBI8HMQOShwclenHGRVTX72+1TTNOlWx8zWpVMcs8TJGLmIBgxXJ4x9O/XtXX6tZ3GtXMVjcaksERUvZXEXE6TpgNuIIyRkggYyM1y+mahZaXBd+HfiAfLaEl7aZiz/IcnejDJGTn8sEV0xldJ2u0dtOSaukr+Xb9Tb8DataWdi4jhuGtY1ijeVm8ySFicCNwOoB6EDgHpXaWl5ZXzg280U0qfNg8OgORnB5HQivHtA0LVL8aleaSsb6U8rnfMpQXao44KdQT1zx04616Bomi6gtn9vt9QthfTDKOke+KWInKhxwTjJwV24z3rKtCN276kVoQfvJ2H61oVlf3dvPbaZ5VzaSLMt0n7gja4JUcfNkZ68e9aOm+I9O1S5NrbMWuDEJHiOCVUsVIYA8EcZHoRWd4u1i7082Vk2nPdLeAASW5z+9UglSnUqRk9e2O+arapYz6Xr9hqll/Z6kp5Vz5i+QDGSMs2MnvxxgYANQlzRSl8jJRcormfoP8V2TaRpMl9bH7RHGFF1A52NcgECP51wQynGMckDFR6jdpd6RYRxySLf3IhSeMDzWeNgclh3AyefUYrqtTltodNuZrxfMtUiZ5Bt3ZQDJ478V5naWljaah5F2JpSyLNG1lKWntPmLhTjueOPr1qqb5lr0CnaS1OvsrrUV1aaJ0tpEc7ggZ1dtoxuUkYwQB8pPUNya53xNo0caQ3Gk2dks07lbvTkKF5lZiCyYO1XByd3Y96dqGqzr4gtLzT71r6KN1tmttmJUDDJd8D5owcfOOBk9aoaBpCWmq6y8tuupuhkuJIFws1rM2fkR8gYK4+Yd+1Uo8vvf1/X9XHGKj71yPxDbNo+mvbNHql1az7Tb722mycckSY6sFwQTwea0dOs92h3el2cT6jJFkQXsVwFW4yu5A5yOQMD8BitG70K48R6f5a65INOkjSK4SJVd3wMlS578j5sAjFWtV0W303ToRZiSC0R0V7aIbixZx80ZPR+mT7dqftE7RvqV7RJWZH4O1WeMW1jqk15Nqc8ImFvOAWgUcct3GR1POeK6qeN54kUyvAd3zhMHcO4yR096xL+G10y8tNQWFFikYxz3qNghG5Gfq+Dkd6h8Iapd6jE8hna5tjcTBTOnlyLEMeWQABuHv7+1YzXN76MJrm95FpfODajZW1hBFyzW8ZwqtgL85x2JPbkEU3S9PuZrSxm1Qwm/ii8uaQ/ecjpnGACOuecZOK3ZYUlILqCRkA9Dg9cGuf0hXutQ1+1k1SWcwyrGBEFXyQ0Yxzj7+OueOnFSpaCV5JluOS3ZbZtVaNbk4ClxsyQc8HoRxml1GYyTwNp93Zi5RC6xyYJkQ9cEHjOBVS7vYUn/ALImn+zvbpDMkzdZFDYGD0DEqR698Vz/AIo0udNIs7eKytbeNpVkuJ2YYEanIjYAAufXpwDjNVGN2r6FRhdq5esNQlhje20u4aWzRQixSxHehJIIVwMEggjHvnpV2G+i0rc1ut9JbjYPsnllmUvkgjJyST2HHUVcnmvrDTJJ9OtBeOvW2yIw3bKHnP4npU/9mLKQ1xFDIUU+WhBwCTna3PzAHpQ5J6sNOu3yCe+t720nFu6OikpNvQgHHVM+vb2rL0eERaiv2owCZ1xbtBz5Q3FijEgHcQByeuDXJ+Xc+E7n7do9o7w3kbOlsJppDJISMlVAIGACx6ZHPWtPRWkupZrLWZsanf8AlXVtc7CiSFFGAOByOAR15NXyKK02N1QsnZ6f1/TO21Czg1G2lt7pd8csbROB12sMEZ7f/Wriv+Jd4bS40+exN5awRhnwC0kESgYYFuSo4xhiQTxjGBu6Zq8UXn2l6LSx1GFtiQPOQGTAKkMRyOT0qpq3iKxgtbqyupjPeXKn5YFEoTdgL/sgDI5J9zURUlp0MYxanyv+v+AOsry1fQHvoIblYIQXeRS0hU4yxVd2QRk5/rU1xeyQahZNeX7W8E7CAxyR481z90o4zgHjINR+A7S5jsZZ7kyI8z7nR9oywUKcoOFxjqDznmtLxJDM1vbzWlnHdTQTo5QgbimfmCk98UNrnsJ2UnFGbqejtJeX8sM0U0VyFW9g+6SqnqDng7e/qPytaZbaTrOiRRokdzY4/d7uSEJJUZ6gimeJJraXTGa+tZd0qmBisbOVDdiV4K5xnkVF4Gtms/DcE17PEZZFHnMhIi+TKhlDfdBAGffmlduF2U5yUeZOzucjqmk3nha+FxDNNJp4Jbzos+ZATjG71XtXdeF9dTV7YLJtW7VcsuMbh6gGrp1CyltDOk0MkUinaWbAf256g15g6XdhrrSWNlPYwzS4T7QdmHAGNpPHfGD1GPerV6itLdG91ioty0kuvc9ePbB5o9SK5O18Wi2vUsdcgFrcZ27twOTx2HsQeK6uN0kQSRurIRwVOQaxlFx3OKdOUHqhsEsdxEJYXEkbchl6Gn9ccULgYAwAB27UfWpIQEkDpQKQDA7ClNAg5H09qO3FH4mkc4zmgBetBo703cu0NnC9c9KAFxx3o7dsUhbjjnPp3FKOgoEHXn2pOB3xRnBpm5/OACjywCSc85+lAXHFgGxnnGaUnjPFJnjOD/jQSOnr2pibDLbu23H60DAAA49qRuSvWlPHSgQvNFICMetFAaGDq0F1amRYpovsdy4fzpss0UuVC8cDHHX1+tZXiXUj4fs5r1Az60JBuAk4li3YDMDgbQD6ZB/Xppbd7vS1S2vVl+ZXSV1DhwCDg465xjNc3Brypr95oV9pdxLCj7g8oEgjhZc7iecruyBnnFbQd/Ox2wV9LbblXQ5dWvp7bTtQ0wQyxobm7fKh+XJj2upwScHJGMbaj+I99p1/4dv0vbCSC/jZYo5JoA7RE/MGyDwuFPf863NMtLKHxHcrp0t4lxaW8cTRyktCYjkqFz6c8g/nVvUIbSbXbGVPKOoR7osORwhGcHv2JB9c0c657221/UFUjzJx/D+vkQ+BYbaXwJpcUbi4t5bYBznIO7O5ePQkj8K5H4i2B029s20uC7MHks3kWcjL5GGVTIqA4JIIXAx1yal8QDUfC2ryaxZQfZNJE0YltI5dyTO+QzhAMLkkZ6cgGu4jjh1vSrS5uIVR2RZ4mPzGFsZDA8dOKafs5c62ZpzOMva9GY1trmmwaVpz2891O8JCN50TvOq9HLgjcCO9bM0kGsW1xb2U+yRolzL5WcI/I4PUEVRXQt72zyXkgKxFbjyQENyzAAkt1wcZ9c96wrDSzZ+JrW0iuFjihMqACby5CjAFCB1YqAV5yKm0XqnqTyxlrfUtW91qHiu3lhkspLbRZyIZJBMFlO0sHAXHCMQoznOM8VdufCFh9mjGiBdOuoJPNinjG/5vRgTyP5Vb0VpFa587ziylYyXIKM2C29SAMghh+X1rHuLhNR8UarpSNJZ3ZtEWOZG2NIMtuwDweCMEZxjtii7u+XRIS5r+7sc1q2n339oJqC2UCX97bSx3iwpvYhAUkYAEfKcjABOTz1rT1q/t5LXTtS09rGwurENhWwTJlQMIVzuXJI5HUdqyPiL4V1bT9Mtb3StSvZrexV1bMmyWGEqAFyCNy5BJ7/h05XTm0qG509td1eC3W4YpcQ28Ls6tnO58KQAeOenPNdNlKKmnffZf10Naa5/i2R6h4N8VDUc219AtvfE7UZRsS4x2/wBlx3Ga6XVcz6fcLDCJ5UG9VU4KuOQR6MOteV3yubvVLbw9qLy2FsI70qHDsyqylmjboGBzmtDXvGF/dW102mRC1KKoe8R/mCkdWXBHU8Ht0rOVHmacRToc0vc2N+/1a1lnvLNbq5hiMircwyja0akru2r1VSOd/IGT07dnDEkKRxxIojRcJjsPrXnuneC2nuYjcB7iwltUmL3Lh3+0YwQc8lCOo6flR4d8WQaZaXdtqFubVbVlRbVct5JGQ6hjnI7gHp09KicFJWh0M50d+TWx3d19r3wta+UUBzIr5yR7H161iXiQRtql3pVmY9XubZTMYwomUj5VJGecAk++K6FHSREeM7kcBlYdwelYPiDRWlun1GzlkiuXjEMwRd29ATjjII6nofzxisoNXszGGjLOnItrPNefaJLi0vFRhPI3EYVcAc9AeTn1JrNv47241eVSi3lnax+cIpdrCYNwU9MgrkHtjHeo9Gj1H7DcSiwjkfeM2v2rbG4xnKY+XJzznjPpTr2+W60UTNYXNjcectu72+GktW3dW2kEqD27g+lWlZ6Guqldmp4YleewWVrJrRpCS0Z2qRjjJVTgE9/1rVjkDxh15RhkZGO1ee6FoeuHU9Ukvbu3e2IZLa62tHKDnJPykE/N1z245xWvqWtTaJbwRzW7xQxLl2jZpgp25QA4yVbDDnnilKHM7ImpSfNo7mkl3/ZmoW+niNvsbxMYsDLwFMcEd1IPB7YxVRrCzfXtQS5Qz2d3GjlZCXVJBkFo+y8EZxggjNTaNJvaTVh5d154EZa2czEDI5HoPUAdu+M1UXVrC41W88PWEjrcTwzXBcrjyJMjOc+5yPpTSd3b5jSa2MrxV4Mkyt5oTs92kbHbcyF84HABPIOO5Paud8NlLm4sL+USyLaW5hL264ZmY5Abop2jcAefvDNdfo7XE1jbz3st2lvdj7OJbh0aRAV4dcDaFY5BBHUL61iX72On3l/BbLLc22nqt07WZDtDN/GrRj+BwuSMYznFbRk17r1OqMpVIOEtX0/r+vyO+eYLCl9bzL9nmKFzLnG04GR6GtBuMlu2evauT8PeLtP1a8CWoma1uYluIpSuVyeCuemOnTuecGuhsr4zXl3bSxGOa3YdOQ6N91gf0I7EVzSi10OGVNp6o5qXxPbtrv8AZtvdifUYJN5toELJJ8nCb+iHJJ5PatWRby/lRYI0tNufMSZd+eB8uOnUnkHHFWtR0yK702e1ZzE84x5yqA4Ocg8ehqewS6e0VdT8g3CnG6EnBx/EM8gn07etDkrXRUnGycSGeBfkiezjuXyGVmUbRt6ZznBHakMQj2JeGO7M0u4LIo+U4/hB7DH1rLl1+PS7lYL5bxTM5CJIhcoMlVYsOMMR06gmneNNVvtI0Ce8toYVmTao3KZMliBg4xtGTyxOB6GhRd0u41TndRatfYoWei2GtfaNWeE2cN2N0LyYWTJGCTzjHyjA68msuzl1Tw7deXJOXicqyPsxBJuzxns2Qc1VsrTTtT1uOCx+02NnCqOkU4XyGlUAkRk55weQOuQa2fH9rJLOZJdRMFnFbG5eExGRcocbhjnPzKOPrW+0uV9TpiuWXs5O6fR9Dr9NvotQtFliwGx86Z5Q+hq2e9eYeE9YnivA8sEkLjcJYHbBPIyMHuM5x+VemowdVZTkEZBrCpDkZy1qXs5W6CAglhkkjrxTvxoA9fyorMxEx6HAoxxn+tL39qT+tAg7nI/GmnBUggEd80vXJBz2peTn+VAhqnOMcAcY9KU9RnNNKnj69acRweeKYhCOOlAUdacTxxg0g4oHYTODzn8aO5NL0GB1xRjPegTE4J54zQenWlP50hGRjkfSmIAcUUhJ7AUUBcydNtDHdrqclz5KyRmKSzhJ8kSswyx/2gRjOB3zSa7HcGSZ9LtyNRjt96TKygtgnEZB+8Cc8E/iK4iwvbrSLmxtGgaV74i2k+y3GJ0uY+GB3fLtOQcntyc10rX3iK2dGvLe3eQJLIBCN2FyAobB6jqcZBreUGpXud3I73NbQNbt9QhjgluIxqaQh7i3KmN0OBn5TzgE1LE9ne313OkMbzQBYvPTDPjG7AI6Yz/OsPSrCCaxabUt91eXLJK8rf8ALSM4AHAACnn5fTrV3xZcQaNoUuopbyqbcqyrbNs3cgANggEc9PyrNxXNZdSXH3rIl1OHTryBZNXt47u1mPySFMrEvGM9xn1rB1611FruW2s9TmXSSqq9vZoRLF1wCRyAcbcjB/nW94avrS40ue4tLlp9MD4iaRSCgwNynPJwT1NS+I7J72wNxYXP2a4Rd6XMZzwOQCB95fpz6U4txlZhFuErPYisdQn1G1d9Kg8nyiYyLtsPuAACsOSp9cj0xnNcXqc97q1z9n16whmuRbsLV7WQqqTbzlS3UEqAR14GcV6BaBBdwSzoEvp4AruDhZdvPTPUZJ6ZAJrzyPUrfQ7jV5ho+oyaY8zo7XRQJHKCQ3ltnkk4xnk9jxirpbvlRvSSbdlqdbaQyBzfXdxbx21nHGJDBIx8wopyx5A289MHpXGfEa/trjWobGF5odXsLhFi8rcBIkgVsl+Au1j0z0PvUem+H9UvPCseoaYscklxZkS27sygSA5yik7SeBz0zn1roPCvhHTtWtrfW9Yu59bubk/aFedtqICoAHlr8uQAAevIq0403zN3tp/X4lcsab5mzM0x38R6QlvpjtexmZhqlndzBJZU4DRZOTgNyp4GPlyMmsvxvpNlotxb/wBmzFUuld1jlJYxFcAqT1A54znHNd1qvgPSLu4hubLztLuoeUksiE+YHILDHPP+FcV440jXRfXuqXdtbskMALzW6ErMi9Tt67vb24pwqRk9H8v63KoVEp+67I2/hbYQ3NveXkqxvIubcOmCvIy2O+eQDVKzF7pt7Ppd3PYm006D7MLeVQrzQllcOv8Aewo/MMPeuQ8FeJdZ8PXa3Eyoml3jbnsZMF1AOC6sOhI52jPTvXovjywn1O1s9a0uZbi2RFBj8sMpjZgd7dyB3HYZ96bTjP3tmOo5e0vLZ/odvbXEN3bJPaypNBINyOjZDD2Ncj8QNJtjEmqNBI7o8ccyxdZE3Dr6nt/wKsSXxPD4ftntNOtVQSziR4gD5CMSA6I4PRjhlI4G78K3PGWr2914VZY0uxNOcrEISzI0TBmDgdFBGCaxjTlCaa2ZzxhKnNSWzLlhFqKNbxaMFh0WZCf9JRhNanptVW7egPTntim6jeX2k2cEczMzwuFjuZgHFxx3C/MDgnoO1dMHVip3Lll3Dnt7VyPjnQb7X4VGma19kiA2SQ5+WRwwxyD8p5I9+KmElKXvbGcWpSSehraHOl9ptzNp1wGaaaRlkZWIDfQ4JH5cVk6T9g1CG4wEN79okt7hZJSqT3CjJIIOccdB2zwcVy+lCG5XTdP0+O80a7YkzKpdArqo2Ox6ENyMA89c5rqb26tdFm01p7D5HmSEqE3LG4DBZVc8ck8k84NW42dl1LcORtJnQQ/aWeLcyEICrgDqfb2qtcwmO+iurgxraRZVi7kdehx04PrWRruuT6Yotr+4jgvLhi6NFiNFiVhkB3yCxBHXGMnpiq9gt01lezx6r9ovZlLwJdsGQwt/yzIGFJBDDcPbqDUKDtcnldr7EXjLSLaOewksba5LhmkNvpzeVI5C8YYdBkg46d6PCWkW91pmm3sstxHerIWdnIEsuCcru6leoOeTg0t9NbaZqFhqZ0q4kiEaRW11bSDasZydpU8qoU9MfjVHwlpVqmvSa1YyPd6bCZo1eSYOySFjllXAxx1J69R1rS75LX/rsa6+y/rXyImj8RaBqn2WCx3abLOyQpG6skgJLYUEgowUEjPGRWtFeWNxPfrYW32XxDCnkzJ5GfNDfdJxwwJxz255qXxjrdta6hooS5jdx5l0kfleYJNo2gjkcjdkYOaoancS6v4ztNO0XUJIZHiEt/dQIqyxRrnam7kEk5BBHFCbkk2v68w+O0rWMO38PTaZr1xFZ3BhiuLQXAksrfau1MI6ledrHA5GeecVvpeavo9iur3MdzdzJCWvYJSIyIgcKVC/KWxyTz0PI4Fa40/WtMQWukG0urSVy7SX0jb0JHzDCjBBPP1JqLRNOvY9P0mIXzXaxF4r03W2QAZ+aMcZOCNoyegzzQ5prWwVKrmk5Wf+Rpy6xbX2nXL6Pe20ssUgiY48wRtuAIYZGPrkUkniPSY78Wr38KyFSS2cxqB2L/dB9s5ql4q8Pm6s7mbQrSwi1mYFBPKuAVIwS2PvHHTOcHFc9pupQiCy8NadZWlq4hd5VaRJAZUIwAe7FgScjtURgpK6MY04tXRq3uLzW4tThlMunGHZCJTmN5CV2lAOdpOAWPHp1rX/ALUtLzTjI8coSaHa8BTzHbcOF2jOSfyxXOa5pyaFbSP/AGlIn2q9AgVlVIU8xNoTHAxkDpjnBrS1KSLSdHtZJXnj1lIkJ8pPMeUk5KMem0tkDJGO1DSaVi2vhaZ574DJt00pNXtZbq3tpJ4Le1S3X5ZmPSTcwCtgfLn1IzxW4dL1LTfDI81LdNJQ3U+y/J+0RK6N+6OOM7icEH+7VXwxdJrniKLUTbXVlerdtLcxq4aJzwqIPUAckkfeJxXfXVzFq9/qmg7WylsrNOj5GWJ+X2IwPwNb1ZNP8/6+ZvUm41btab+h5jHdXszQPr0cazGCP51HKny+Hc9AcDGRXcaF4pYzpDc3K3MYVdxVAGTIyDxwfp171wNhpus3ut6jqutzQWVutuYkgjTcsIUExqByGBGR+BrJ0uSSO6kaCbyUmO8xjmNW6Ep6ZGDinOmpbHWqcK8eSWlvwPoWC4guF3wTRyIOpVgcVL2GD1ryHw9qCpdwoy+VHu2Z8wAu3XDY/h710Np4pntXMN9OsDrIyKk0JWNhgkYbr7c1zyoNbHnVcJKnLlO96VEd3nghzsA5UL1/GqOl6rFdxosjRpc7eUVsgn2Per5+9356ZFYtNbnJJNbj+euOlB65oB4FGfekIQ8EYxzWJ418Uab4P8NXmt6zN5dpbLnA+9Ix+6ijuxPH69K17q4htbaa4uZUht4kMkkjsFVFAyWJPQAd68Y8NQT/ABe8YQ+KtTjdPBGjzEaNZyKQL2cHBuXX+6D90H/4rICOj+Eem+IrqTUPF/i+a4g1DWgpg0oyMIrG3XJjTZ03kHJJGRk9CWFekc+/1NHT6UhPHfFAmxSRnrTTjp17Y9KQE4IyOOOKVjgGmJi0h6UN1+7170ZAIz3oE0IyZOSAaKcDgc9aKdxWRxer6vG8llPJDLa38Tx3MlrKmwuBkFA+MMy5J46j2NRWXiSDVLoSSTB55Wkjsba2cAuu0nbIM5BYDqRgEDkVLcWt34t8P2N0IoP7RtZJVeJ3aPy5OQVyM5AOO3I9Ko6Fp50nxgn+gSxafdLuiMSjNvOoOY5MdFxnBHBP1rotFRfdHpJJpp7mx4ev7bT0tze3MiS38cbKbhwBFtQL5foMEMPUk966iZ1VQJCq7iFG4ZyfpWN4p0f7fZ/6LZWs0+4kiXCh1IIIPBznPfvg1zHge91J3v8ASNQnj+2abt8oTP5ojbkDc4OSD6GsnFTXMTyKonNPVdDotT1e50+W7e20q6upoWTdFEM+eh6up6ZX36gYrGi8R6dpmry/8TMf2VduQ1pPC3mQzMM7VBxhGAzjB5PbNdLYLrM1wsupGzs442G2O3JkMi7eQzMBgbjxgdq4LxR4BWfTb8w30M22V7q6Xbhwc71I5O0gZwOAQaqPK/dZpho0nLlquxj+Mdc1K58Z6TbaPcW93pd/GUtbht0U1hMHxkE9dxGwHHqPr2ejySrDFp+vwTC++1s4nvsGKRxkJs/vDbj0/Oq+naUv9m21nqc8iWt0Vnie1cDhnVthONygtg8HA9RXcTW9tcqI7mCNihJAZRkE5BI9Op5FOc0klb+v63HUkoe4tUnoznbDXYrNjYagsMNrBG6PNGjJGpWTZgZ42/MBwTggg9q5D4WTzaZfasjiSOwOJ2juj5bpESQsqg4BGBzj1/Cux1GyihtLu1ykFmImkjmugXQOxYSIxJ+YMDnB7n6Y4fWNA8QC1S+OowXemWCq2msWHnSQkbgxyOWHyDHfbnrVw5WnHuTT5ZJruewQskkayRncjDIPr71heM9Ys9H0C9kvGD7oygiB5Ytx+A5615P4i8e+J9Y0PH9jy6XaRyeU+oq7jzZBn7mPuA/7X0rmrLxCsnh17G9tFuJpJPPE/nt8uOuFPB6fz9KdPCP4pBSw/wBp9xZ5JZ547uNkTGFAmY+WoHA/qPqa2NO1vVNHsWuLGZmt5pXt2tz++QK3JKJkYOfUc80eE9EtdY8PPt1AzazLI0VtYKyoFVXBZmH0yce3FW/iDp2jeGbqG2tbe4kuBKspnmbcjq4I2nGO4HA5xzmultOXIdkqkJe7JbnVeHvC9nNbadqz3RngitXtmjV8pgxYJfJ+UjGMdBxXG6d4t1DTPEOnSQ3Ul/bsm1AykmfeqhgAed27bjB5x6Gumu/HGkaxbaZY2ZSz+2x+Y8ofZHDKytmKUY5BYDORyCenWvBfFviW31XXPten2kdgUVGJtpW2BgRkxoM7QMHGPrRQoyqNqaOOVRRTcz2g2/8AYviW/j0+A3qfZQZ59QZx9kV+WwBjGScAdeMduek+H2heH9W0/wC3eX9ve3lREnfcMsqqc7c4OGJ5OTXkul3l5rWqRXF291qiOypeXkSYWJDHiEkjgfN7cnPevVvhh4r0u18JPY308NlLprMrGQ7BKpJIZc9TyRjrkVlWjOMfPQupL3LR38jX8T6hBDqaaFNZSLa6gIw84YhUJbaNvHXhfQCuEa8sNC8QXGlTwiO48yST7XApljwMbomQ56qWweoIIr1i+0uDXI9PnulKrHl/KDZDBlxtJGOMfhXItpdm/iOS00qZ0lW4FxHtRJFDqoZssRn720YJzyfesKc1y8v3k0akI6SC/e2tpNMntLzUb2wu42XZIxljljUECLIUkFi5wT3GCelaXh5v+Efs/wCz9QtpcXEvmIjzCZiXyWAz/AvT1AHPFW2tIpNIS5tL+XTSzmQRs4VBLndtYHkDK5IB9a5f4i+ILWWzSC/sp7WdXWSzuZVBhkIAZu4YL2/Hmhe++UjSXuo7+1v7RrZFFxakLGGwjDbs5A9scVzms6jo/wBqe0s9Z/snVFgdjbxqqeZtHRlYYJHbBzzWP4fSwXTlM2nwwWF+omdHLSPKBnKqCCDwN21TkDOK6HTdL0TU7a8uLaX7QlxKlz9p3ESphQVYMeQPQ+lRyqDb1IUYwer0Kc/h+LWpNNv5tPMM7QCKSQON8RwCkqEcHHOfUHpWJeaP9iv5dJZxdz3Ei3EUyW/75ZMZOZQcIzBCQcEYHTjnS8K+IZ9R1aZre+ivrOEi1uIgMOuGPl3KH+JWB2kYHIzXReJpM6bNH5STwxAvckyFTCFXcD8vzZJAHHTrVc0oOzLU5xlyMzNA8QTPa20moSNNbT7lMoQF7d1LZWbbx0Aw2ByOnNdBp+pWN3b3E1pIrpA7CUIhDKw5OVxnkcjjkEGuF0nxB4an0Sy2yX+lDzd8U7AF3fPzIHwd+Q3ccj6cT6PfaXJqeoWU8wubJDHFHeucGXKF9ryLjOACBn+7jrROndt2sTOktdGjV8c3eoWfhm71nS9T8lbaLz0jESskicAlsgnocjGO1cb4U1BtX8Yme71Cyina08oBAFR24+fBwfMwPY9OMVYstWhtvF11bf2nfy6BFcRSQXAUSW8UzA4V2xwhzgdACAciur8Q3GnXmjTM0du95PIIYiiCUx3IP7ssR0w205PaqS9mkrblr90nTa36nQX1lBewrDer50YzlXxh8gjkfjXJa/p76YLOVtQvpbeCCe38l4/Mikj8skCUjByMdcnp9ataZ4xheWeDU4pLZrdP3tw67I2ZTtcjPO0Nx3x+tcj4i8TahrltqdtbPNHZvtmg+ycytCpCybcZEit8/YEAE44qKdOd7dCaUJxlqjj/AAB4kl0C4mi+wxyXF1GQqbmbymAPyqG4ILYJ5zxXoHia7/4RzVLR73aovPLkm/stPLLeWwJZ1JJI7DBHU5zWLaWdrpl1d6j4YaO+n02LzDb3UqSkxuOJUZMfN1yp/rXeeC5zf6KtlqGnypcW6+VIbiI7ZEbkEZ55GOO1dNWST50vX+vuNari3zbrqYet6bd6ho2lXfhq9Y2k960jJKxQNDLnKPjkqHJ47ZrkIfB0154eu9b0a88ySGVwbJpCRCEOJI89yu0gdMriujvbp/Dvh25t9HuEvlgncXlpNjaIycFRyCpwRyMis/wzLczfD7Vjolm8Uckywl4nDyNuADFsKM4G3n/aJpwcoxbjtf8Aq4OMo2SfX/P8TEtXkkhjlaMq6fu5NoKsRj5Wx64K1PHqf3LeOF2WXCvuUc/ic96tanqkHma3LPbyRyzWiRMG/gu4uM7eqgjArkbi6l0aaM39lcJI6pJGrjIwec/l71qo83Q9GFdciVTR/wDDf5noFzqTaNp+6ffPaDMiXMT7yhJz0PPX8v1rqvC3jSHV5Ira4ki82cHyZI8gSYHIIPQ15ro+si5HlW87Ogl3iMA+W2OBuX9MEVc03SJv+Eo/tTw1tNgzIssMZJ+zTEgsNh6LkcEcdq550ltLc5a2HhyXvprZntqngkknvXO+LvGvh7whJp6eI9SisPtztHbmQNtYrjOWAIUDI5OBzXRMSPp1x1zXxB+1f4lbxD8UjpVszSW+kRLaIq87pW+ZyB65Kr/wCuBnkqN3Y928WahL8XPFbeDtBuWHhHT2WTXdQgbi4bqttGw9cfMR/TDex2Npb6fZW9nYwxwWsEaxRRRjCooGAAO3FeG/speG/GfhrQL2LxHapZ6Lct59rbTcXCynALFccKQBwxzlRgDPPvOOOfwoFLsAJLEYPvQSaBkD8KZGmCeuScnnj8KLkgSM49TSk8AGkOR05BP6UHgk+lAMXJI3dM96McmkGTnnJ6daDjkHpQKw/LD7mMfWimg5HzLzRTuB5retqt7qNxfac8ljLGHaO0gwJrmZXyyzAcEAAYxnIapdM8QW/iPVGknW30y9jihLv9ow7Rh8um7jaM4465BFVZvElpfa3Z3K2lxpdnbySTLfSNtM0oAAjY9Nrru4Y9h0xWiLOSWIaroGhidmWVkmlcIl1HLl8sh5baxHBAzjg812tWXvKx6jVlZrX+v61Oz1DV9P0+eKK+uooXmUvGhBJcLjOMdeory4alpmh6/qFzDq0oiu5ulqvmRhHJ27wy/K6MWOOcjqBTNP1i0ijXU5NAa9bTp1WS4t3MciO3yrtQn7pYfd6D0pmj3viCK88SW1voM9418TcPFeAI6A52lumfoOuKUKagn/AMAqnR5b3+eqO3sTNpWtNYalM13ZSxyStdOSRvLqV3DopGcDHt6VVnv7uDS2vLh4ZYZEaG8Wa3Mckkm3CoxX7oI+62D94euax9FiNvpcWpavdXEB1MCWGJoiq2txETs2g5wpX16gGtvwx4xtp9LgivDKmqN80kTwMDLuIw64GCDkc9voKlxa1SuTKlror2Ob8GWd1BoGqGyF3Y31u6LEl5IQFt3+6pGMcAsQwH9RXdjUL1rNEkRJrvClobdTuX5sN8x4yAD2HQ+1ZV5ZvqninVrWe7mtHkt42W0dUeKZFJCux6/ezlQQeOvNGinXbbVES8a6vYLyE+aGkjDWs6H5mUAD5WyMDPbNKfvav1JqPnfN8xmqavqsL6hYJp1vqNqYi8bh/mjXph1K4JBGccdR161X8DXVp/bM1hLeJMtuM6fG8akxo3zECTqW9s4wB6Guj0q8tYftMsrxxXIbdfHDKoYDg5PTgdK5bxBe6fb2lxPaXCX8lxNzKkYAQE5TkYDFedv06jFKPvJxsKNpe5bV/mdP4xmNjo19qbASJbW7F7d1BSYZB5OM54OMetY/gSXSdYl1DVrLLPfRx+daywAeURkYB2gMD/Sueex1vxpLLpV1r93pUttH5N3GlsMXahshhn7p5AYD2OcGqunaPq3w61KeRdRtb5bvIh+1Fl887tzA4+7IBkjsRnpVKnFQ5Ob3v0CMGr03ucj8YFsPDvxF8vTkNu15brdyqqlU3glcgjpnH5/Wk8Irc+M/EGl6PYmf/hH9Ola6kaVSpC5IznBGTyoGfU1u/GLwXqnj3Wk1Dw/JGLzTYEjexuEMUjRsScjd8pzzjkcgjrXn/htNQhsILJ7q80oIGtLtY8iSKMvh1K9yMdBzxnNdsOWdFNP3lv5f10KpTq3dN/I6PxH4XdfE1zo9ncMkrzCKJ5W8tYkJ+Rn/AL2cnke1cR4+0G18MeOr7TdPW4vba3VHEqoG8osvzIcHt/I16Z4jgu7rVLa58QQBUuLRYopWUx+aIyVJdSchskEjpjpmubudFRUt4xAXyxBRnyB1BO76HPPtV0qrjZ36GkqHt0pHongXwHqnhvwhfQLqli638cbsXGRHGvIw/TofQjuK5uODU7R78PaWk0V0pPl3EZEUyq4yytn8O578V13gvxzp66HFo2s2t1tiAtELwlxLHgjLjtwMHt3qprN1YaDot5omlNbalpb7pEY4ka3LNlkPPIx0YcjvnrXKpT5nzLVkU1ODcWtDrNE8U2Npo+nwXNhqNpMsACW62zygqoAyrKMEehOM1yVvqVzrc2sy2sa2VxfSpaiAZS4hVW+WVCeDnLErjqp5rV+FV7c317cXd7dXTCSEQwwSyFlVUIOQT1J3Z+n0rpfGulx39tZSkQwzQXUbi9ZQXtwDnKnrgkKp56E1z3jCfLbcymoxlypGXbfv/E9nZ6tp801/FaywtfNB+7d+Nsg6qNyg89jlaj1KRNR+yQ6jH9mitR9nuJpQH2u6YK7B0B4wx4q54pg1BrSymNylxCMhpocwlSRuVyQSNvGMcDJGaz9BewjmvrnUNYmnmMCXMzMu0TQ7cJIFAyGXHbj86S1VybfaRX8U3mkabodtYfLe2PkefYxh9xTysLtVgQw+91zkDcPamWmuaNceHNF1PXkOnSvH9ltZYJCZJY+AdoX5tnHO4ZFdI2iRIkF1DtF4JMG4kiEhO8gGRB0DH5eR2ByK5HS4bm38VS3d3a3dxdWzSxqBApdFc4Eq4UbwDn8D3qoNNf8ABNIKM4+aNW30E2ehFvDEgu9TiKhLi5lyLuMYwu7PGAF+hWqE+uyXeo31j4ks5rby7STzZg/lmJG25Xaud0eRjfzwfrV7RrtdFnup9SeaCxkvJNrbWUq4Hzb4+Qqv1GOen1rN1KTSfFOoyyWGpxNHdxKJLmZGie32g/IgwC24McqfTv0ppNvXbuVH4nz6+ZJ4d0zWLrRbbSruNLaWRpIbm6gRHe3jVMogPQ53jnr1HvVa80TUNK1K/S8sGvdLvmiiCw8wbc8sUALrJnn5ehPBxkV2PhhrnTYYdOultntmLJbXMUnMhXorJj5TtHTJ6VV8Y+JorKaLR9P2y65PLEkKOgaON2IIL+gwCeOfSkpyc7Jb/wBXI9pNyaj/AF5nN+Co7JRqNnqd3dWl07tbS2s7ooeNuIwHx99c8cg5zxXQSrBpmvWekvcxxvd2rNa3BcrI08WeZACA5w2Tkc7TmvOroy3evanqtnfXllbywtLqKxjzIYZhkDJIwVO0kHHBPJFej+Rp2n6XBFrUVxqVjDEZrW+kQ3MqKV5y6DKk9iOo71VVW179Cqsbyu+vT+v6scCJLPxJqeq2MGlXF5fySeY7R3aSqFCLmRRnZneBlQQSG61pxaffavp90llfTQ6oVjjlt5gImt50yPlXqkTg4BHtV7wj4Th0ueaPSWB/dtPo+qrEDtRkwYpMffxkHJ6/UGsDU9O1wrPe+NTCDLCIJr2H93JpzbfklwnWMtwx+npWl4t2i/69P07lOfRPbb+v67F7wnp16+g6bBbtZ/ab5Loy3BgAWBlADRPg884OT3XvXqmmRPFYW8c0xmmRAHkJyXfufzrymW2a+0TSpNJtVZbGySe/0fMiLcjJwQRzuPzMCQSwxmvQNB8T2OqiK3imjWd1X5UyNpIzgZHOOmazrpy1XmYVE2r29f8Agnj3xFt/sHj3VZ40MaBFdl3YSVGUbh9eTn6VsfDDxXYaP4Q1ZBCjXMVyvygYDBxhWPsMYP4eteY/GW7dPH+qZu2aONtuG7HP3SMc8U/wRdWmsF4oiyXCnFztwElTt8o7cDp7V3ew5qEXLsjfn9pU9lLp+J2z3V3c6brRvJSk75IvJdoy5bHHTBzjA71QtpWt9PSw1MTTRR3dvdCRHLq0QUrtVW/hPPGeuRWvd21rFbAS2TX8wkB8iOXbGwwRtY4yBnByPcVoaXpB1C9fTL4T6bHNI1ufOCmQjG5AB0HfB+tLmSV+n+RvVgtebpt6dTduPBVkng5rq7thBqzstxLKiYZBuyUVRwAFzxzWHodzdaaFubN5YncmJGIBDjqVwevBB9q7G50bV9N0SC4l1q7mm0yOQQxsqYl/hRmOOuPXPU/WuW0vS9Qv/FF1a32mrY3ghyAWzGxbnzNy8E5B4HXocVyxldSu7oxo1moP2mq6nQWPjC7E6rcQrIo3M+0bmI4Awegx+vtVb4c/DPw1oN3N4hjxq2v3kjXE2pXSguJHJZti8iPkn1PPJNY93pt9ZrPKIZJLJJGXz1ACNg7ScZzjP/66bpPiO40+VlsPs4Uo2fmG1gBnj1YenfpWU6SkrxOmthKdaPNRsn+B7DnPA4NN3evP0rnvDXii11U+Q74uxwPl27zj+ddFjtmuWUXF2Z49SnKnLlkhOxB5/rTj0zjp6UgHtz6ClwenPNIzsIR7Zz1pp64IAGeKcAMYA4FHX6UBYbyOOM+1IeFwRyD2p+D74NGDn1FArERUnlSxHs1FSbB3Jz9aKBHnPiey0/wfejULO9ht0uIJQNNn+dZn2/L5anp2B6cflT/h34wcQjTdaaFfKB8q4jTZGi4B2NzhcZxnpgVQ8T239ueFpofDcEL2ljO87y+duZ9pdQq5yc8dc4xjGa4rW762uNVtbWO7gs7K8RZrqa1gZvs0UgHmIQRhSMfhk16MafPG0tz2IQVSPvav+rHQabaaf408fXbGSW106YtNCYWG252kDKsD1yd3c+wzXXaPY3Gr6peXR1y4h1bT5PsT+VGu3ylfcodTncW65yOvavO9egtrawsbyw1SzEduFgt7MOS8QVTtkAPc/KcdOeCa9E8FaW+m6x5tlcpPpt9Z5LJL/wAt0YbmA7ltxznuKVW6jdMupdRT7af1fyJY9JhtvGElrcbbjSpYWnghuEaQQyAkOkfOF4OeexwKyPG+kSwQTTQWN3E8MwaC8tyCPKcbSrjOflPHToR712t/p0V14j0+Z5JA8MckoWNwoPAX5h3HP5iqXjvULaPRdQ011neaWzeQiCURuq9A2cg4z6Z6dKxhUbnGxz+05XFx3Kvg8f27Cbu+tEs7y2i+xHyXDEqQDnOMr2IHYg066s7a8WG/0m9CXVvIftHlHfJJkeWTxzuOBjtx0OK5TwfoFtZaXFd6k2pSWc9u329pZ2jjibAKOQpy4KnOecZycc439G0uK2uhqP8AYjWcYCLbzK4ZkTpkxr17HLAnLE9qckk20/6+8bjFSbTJZ9IvY5v7T0fV7i4vFAtmgu2V0kKtnZIVXjgsN2MgkHNWdFubrVbm+n1izjjsJVEcMEoUvGoGHORkMN2fQjFdLa2cFrbNFbxBFcl32jBdicljjuTWNqFvHotjd3cV1DAHu1maScZVN7rkfXqM+9Zc/Np1MVPmVnuUU8PxaRLb34neGO1ZIx5kxkCoWwW3HGMg8jtW7qVlBc3dldT4b7M5kibJwrlSoOB14Jq1cwW2raa8Mv721uY+x+8pGQa4/S9WuvCp/srX7WVrGMFbW/t4mk81QSfnVQdpwRz0JBpLmnqtwi5S9UdlgrMm1VZiAHkI5wOg96+bfG2i6lovju5l1EXE9tJM0/20w4SRZD8uWHAIPB+nvXrsPxC0OG8mS7v/ACn2F3tpFbdGFONyHGGGCMqCSPStXxjqHh+58HytrN9bpo9+giS43ZUswypBHcEAj3FbUXOjLWOjCLlTkm0eJ32tXWs6PZm7aJY7N2eKYr+8kXgEEnhvlGO33auWUk6C1juAdrlowXAAQbjgHr9a5DRNRglaKWM6lBpkke2RBJ5gjkI4bJHGcH5T2Jr0zTNLsLywntoLi4fVBE0yw8OtyvUAbjkSY4IzzjIrtqJQ0aPQoVFH31sY1prt1cs1lfWsBG4oji32ygjrhh246nPX3rq9GnfXbfy7u20+BdKt1Est2ChkVgQmWHKjAP1rkvD9hq6+IktbG3WV2y3ly7Q0eMdm4VhyeO4rob3xTJ4cec+IPB0+p6k4Rbm5j2PviwQCwP8Ad7gcDJORms5xu7R3M6tRqNorVfeVrLXmTwnp50ICO9+1Ga5keGRktdpOCpA24IBGAeQ1dvLqWr6tpl3a3FppqSQypFcIzO8coZVYp93K/fXOc8Zx61i2dzen4eeRaT2k0HkmbMsTD7JCAXKOjcuBtK5HPQ+9R/2PJenT9QvdVaxu9beMlbFwUwI/3O0dwOhJ9R2rKSTfz9TF2lvudKuk6z9ssIpb+QL5c7uiRBoEY4CxnuVAY4BOfl644qj4i0y6tdH0uyZt8lttEWoBgrFxk7CpGMEDjnGQM4qpruqXdpomp2lzqxOrpMzRPBJgyqMFkVONrBQQB0zzWL4yudev5NEkttOvMtEs4EcnmysA/BMYIUMNy5wD9456VnGLbWqJhCSdzq4ta1G8Sxs9M1C2ur8xC7eR4/LMqZw0ez+A5BGT049a6HTtSstQaea2n/fIRDNE5AeJgT8jDsck/XtXLaRJrV7b6fcajFa6drdxdS7YBGwWOHb86uc5JLLkEHqQecVzOqaBPqOsprdrqN7b3F60S3iRBFVmQMpKA/f27CWU84wQc8VLgm7bEezi7p6Hqt9bm4Ee0qrxyrJllyCBnIP4E1zc9jfRX+o61qSAeVHiKG0bdJ5cbblI3fLuPPXt6U631WTRdRa312+juIwYbeKYt5ZO/cd8i8Dt94ccfhXTTxbndWb90yHOeg/+t1rLWBCvH3Xs/wDhzzu88VaXe6Trkd0jLqk0gjNqUIfywMpJjt8uTkH6VJ/p08Wo22IY2e2MFrNKd1zG20BJGJALIc4z1XHNVdZ/szR9ftLS2t4BpMxhjuGjj3kAE7fmU5IOcHvXQaRcPeJp+p2d7KIF/c5S3/dtHvICszdQvZhjrzmujRK6Wh01EoRTXXX+vuNXRtI+y+HPIsoLTSr+5gHmtAgljWXbycHhhnP1rxqx8T3Xhe4tPDupapqlhDDeyLeSRW8YAjfldvLeX83Py9n46V71bLFCnkoyhlUyGMMWIBPUd8ZzXkPxT8NeG/FFld+JNO1mL+0o4PM+SddhSPhuMZVu3J6jFLDzTm1PZ+Rz07y93ueq6fE1uyfZ5hPYSxjy3LbmDdue6kc+x+tYnj/TLW7tEur15rWG3ikWS+gkIeAMADuTo8Z/i9MfiPHLHUJfDPyppOrWt/e2qIh1G6E1teZAIcNgFD7qcjPPSvU7H4j+FtTtbexvL02lzdW5SS3lVj5ROVKs+CAfc9etOdCcGpR1BQnTamY9hr0tt4aCa3OkUlqj21v4gsVaSMFR8pkGMgMAvqp9QcVx2o3lyujWWq2epwvNqsgnmR4/LmimVtwIUdvfA4b3qLxhDp/gPU9PXwdqTagr20hutPuJ/OgkiyQu/b15yMdeKyr7xU7+E7zSr61s7b7QY5vtEcbs0HQqoAJIXjAx0Ga66cL+/Fb/ANbfiddG0Vpt/X5Ffx7of/CVatHrNhKltc39pHdMAflMg+Rz7Hcp/On/AA78KXWg2k+ozMs1xcMYViUgFNrfeJOBzjj2FR6RbX1x4HfUtMlhutB0xpvNMdwzXEU7svmBgQMrjaRjoO2a0tG1BpIIbmAhZcBlYHhu2Afr1PpXReag4J6LT/gFUadKc1U+0v8Ahjq4PJREbYZBt+aPdhSD178H0PtVTVJHlZZmuJiYguxj87IV6fhRZSTEObiPyp+flL7iBkdMdalWSMzwKQjFT86Fcbh15Pr0rnWjuei0mtUddL48GoeHZYZNPuFvpo2iJh2yRqcY35ByB3xVTw3q9/rk8UPiHVZtMaPKxrHH5RnKncGLkkZwORgd/Wsm8ks2umaEmCEtujTcSQey54464OK5rXoG1SKIPPLbsjk7UIDM3HBPp7e9RGnB6JWv+BxfVIqHKtzsrbxvqFy6W3hPR7+8tLRHadp5I92AdownU5PII/LFWNUsNU1/SXOn6NapHtDwXCvHHMZMEE7lJXI9xiqPgrxdYaTYnStG0yS51ZY/NmWW7RPNOT91nPOPTsKf/wAJTBqct15fhSOa8s8XU8dpeKct/EWK4zwc9DyPxqJQal7sfnf/AIJyKDhJ8q/r7zKutPv9FNsNWT7PfOqN9pQ/un4wygDIB3YPB4rp9P8AGt3Yhvtm25iDYIkbDL64bH86z10i5k0831vqsOi6fejZa2l7MGYNJyY2OSpz1XGWFZ0tiI/ENxDbm2JeAy/ZpZuXxxtTIG7pkAjOM0rRkrP+v69TpjVhXVqiv5/1/XmepWPiTTL6RYkmZJWH3ZEKjPpu6H862RjjH5jvXz7Z6hEyyKJFjgdidpQspOPXt37cYrrPAfi/yL1LGeTzdPkcxI+9XMDjnnHQH0PIxnpWU8O1sYYjBKEeam7nq2Me1IePwpSRnGcUY44PWuRo80aev4UE896XAziloEJ0opRntmimFjyjx0otbqNNEt0hk+yQx3tzbsixPG7fJwOQNyn94eB071lanrFrpHhe0msL290qF7ho7u2uAhmnjIO5kfG1/wDePbjiqsLaJe+EpEkuvsWqxuIJXaAPJJEG4QHsB1GCO4rXOiC71GWQ6qNT8KWF3DcQwyo8jQsvJjQ4+Y5I+8STuxXoxcUrPp/X/DHtuHIlGW1/v/4foVfD+kW/inw1rdtossVrO9xHNDYsflhC994+8GUnoOCBVn7HqXh6S1P/AAjarq32uGKC5jcyW7KS3VzzHkbVPHp1p2ri3s9TfXvCFzDZJDfLYtbshjjkkk27ztYYXtnAH3Se1dfoPiWwttLYXGqC8cvJK2ZxI8cQfazDuUU9CeSOaiUpJaK6fQidSXxR2dtOvQx9X1nVgqavp2jpDrEqmGO2kYyO5WQKwOCB5fbsdxU0/RrweIL3U9G1+A6hBJKWglliWIwqRiRRk7gyvlQMZxjkinQap4aD6petpf8Apk0xdGZQxnPAV0P8GcA849ea4vXpk1LWJHY+VdkLN5ccv7xJFUDeD68A1KaeiVjWjg6lW8XG3m/0OvtBqHhCzns9VmgktruVbSzTYX4J2pubIyMHDA845Geleg20EqQQJcSCaWNAruF2hzjrjtXCnVYPG3gnUrPRp5bjUbVEXMmA0pUhgcgY+bafTkdq6S58QWS6fp9yGd47q4S0ba+0xO2RhvQhhj61lUUpbrXqcNVS6rX+rG4MurDle2a5y8u73UILvTzp0SXAwYvtHzxMQcruK9D8vT+dU9R1+2ttNK6PM2oPIm54ZNzmOPdsZyMZABJ68HBqbT0PhfSotK8qW6KMzwyxIMuM7syAfdwTtJ+lQocuvUyjBpX6mlpWrPvS11aKCwu2C+VAJMg5H3QehIIPA7Yqn4+tZ5tDeS31ZtM8sFWYjKShvlCt+OMEf1qp4iC6r4jsLS1+zSvDCZ2WXpKuRtA9sqTkcisbxHLrGpa/pekX1pcWlrFdfaIbsMCkzKhKRsw9WyMjnpwOtVCHvKW3UqMdVIzfCnhrSNVhtrDUdOlaERJPNI0igeejbQisDuAYHJXA+6Koa/8ADnxHBcRWuka1Je6JC3nxWNyAPLYMThSRg/QnHHvU9mNavvGV3quk2BtBczNbM1yyyNFKigt8ueD8pA9ulbGh6p4sutN1hm1fR2kgunhWR4GZVUgMpRlbnOcBWXIPGTXS5TT5k16f1c1lKSlzHiGr219pulzazBZStZtPsR51CxiXcQRzzuB3AY4xkV1ll8QNQ1+Kyge1ggvrT95HLDhGAx1bsMflxTPGNlrOi+GLaDxFpLSWMm5oo/NG2CRuW+YfdOBkA4BOe+a4Dw1Y32o6s8emRi5CkA+XnLjoAevNdypxqwcpdNmP2jVRcuqPWbTXo5PF1nqt4HN2lzGs7hQihSdu49gOR9SfevYfEv2RdIvI9UleGxnTypJI87jnIOSBwMd/r0ridV0hvDfgF4Da+dc3oWO6nKlhAMZySATgEdfU1zE2rQNplhHpVzqPiY3hWG7067JKZwOUJxtIPTBNcDh7Wzj0/r5DqKM5Ll2X6Gl4U8XDUNd1i01S+uJNLjdoIrWKEXMMkfljcvmKu7IHPpg96NX8S6DoeiJZeF9NNjLNMkckVxZukiwk5ygYewwCeOuK4/QlfSbua5VLi0jhmdQ6MAY+CCGIyQe2elTWuoy6rNEJHe6uGxErSOJHSBfulCOvJIzjPqelaThFS02OuhglUfM3ZF7Q7PUtTv57qyhF5c2gO64uCBhTkAlSQffHtXqlzpLx6No01tq32Y6YoleeQCRZEABdWbjCnHUdqd4B0E6J4cjhu4kF3cEy3PO4sT0BJ9Bxj61LZtDYWOq22qTwtp1o5AWRM+XblQQHHdfvAHHQc9DXLObctOhx4nEe0laOy09S54maOTw5fMzLta3Yxtt3jeV+QqB1OcYxXmn9la9LFZahb2NjLPpd5MkkcCmAy5ZfMGScFGOGzg8V2tjd+HI/EkdrBPDNqNzEXtmaTzE2dTFGegx12jsfStq9McskUYuHUrlGgQArJkZ2nPfCnHI61MZ+z0t95hGbp6fmclqNut7eT2NxY2sup/Y28/zHLiKGSTEYUkANsIyeBwvXmtVvFOkt51pdrNFsQKyXFu0az8EMkYbG7p9KxI7WyvtZsri50+7ivp5zKIY3A2w524dem1v4055UE10fjS0s7jw3ffb5UjjiUzRyyMFEcij5cZOOvGO+aqVtEy2o8yjI5Wzj1HxLrFzJGH06BYoJ4baSEI5TkhtykjduBH07V1Ok69byRyW2oww6ZcxP5P2eSRcNk4BXHXOcY7GvN/CDywNZXMcEszwWpurl4GZAkEqjCHaW3MGUkBeo9K15JF1TwfN/wkel37WtuzJHcSpJ9oSbkhtqruADYG7ocjjrV1IXdun9feXW95cj2WxF4r0XUNImkv8Awnrt5bLHOHuY7iQNHDvYZAL9j0AIOOOgNTWfg7RrzWNfuL23jskZI4k8mfyxdw4BWSZBwxLn7x4O0e9VtNil03QXsV/tK/1mWAPqFrdIWJVjt3h2XC8DjOelc54Ssn0q8jS1tZ7nVZYWSS3aBlmtIsnDKWO2T0wQA2K1SlytX26/1+YlBuLknqiyqvpXgk6HqllfzXLtm4s7ra2wB8NNAQcqAORwV+nNcZ8U/C1p8ObiyW2uJryy1FJCTKQ0oYHPG0Z24Iz24r0HxL4J1zV7mz1vSNbS/WxdrmGF2LBJQclFTHyhsAbM5XOM1yXjA2viO/0yWfSJNJ1GBPJuo53IXZvyNm/5tvDEAAYJFb0ZXknfR3uXDmk/3bOIsdNtWbSrlJI7C+EzIflLBojEzElOMZIBGTWs9nB9mmsrmW1lWUGN1WEYkYHKyo7DcvQYOe9ehfEqPQ7DRdPt9IshtW5B+3zL8zFkbG1z1BAbPbjjrXFWuk3GtbLeK3hnHlvcO4lEZVVx87YBKKccYHPbmtYVFJc2xunFq9v6/wAzsvGGv3t34StbTwekQaayhvdXciEQfZ8Msqk9fMJA6AkjpXAaZC1uPtFjJiBwBbRySYZWOeWPGOCDkYBPameGvDf/AAkYk03RfJTULpjGJ3iAWFV6BuM8BfTJye5rJtrC+N7/AGUYnkniYRuyEMjFCVI45OQDyPUVVOKheKZlTp+ysuv5djsLK5tbS6uo7a5nlg83b8xPmKwGHJ9FLA8VrC7ILXFvPDCETDPMu8D39c9s1xjzWv8AaMiXMWpLqJiCQzxMT5eMjLA8EZIHP4GtCyMMatDdXn2ieRFEpVdoJ6kDtjj86JwvqdtCbUeVrY6Y+ULmKbbukuMKGjGVkAO3OD3z+VDQvNcyrGEkkyQgjUbiQOOvUg4rFkY28UkjFJQMbIWkB49xj6d81c0MS+KL6bTdOIuL3yTMquVTaoPA57/Ws+WyuXKpy6z0MFtUPh3VdTls9Jt7nUbmNZVnlQSNbGN+dqY4LZ9s4NctqfibxLqGsSalJqSi+uAE8xEWMIoHCKO1fTL+HfC9v4ctodc0o2s8i/Z8OTJMzDkgOM5BPI7VV8GfDrw8kJ/tXwzarfWs7GOSY+YZE6q+ASO+MeoqYYqlFNyjc8iu+ZOcHbX0PM/CvgDx1Lpy+JLXxBayFVEsEHlpI8o6vtZgVRuo6H6jrXW6NHqN7DNqfivQbvUtEmiE5uLqcLLBzjEcWRgdSQMduteyHaHRU+RYwOAMDGOlNvIVuLOeKQLsdCpyeOlcU8W5NtxX/AMo1Glyvr16mLH4Y0X+yptPjsovsLj/AFeApjyP4TjI4/GuU8Z+FYbaNJtJso4La1sygEKktIQwPIA6jJOSfWuq8NanFciSEahaXLwkxysJP3gcHGCnb696Z4ovZLNobu1jkuzb8ywQMQ+xsgk47DGefSs4ynGdrl0as4T06C+BNbbVtMaO4fde2x2SZGCy/wALehyK6U+uDmvHdMvG8JeJj5Mou7SUAFtxDOjfNyMcMOT/APrr121nhu4EntpElhcZVlOQaVWFnzLZhi6PJLmj8L1RIfWkbPykdM8j1pT27ZpT044NYnIIOnHI+tFKBxRQCTPDtV8CvoNpcyTTNeT4hMM7YVFDPgh0P3eT97oPUVZ8GRya3qE9nbb7aGGYXc1n9oCwTYb/AFY2jI2nBzk547V1+j6hqmta/e6bd2US2kNvldQlT554ZMjYUBwGyuTnsR8oqpdaDF4V+w6qLiyt57JZIlydiXCHO1CDz5mO49K7ufRwl8X9f15Hr/Wp1Fao9eho6pBaNY64dVsLN9UZNxjt9waSPAAcNjdwTyR0x+fmOsafFot3DYtc2ep6atwrCRIVDkuuWAcAgAbRx79K7rUvst14p07VdZsrs2tzahbY+cQIGJIYbBg8hlyOf542vD2l6JPdXF/baQsSxT+al3JF5ayHH34wTwB06DPvSjP2auyKVT2Su9V+tzyO6SWa2S4hnSVchJI5CFLIDnIJwM4+nFa9n4XfU9IvdX05bWKO2UnzXz87KMsVI64HrwTxXdX+uaDq8tnpEM1v5Mty24FBvhaM7gQhBwGP8R4wa5+K7upvFi6Hpt3MyiOWKO5jdCj8gvvRFCbRuIH8Qxx1pqTetrHoPH1Zx5Yrle+vYvX2paVoS6NqWltZXpQxafcXUM2wMWUbHZUyHAOeOSM1U1O0m1G3udP1uKSy1+IzT2bF1aK7jDhj90Y4LdwCNwPPNWPHXhaC5t9UmTTjLDHbL5D7xHHbOgzujXOeSFyMY4BB610Vz4SguvDCafc3Nwt98s329juk88D7xJ6jtt6Y4qeeCSd/6/pnm88Y2knqXk0d7aVzbrvnuoDFLcyEMYSAANoP8PU7QMZ570lzo8Wn6QhtXuZ5LOFwnmzMxZSp3DAOCSOgx1Axio/Dmqao+qXOleITZLfRRrLF9mB/fx52mTknHPGP6VuwXMVwJzDljC7Ruu0ghh25/D865pOUXY5puSZ5N4V0i61S/h1qdBFNaNDE1tC7JJK+wElvRWyGIPTB9Tn1p4/PtxHOqkkDcAMjPtmvO/Bqo0d5fw3flXcsSRajYeWsUlvglVxnoQM8Hr+Vd9pS3AsY/tWGkXIVgSSyD7pb/aIxn3q697+hVdtv0PM0ur231LUIdLFsmkafdmYqzf8AHzMXG2LJ53Eg4/DPerPjjR/tkYvNC0W7t9TWZZXd4giKQPv5B69Punsa6PVdEj02G41C0v3huo/NnjEioyM5O9gV43dOOcgdDVeL4ieH7nVH0eO5kOskBUtDA+ZCwypBAI2nnnPHetFN35oK/wDXUHO6TS2Oci8Qy3WrQXEuoLd2v2cmKxuFVlf5gWY7f4wMAZ7En3pnh7xDbLr9/rd7vs1jRojY6dCWWUAZWSbbnLD5lB4UE9T2yPie8+gaFo+lyPZ/bUgHnTWysreWpxgjPCk4IORgqcCt7wb4cbW/DtvqUV29lcSr5cRjH7uaAcYkQY3ZOTnOelatQUOZ7PQvkjyOT0Ozk1x4tGjvb+wYWpt1luj5issQYcqf7wAPJHb1ryDVrODTLnULjQ7xdS0u0ZZFW2kAEEcvABPRvmOMA9PStnXNSgl0q+0bVra4u4rO6a1gdTsMIVRjIQYIwBgsecnOKyBpkPiHU7htL01dDt7O0Iu7e1Uu92/GwpCByoPJYc9KqjDk1/4b/MdJqm7nPG7ikhYXvnRLM4jeSMbTGpOBuHbsecnn3rJ0wN4VvrvV9Gu5WeyDrLcRsGLJjIJQjoQvIA7ZzXf2ngq4t4pLvVtU0uKWA7hazrgFsA4YjHDLnoD7dK6n4b6fY+IvDzayMpc3xmgukZANkRyDDjoMAjkf1IradaMYtrVG1SvGyTVzS03xg2neHdIu/EjiUajFC8c9rEqxo0igiMjeTkdd2AMVj/EjxfrGiXs7aPppAt4h9pleITJIhGUAAwQcl/avJZtBTSLxNME0QMUjIplyVZQNo2t0HQHHcVv6Xrus+GtdsNQWZr+DyRbHzZdyyQbgdiZ5DDkjn2NZrDxT5lr+A5YXlXNHU7rwjHPqGj30lveKYLdmFspt1SS2d41KOFwArKzMCMc9frq6pd219pw06zSKW2iuo4by6LMAkjDrxjgsdpZW4JI7U630XQ/GFzJr1peXsUd0iR3NvFJtV2T7pcc5IBA9CAKfZeEbC70S0tLO8imsrUtBEzxpcB4sgkN237hkNgEc9a55ON7vT9DlulK8t1+BzuoeMGtb61ks7K1lS0v3Ta8ojkjVkAcNwQBufOR2X3rJ8QNrt/dz3l/c29zY6TcHy4ZHWQJJxlmRVG9RuAGfUHg1f8T2Emk63bRx6Rb2ouIjHJLBMPKvF28oSwxGy9Qcc5xmotA8IaNraXTxXET6wpYPbqvlQttIH8POOBkA9ecc1ouVJS/4J103CCU+hpfDqfTbW+kv/wC1ntRfXBR7F41jje4KjOME4xyBg7efWu4m0/TbWJ0E01qo3GR0nbC5HzF8kgEg9TXBa1Lb+G59O0Oa+ubSwsnST7ZbxIrBSpyGOD0OW6d/YVhzeI7y5lVxqV7baddy7BczIp822ViAzLjOME88Z5qJU3N8yehj7CVaV49dTr/Elw91o81jYazcW2pxHbb30o2LPGSNwVzgNgEZHJOM81Q8HXEzeMrOCKabVY7GBrKS5kA3RIM4ZmHDZKqRnnDetZN3qK2GiM2k2dlqENtIv2fU3BYv0PA/h43Ln06Vo6X488Hadd20t1p82l6iloV8zyS0ewEKfnX74yByRmtFB8j5Ve4505QXKkdR8RdafwZ4evfE1lZLctAV+024G3zlLBc5H8QyOT24+nl3xc+KHg7xN4Qk0qwin1O/ukR4JlhIS0kOCCZGxgjphc+lej6fq8/irwpomp3dqiQz6jEfLhcsHQOQCwIHG4dOegr5r+KOnJovjHXdIDQCG3vTPBGScCOYBwgUf3Sx6VeDoxlPln8S/SxzNKMb9UImlXOs2R1SfUXO2QFZEkIW3YfdUjJ7cY5616T8L5RoPw28YG8uryGCTaI7u3gLOm9So2lupBxx2z2rx3Q9E1JLvbcm7hgZ95gmG1D/AHWK9z9B+NenfCjTtJ1nxRp8WvXgnEqSSpprSME8xG+QuueWwGOOa7sRBcjTen9P9DZVOaClKNv+AV/hpNdWHjvSzZQyefJcbZd5U+YGzv3EZA9fqKu+PTbw/FS/u9DgS2dGU/aBuCPNt+cgjjI74PUVveJ/Dzah8a7VtO1D7DHK0bGUONySCLcFCZBwQAAenXvXS6v8OdZ1h7m/1HVbD7dLvb7HHbFrYnbtXBLBgTjJPPXvXNKtBSVRu10ac0Iyu9NEeYaPoqa5rjRXE2oGO3RpLmWEBnDBSxJzjjIH15q5q2paB4h+Hls8NpJZ63bLmEmHYLpSfyzznnniuV024nv0uxFZajFq6o1rPK10QZX3AKg6HqrKevFaupWMelQWUTzo0bws63MDtIhdTho8HkAcc49e1byhdq7/AK/4Jcal53exunwroZ8K+HNetdSMtuZoobm3ul+ZWJwVO0gggg9e1XfHiTaLrWp6r4bsorX7HIts88UgKrIVySueQduMj61xGhXdpa2uu2Gp6cWmmUXNtdRQAtCQQo3sfuxvkjPvxXrnwxuvD19HcafDYPHHOy3Elret5yRuAwYIx6nABz1wayqNw993aX5O3/BJ5nBPm16f157HPeGtY8ReN1tLS5gjuILNSZroDZIxfgMyjhsY6ACrN1o114b1KeR7vUoL+1cXFuYSXt5geNjcZUMePTPBrpp/BtxB4gfVPBGo2aSrN80EjkRRjaCYztByp4OOMZ4rf169vrjQo7uO0smmgDJfW8khPl4+8AR1XjPr0I9K55Vldclkn0ME7vk3X9aGbZ/EMCW3Gp6c8Nu4C/aQQRI2PmAXqCDwVPIq3p/iI+JvEUseh3FzbW1nGftEzxho5GyMJtPQ8nJGCRXAXWpXfiH7dbwG1m0qEfaIrmYFppI15Ei4w0ijON2D39K7Pwhr+l3d5C2myxxTOg+2QRxEI2FB3Z67hkHnnGaidJRXMlr/AFuKVNRjpr/X6mZ43n0zS9ekl1LTbmye9gIGp2EhaRZF/wBgdVIIPTvz0qX4e2F3qtnc3Go3s0lyZJIAHDxzRADjcQQSp/un1rB8aXsuq+JgdQsZLe0iO+yuEkVgVDEGQZOM+mfWuittTm0LULC6ac39tOVtru5uIjbPGGbILKeDyeD9R3FSk1C3U6a0OWjG271+7zJfF2nJDbPBehBeXUscdmYYyoUhAuN54wccqx+hqXwhq7aN/oWriOBA5Uu42lGOMKR0A/nXXaglzdxSLaLbMRynn5Ksw6cenUGvN9ZsJI7hp7XcgDOLq1m+eQNjOFxnK7STn0FRCSnHlkRTkqlP2Utvyf8AkeuD86D+GK5nwDrkWraNBC7hbyFMNGWy+0cBjXTEVzyi4uzOGpTcJOMt0KOnHIopAARyR+NFIg89vdVt9K8TaldxTTW13NbpKbQW7Os8gVupx0wFGRgA461cl1yy1WfSLy9gSHyj5iRTEiU7lw0iKRyq5PJxwCaoWl28t6/mWkmr6KJZIbOUyK5JOOAeuBtIHJzxiuas7C7ub+G3M0JR94tw7SyC0Xfl0lxwDkbCGPcn1rt5FbU7owXXdHfaxp15qOs2UOoafFc6dbSLLHerIAwB+8rIevRckds/Sk1+4EE0llaRwiGxgWdApw1vLlijAd1wCCO3HrWpYTPpPhhRrKbTaRiOQQbpuBwMcbjxjtmvPl1+B/FLa5pOlGS3mJsWDkxy3krdWC5OQoUfKQOvHSsoJy+X3DhFzdl0Ipb2a9vxrE+kajDqgQKsit5MV2uMmEvxgEAEdTkY5zil03UBq3jHQ9XSebSbqfzLUg22UlxkhHzjDfw5OCeCK6ma8trLV9IuL4S2drEzWsME+ShZtu2RWJ7YxtPTJI97fxF0e3u9HN+6ziaydJy1uxV2RGDHp1wBkemK051dRta5Tqq6VrfoaOpalGly+nTiAXU0ReGCSbaLgdGUZH06dOKy9d1eXQNFe4ghv7/y2Xzo7hM+Wp5JZ+OPcZ/KsjW5tCu7GbVtRutQkjsEV5bVnbY5cfcBYAkkEfKCAcjjFQ26y3OjQ2lxLqVnBfWrwRR3bxzLLGSdoDDoVU5OeSM+lZqmrJsiNNKzYzXZ9RSG38UADTbu3xEySQE+aDyE+8RsIOAwAOevt0XgvxENa1XXIdgURSI8bIrBZFKAEgnryOo7Eetc3pvjZ73TprPSbeGC+tp4ZYbe+nwptiwXerYyUBGM9gea57XdU1XTb+NYdmmavpFzuWJJ/MjvIpwd2FIGRuTPt04wK0dNyXK1r/X9fM09n7S8GrPoVvizeQWviLVrzT5As0KRFyinesyZz1x2288j3rb8K/GzTJ7ZF8TRrZyeUGW4hYuk3r8uMqR6c1zNvrVp4hkuF1608u+v7hZYJMiMxAja0ZL54yvAPGTzipfA/gjw79jng1zR2vX1USLZXgXajIPmKEq3yPuT29uOK15Kbp2qJ3QYim4pRfQ9W8Va5oCXWl2GqvHI11uuYlaLzAqKh+dh2HOASDzXnNjdaktpK2niwWxluPsf2lRlI5Sm1ZI5AA2SuB6A8HrVrwhp7yaJbaQ9pb2v2hllsrqOM/vwWLP8+4nATK44ODVjxoulQwjQpontU064a6S3V9iyRN90q394E8DHGKiEVB8m/wDW5FOneXs+5xvxetIdX0SeXR9Mv2sdKby9Svbt2hmkkwACSfnYDJznC88etT/s+fEtbe0h8Ma8qwQ2oZLC5+bLL1EbDB564Oe2K6238XeGYPAU9v4m1u3lnvopFnQN5s5Byqgr1JVQOeBxXn8OgN4T8ZRrqsWnaxp0cIuYFC/61CChlI54GR75x610R5alJ0prVbGcqd5pL09TvdY8X2p1t5PDottRW/ie3ubLcI28wMcMB/eI47k5Fc//AGnO2mjUrRP7JXTREt3DOhCtLuAGN+C44BKjBB4NavjbS47zxn4a0PR9Jgk0iNA1xNbBEALZVC7AhiuVPSr9x4Cv9Ns9PuX1ie51CEmR7V1DRTuAeFfblT0Cls81nF04peZUWvs7nN32rah4z1C102e10m1leFvMvnhIcIqls7v4VxuGOnzZp+leK/8AhHIbceF7UBBDGl1FdwSRLJJgFiq4HTd98Z3ZHpmtTVZf+Ej8RaGlhZl7LVY1u52gYLI0f3ZIiePlU7uSPmzgHivU/FFnHdaPcOUjM1tG80DOOI5Apw3TtUyqRhaMlo+g5zimo8tvI4TxnoltqNnLqyCKWyk2zusSjdBwMuRzkevTA7cV43qXmatrhS0w2k2AVppFJ+aU8hVx1ABBOPWuqvru8v7me+1nXZIkhhz5CWrI0oZMlVKAKu4HODnNdfH8PSNJh1Pw9bjT5ZoVkfTjL5gU7AAQxx8xULkHjI4x30i/YpKTOqFVJKnN/M5LwzPf2l9Bc2UssMK/u5okO3zUHVSPzweveu70bxRo/hDSYIruSWOyYs08nlH/AEdywGWAHKnIGQTgj8vOdSj1WxkBv4J7SUsVTMbIWH+yDwTwc1B4ivp518PaRPLHLbSXZmeFyWyka7j9AX2j9e1OpHn0ZtVw8ZQ5v68juPGusR3NuLrwxe3M8Ny+b2KVFYRCQKuQsg3KT8owBgexPNzwtp+sxeFYYlaJL6GaUxTTMRILdzgkFf8AloGUDniuLSO1MMH2WN9u5pCsjhsu2B+YwOM+ldPpFxHZyzaba6letLdQ+c8HlAC3c8qyMxwW3KgK5/iHFRKmlFJdDnnTlClyrv8A5mlaS2d2msz6hZi4vrVUu41nmKszBQrE4x8uRyMeoqh4e8K6nr95e313fILSU7RM43uTgghR7HpnjpgcViW07pqMswlxaTvJa3FxNEUISQc7kx8rZGcfWuj8JeIX0OORAi3FrjdJHG4JzjllPQ5/lipnGUFodFCFVU5Ojv8AoZE/h+58IWtrps7pNBBbiIybcLOg4yR3PTI7HpWz4bh07+27K3v9NgngvrZo4PtGHMcS5JADcbSRyeDxW38QUi1bQLDUbQ7oiTtYDnDDj8cjFc140022l8OaHrGnahdReRG1vvY5d+uFwOAc7uRUwnz6N2b/ADFOftcNFNa7fcP1C0aPV5NI0jUbnSNCW4kjjaOUbVvNmVXdjcgyfu9OCe4pvg7W10TVruDxbLFLcIryfbp7QLc3DEqMBVBwo2/jlTTtDgu72zsby0iNxcxR72u5Wa4TICLIcsVO/aCpBznHtmtLx/YT+JY4orPTt+o2uWNzCRzAUyCh75Yj5evymqdr8kvn39TzlaT5Zf1/X5nDeJfEWn+MvGrT6TLH9gW0aFriaPHmMm5sL0IOcDn8q8w0h7q78SJfWdy1nciXzBNIwUQbfmDdOmeMDqK9a0Dw94Rv/C94t48Nv4hjHzRhmRllVjtITuX4yOfpWror2fijxrozapYW0dxZI6tJAcQ3DoMxgL1GOTg+nHFdVOpGknFJ2S/r1uaVWqkbLaP9fiZfirSr3SPD8PibUIbqXXLm5FxLcWse1bVNoILZHBOAPTJqPQvGfi2/vdTktby2kUwy3slpdREAKoAwj5BTqCB7e9ej+NfHvh/SLK9tJ5rfUbzaYzYqchyequ2CF4Oea8Y0rw5q2qWkM11K2jrdKZLLC+bFOhJ/dbx/GeAA2MisKT9pBuordr/ov8gjJSj7+5QsdJuNFsNH1NUsV1APJNlp/MdW+8ryJkjce2ehAzzzTbqcTQmW4QR3TyNKpL4ZsnOCvIHOT/Orer6NeabdC7e7ttQidzGYolK52YzlTzz/AI9KwfFOsxT3BOnWlvaFYtgit920yc/Pzk5I4x7d+tdkbz1N4r2WrR1GmaVoPiLT7ifUW/s7VLPTQluynAllV2Zmx/HxtXBH0rktB1bUtM1ye80e9shHbu0UltIzO/n7SUkMfHToGB4JxXV63oiabLBAL6506Oa3e7JvIQNqiLIQY6lz2GCMVgeGPh34xiisdRtbKKcX8gngZpFXzgw3neD90YGOalcru29H3IqtJeuv4HReDvFWtaG8F9LD5ttaTFL+684MixTBQgZScjY6cHJ44ruf7X0/UL+1uvEGmQuNUiSB3tl85GlTnII5BxnjrwK5zR7HXE+33Wn2FlLp0TNa3f2qMI5GRuiaMDkBsEN1A7mtLw5cusYi1C/+zaI94YRLA3mxTTpw4BxujDDpjvWFVRb5ktfJmKSV2v66/wBeRf05C2oN4gazs30WJhBF9nIE1pE3G8qF465YcAg8g4qj4euLPT7zU9P1GJ4NPuZV+zyxuySqyn5Z1O0HGMkMPTBp/wAPZ7bQda1LS9M0m7ltJbry0i3Ayxq2flZmIJUYY4boMd+De1Pw/Jf+KNO0i5s7y1M6SzC7mlEogKIAqQt3BB5UjtxWcmk3F7W/4JcZwbaqfh+BU8Q6Tp17q+mm1u7q9lW333Mqy+aJYs4LqcH5yc5XjP61vPLBpfh3brN5Nd+E5kV7a88pjPatuyFcdSueB8vGMHiuJuby/wDBun2tsZ7uUWt6Y2SKJROkpHypwTuRgQRjOfTPFWrbxnf6fa20GmpItzc+aDpmoRfNayqQd6MQCVIJIUjPpQ6cpJW1X9fcVUvJKDd0tv6/rTQ9C8Ia/Dfw3P8Apy3cfmM1mxgMBkVQflUH7wGDz6VAdQt5NFvrvRYmvrxHLfPkyqXA8wAEg/KO1LLf/wDCTaTpV7pM8jWVyDb3awRgm3dhwxQjcpDcHocGqE2gXfhXXLfUrMXGoW6RfvA8qh88hjtHUEEfTHPFc3LG7vo+3p323MKai9b67pfp67nOXNsukSWGpW95dhZ4zIyxqVw44wTzx+leieF/Eh1mxaWWLFxAwVlRgocMOG59+MZ61asrEX0FylzHCoLN9nmt8Bo1YAkf7LA9R0NcLfaPe6Fqlq+nn7JeMWGz/WJdAHPA6c9dvUHpVNxq+69zeVSGIg1UXvLr/meqwyLLGrx8qfcHB9OKK8htNbjdXN3dPo85c7rWNCVU+v3h1oqPYNGX9n1On5P/ACPWbKCOBViRV2hRtKrhcdsAcCuJ0a+vLnxJqVjKtqjJHJFdTEGLzmLny+ABzs4zn3rUmMuh6RcyanqEmo6Q/IJVUkhR24BI+8vIGeDj1rPtNFeEyvbRzzQy3cLLm58yOSMAhtxPUYyNvY4I4pQikndkJ7tlfS9Nl1azvnvXe21uK6+1IkDl04I2KTuKyKdoz0AOelUZ7PTIdXtVuZ5rTU7+1KGSTcGluGHAlUdMHkFcDgjPrbvL+bSNWK+TE+qRsfJDKYY4oWAwu7kMoJ+6Mc96s+GGsNU8QQ3MN5fSXCmWd1u12+bgBBs7FVLMMj1xWt2k5dP6/D+vM2TaV29DofEOhrqXg+bR5GQu1usaOwwN6gYP5iuO1i91K2sLyz8SpdQ6FDAG+123ytlQBseTptPc4HpXe+IbB9U0W6tIbg28ki/LKEDbSCCDg/SuS/so6p4MvE8UxR6lpd1EzyLFD5UzRk7gW2tg5GTxgj61jTlaOvczpTsrvXX+rHN3EOkjwvq1xba/axlYvswtkUmLytvyRsjZYtxww6duK2YNatr3wtZ6pe2Rs9JgkiuoiZBuE0TYZNoz1wdvr0OM15Dremav8PtJMr2dxqPgWbbHDd3cKyXukZbjbhgXjx2PTOOOd3p3hjxj4f1vQ9OtNFnsrdJnLSxPBuguWxjEYOMMXCkDgjnjNb3Ul53NJNzXdpmf4s8QNoPia1Fqls+lXtq0kUUcW6WWGZizk7uQQxJA6Y6963fACW3jLw8g1WCK6ksJ1hM86hmlQLwCRgggN19RmpJNM0TxFZ3Hhy+gc3tg6iG8VSpE+zfxICcOMncmcEZ65rlvBWrR+GotTsL7ybWe2gkFwGYotxmRdm3vvVGcfl6VVuaHu/Erf8OO/NHlitV1KOjxLFrmtabHpp1EyRXXkxXUgdkbf/Cx+8euFHPoRXda3pVhY/CdYg6NaJFbzTzoTGXwyb3GD8rEA/j1715l4o8NT+GvE1naWGoyf2fcRNdWF3E+JEbj7xH4YYdc16J4Y1K2t/hzcW62Ya+WA2jxxJkT3DAhQPUtkZJ981dVfDKL0uhVnKpFTWwst/aeFPB9tf6LNb3uk6VdKh3yfvY4WbDoPVhv49RiuA8da9Z+KNVm1LR5AIltI2xdIY2+Rm3KFI5b5hwOuetZXh3VNa0PVbWHW7O2TU9Mtfs8tpcwbVeIL8r5BwxXAwwzkZ55qLw9reneIvEGotqoSyENrcfJbqLdJJCuFVFPBJBPGcnrWsaPs25PXz/r8yYwSaffYyX0Sy1AQvLsnWVS2FcBrcISPLfpzjBHsa6nwdoWqX97Y2gFvLpOiPLcO0UTSXEpdQBGMEEjoe3A6mue8P6Lqk8trqc1hqj+GJmWFpkRWZgXHzqo5bByN3611D6m2gpLqOn2/wDZunWdy1vLf7w11dyOMELEcZCBhhSRjrnNaVG9Un/X+ZtU5XBR69zQ8ZeGZtS8R6fZpqmofaZo1NoY08p4dp3YOedufm3HPTB9a7HSPEWor8L4tT8U3M2m6q6S2YVFV3mlVmVSqgYLtt6DjmsO98TQX97aL4hntDBayukto9tumXcQB5iKTgYPG09+a5Pxh4khi0PUIEubeLRxcxPp1rjbcWjg53LKCdhVtzKjJgrkA9q51F1VGLW39f5HHVvTa5jc0Xx1Emj6HcQ6Hf2Oo2qDToZTErwyfd8xASQQeN3PcYJ5rqLTxJd3WkXr61eXUSXc4ghj+zxxkxbSr7Acn7+csc8Yx61j/DKDU/EGox63qDW+pWlzbOlrfqkarxwWeNW3LLuznGQQ3XIrpjptvZ6NZaVqDRJdpmzM7wfJ5JyQAzHB6A8HIIPHFRU5FK1tfvBSizFh1i58Wi3h1G1udP0yxST7SsEgkYvHt2uwI5T6qeR9apwyeIDYQaf4ZuX1W0trp1l1KxmSMnKgsuwE5yScP2PoBXSDw5bHQrIzahPNpb/JNaWeRHcgn5i5B9eSQQOPen/Dzw8ml+J/FF7EuyOSWO3iCoFV0C7g2AAD97GR6HvS54RTa6dPn9/UqUorY0re9sJlOiazEVhcKkQvZN+5iOYzJnlxwR0PPGeteSeMdAbRPG94JFbyJLRVsWYfe+fLkngZ+6PXgV69478OW2tacZnc28tufNaREB3KoPDeuOo+nHWuY8T2+oajpunWEU2nXCWk0VzPLNcEyQxqQWGerpIuQGOOCM+tRRkk00/U2oYhQ9Huv1PNEtxabp2kkDiUFPmPAHJwMd+melelWNr4e1rwXjwpcyfb7UtcBH+edZiMESLzyeMDp0I4p/irwVpviPSF1Dw042xxMi28eQHweRzypHp3/Wqnh7wxra+HdLuoLvT7DVY5WEMtvECbiIL8iTNjJJK4PpgCtpTjOPNzWaf9XLr14yUeTSzItS8SXGreHLSK+svKvYZPNmkUDZKwUqHGOh5OR2rW0/4fXSICupQiKUByTDl1yOVHOCPf6Vzqzz6Hr1vPrOnSmCaVpVjiXcvmZIMZ9MMR69utdbp/j9mm/wBO08JA2drxSZz+B6/pWU+ZL3Fodb9rGCjhdt3t1/yOkl0W2i8NjSBKBGE2xvKed2cg/nXnEttNFHc6HqClLd5HmjycPBchSVZc8FWI+lM8cavDfakLu3kluYZIMRxGH5oHUj5Dnj5uTkZ6UaXo2r2Dx3Vyn2dA+4QXM4klA6+WoAyW5wADjmlTi46t7hTpeypP2svi1s9Hf+vI63S9cuIL6zaW/tLvT9VhWaKQggxuAqsDtBGCSOpHOea2/Dwt4P7Q+y28FtayOLhNuAGBXBYjsMqasRm30zTLaCzgJilby0QIFA3ZJLDjA4OeK4nxLcSSW4t4nvLVdOSL7Ve252sArchFJ+YHGDkEAN2rOyqNpaHjW5noZMfim8XxkZtDjmn0vUr0o8Bg5OIdouI2YgffUZ7EY5zxVXV/C15YWOnXF203mtG0sxaIEQyDGQxXOepwa9ExaajY266ZNbSm1CW89sWWTCMV3K3PB4yD6iuZ+I3jKI6VPpWmRXTPdB4Zrjy2QW6g4bk4yefp71tCo3JKCNqU5c2nzORk8FQy+Dm17UbuayuUYrBBkLFOm7gMvPzMe/bjI4rb8J+G7zUprrQtR1CVNHsVSUwWsq4Mz4YfMM/KCCdvrzXH6V4NvbfTob7V9Q1LUNJBZxbWp80xurbBvZiRtOMFVORnPrXf6Rq+hfD2yvNHb95qMLCSRYbc7pdy5QuRx/sk9uPWtqspWai7vpp/W36jUpNWj8RS13wbLo919vur+zv7YTeeTfOI5JMYyhP8fAP1qlqFxpWsaleXC6VYy6b9m8uOKWJIpYRgfMrDphv1PUVYt9H8Q+OdSW6163itoLUq620ysiMrDKhSOfTLdf5VlavALS/OnNuQrIkbQyjcI2ZsYY/xrgghsDI6gYpQu7Rk/eLTV+Zu/cuXc2pWp8OXV1ONSjXzjYwSrmYjaV+fGc8YOOfSuog8P6zqdjouoW3iGK2v7BF+yCKEvbOpTa4ljyCSenBG3HHelbT08L+K1m05I5bR4ooZ4ZG/eoJHKhoz0wCOQfzrdacaL9sv5Z47fS4riR7vMXqFw+Rzx36/pWFSpdLl/ryt8/mRUqcztFfh3OL0a/1LSdbkj1nfNql1ftDe29rDi2kjKZSRN3zZIxjk9GHJFc54k8OTSZuNKnmTWjdiQxMFjAmBBHCnawA6/wAXOa9A1nUrW6Vbmxv4742pMwntyuVAGfLZuVyeoDDntzVHRtX06/sfKn0S6mmYvdAQW7NhmbBcP3Bz+GMelXCco++kK7abto/+CR+LtCvNT1jSry2MP2p9ljdPCm4W8gy5fp0HODweR61p2viifSdSfTPHptLRpHZrG+X5YZgB0yfuvjn8cVneFfFr2TQQ6rDKlnczlEu9m5ZHdjhiwAA5wDx1rL+K3iDSdRaGCKR7lLOV1uG8tmgBAzgNjBfIxx0qVCUmqclprqChKcuR9Ov9f1oearco3iC8utUe6kuref7XFfK4kkBUnaGDYR1xjGMMOma9S/tS78baDpun+I9HksnvLiNra9jZRHKg+YspySj4HQ9exNea64VieF7eSM2UsPyqsbb23dFJwAew44r1jS2XTtHt9MtEliSOBXSG/wB7S+b1G1QMrg9wSOe1dNayinbVbeVjStpJNbu/9fiSG3bwFrcs8Dy39vq0oaaS8uUjMZXrtGBubBz07Vr/ABOsdR1Dw6q6THLJIkiv+5fDqPULwHGMjbnvWHB4Al1eGPU9e1m6OsuAykMrRxf7O30x1AxVix1bxTaeKY7J4rfVNPtbZVuRaTBpAWPyyNuwd3B+UdQa5GlJpppyW/8AX4Gb0lzxd7b+fQq/Dc3kmgXUunQpDdo5jaAgozEDhiG+Unpzgd/pVi91bUbuO8jurbMTgx21tMyK5mXqpfOVPoQOcjHNHxW1eTS5/D1xC6lFuPNa1xtkfGMHOMqByD659q5v4geMdO1Tz7KztLYiSNJ3udmZGGB+74HDA55zjA61cYuo1NR3/CxUKfO7taPW/wA9jW1Kztby586+U2NyUUSRXZO/IHJzuG4f7XeiqvhTxfDo+iwwM0ku8mUebOAVB7DPUcZz70VpapHRIxnKrGTjFNpeZX+HUkOrfbNK1S4Id/3tra3RLoxOc8E4bopxjjqO9d14ha903SbL+zXtoIzdJiIAqqLgkoCue4wOMcivPvD8duus6YdH2/bY7O4luXlTe0cij5AARwPp1rszZrJr6lGv7Kz8lbia2wxjWYlip4yAOCTjgnFZ1Yrnv07HRiFad3t/X+R1lzGrRyPcRblnjEbxMAdvXIOOvXFcQ0epjVtY0/SZlW6s44/sssqqVijIz8oxycYU+uBn3saL4jaK8s7aTUZtT+1r5aNNCIIwU4fD4wzZ7e49Ca6bUrWOaWWWzhC6jEhKyKoDElcAZPXp06cCsFem7S/r+tjL4DjdY8cajBpy2V7o93a3q7IryXIA+bIJhIzndhtpOMfWrll4nuF0KO2t9KkLSl7bT0mcIZoljO12JyP4SD6nGOtYlzpy3FxfSG9upt9wttNfNI3n24UBguxVAXaTuyePlNX79b7VrzTLe5ku9IWNGW2upMMssykqvCnG/hjjuMY7itnCFrWN0qbtdGba+El1Pwnb3Z1i9stOSNriS1nPmJGwGfY8ep57ivHfFPhebwlf6frXgiU2wuYBcT6beMY/3v8AfQnhSedrZA4/A+xadBY2EWqaXNqup6XNGrDVHI81GThVkDMDsDA8Y6c56Vf8Sa6t/o2p6HMdPn1G4Cw2/lzCZXYrlUbAG2Q7WIXp3ziqu3Kz2+63+f8Al6lybc77o4z4PeNrLU/FEdvZyajI1+jXesm5iCJBfF9qRkceWflABGd/GQDmrvxj/sbUYjPod9aTarpV4YNQKOoaMPk4fsSCMd8d68V+MF/feGfsEv2G70zxLG7RRanCWglMIGDG5HEgGQFOcgDGSAK4H4Ya8lprI03Uj5mnX8yF9zYxKM7GyemScH1zz0qFPkrLmMI+7VSk7ntVwJbSWGIzTJdWo+/NlAoJyyEE8dsYxXe+HtYt7C2ttW+23ItbRzLd2aEASttISTJ6AZ5HsDzXO3Mdle395A6HydiICcFkKqFDEnkgkDP9Kq2FjLZiS2uyS3mY2DLgpnktnnAJHGK73BVI67ndL+WS0Z6d8TfGGjabp0PlRWOu6tI8EtpZ4EihGbBYsBwu3JyevHFeA2aJb3t8wuJFUySEgEhYskq3ODnrjg9OmK2vhuq2lnZoIYQ9ndSBy0W4EJKck8jK9OParnxBhsj4h1K5sLg/Y5pwxmK4Vd4GcDjgEk/hRQpql7hzxp8sU111H+Afibq/haC0/tKSS58O2kbRrbxxKWAHUh+pAwcAnvg1yX7Q91bx/EWdtIYH7XawXswkP+rkkXsM9SoU496x724t4NPke+y8RB2oQS8jdM4HGO9cvCLm9keW+uvtFxIBtaZ2feMBVGfZQAPoK6qdCKqc8VbucOIbtpuzf8Calf3evQ2fmskzbQJBJhigB+Xd7nHXpmvTfBmmQ37S6hbadqGp6vay7pI1RnXaSDkvkEtwcgn6A9vJYIv7NgV1Rzf29yhKoPmdScHaR7n9K9P+Hvik+H7LxZI15Hpc+qbLaGCYkSwPtbExJ7DcenTuRilWi0m4eRpBt01GWrufQXhjw/ofhb+2db02cQWWqOLyRHcLbwHHzMnTbu6t7gdKx9Vu3vb06lYW9k2nTRpcQXlxtMUsgGd6t1QleAODlR2JNVPA+o6dfeGrbS9Zsre2thbRRRxXrq8UkiM6sU5OQCATnBye4pugRaTqnh1LawkOn63phe4FrbYDK2ThkXoysCNp5HzcelePytSblr0+RKjyuyRqaT4kt5dQhkt5o7uaQC3lt2VIJsr8xZASNxGQCOM8dcVmX2t3M2s+fpCXsEzu32q1jbJkVAcKByAxb+NeOSD60WN9oHjTVo5bfQtQ+3TyBJbgSfZ5LdUB/e5Vs9fl9c4FXIo/7NuLONLicz2j3FtbXD2o2bSeOQMHkBT3JNOyi9VqaNJPRHU6hJqVxpkkVgttJcrComtrsH5yw5UuvyjgnkAjPtXOXHgWD+37i4W2gltLpPLkj3DfGgAxtUjAG4HPOCDjFdR4Uili0hGnklleVzJuliMbYzgZB56Dj2xVzSzOIXjupPOnikZGk2hSwzleB7EflXOpuF1Ew5mr2MHwRJa2Qk0iKGWG5LS3TxNAYhGC+MDJ5+oJp18bmyvry1+zTvb3DfbLSeGPzBFIu3crL1GWwRjrubpiqPji3lS9TULbzFUCO1uHMhVREXDAhv4CCPvc9sjFUNJj1CO+vEmmuYgl59onKhVVt/KnknaDgglSByCMjNaqKl7/AHNOX3eZCeJTbWmu2GqahhUuZYyy+YS1rLF98qB1yMAn0BriNQQW17LtiB3s0rRg42Ix3D6nkcV2Pju4a9s/MjMTpIyu0MkeJIOo8wEHkZIUnHGBnmuY0aJf7bU6pElxZJaNdPnLEMvZjuA9gSD+Fb0vhu+h6WEqSp03Nf12C0sY7vV7aO2tYgzYBkumUKno23g8ccZOfSuqt7W6n1yS6utSfUtSt7cw2sfl/ZsSHgspOA4BJGQDgjntXHahaaOw0qfSQ8ljcSvCklxKWkhlHy4XsFGOvJJPauu8L2Umr+bqK2Nv/aUMrIbgjc8bjBMkZZsZb+LgAnv1p1LJXIxM5VI+0vpsbU19BpumRlZ5IpYrgC4W5cfM6kbjkA8uSpyOPmJq1NBbXljcWd5ZRTyyyO7xAicxSE7gTj7o6EdKS7Md0gOracst8sTP9iuHjIk4Clo+SM9j3G78/NDq8+j/AGq70J7i1fbFcbfsQIa1UZZnJG4KCWIPPGeemOeMebbc4qdJ1FpudHYw6fp11Cb27VnkmuINS8tyZGYMDGz4OcKAuPr71zTaZazW17ElpLfXSs0cc4be0RWMPHtG7Jzg7sZGB616V4DaySxkggjjM3mMsrj53ckBtzHrhgwIHYEDtWdcXuhW1zePPPa7o/Os7SBQVnDfdZFU9SSQBjsQM1aqtSaVxp8smkjlvBN1NolgH1Gykn0TUGDW8bMHZZWZAVYjgknnGONpz3rs/FWl2N9qqRwaffS3zESTXFoqrtXGNjs3ByAODnGM+lZF/buuu6Ve3lpLZeXsfbgSRwSP8ih1zhcEnG38ema7jSbW9tJJkuTavEzAq8SlHOBjLDkEnHqKmrPVTW/9f15mUnyvmXUTRZJ/Ka3nhvkMJx5l0yNv+jKeR+FeaeOEv7LxlL5Mdw6zkTExQ+Zvj2hSCMHIAyCPpXqt9e21isb3cqxK7hFLZxknAFM1KaO3gWdhuk3LHGQMkliBgex4zWNOpyy5rbipzcW/M870qKy1F5tHvtQ1CWKS9RGttSLLLKgG9ShOGC7lbPXjjiteXSPsqatpt5Mtvp0hEltJPMxWZz/fZicgHClTwapeMY2XxXo19rTR6ZBFLiHUIT5hU4x5ZLLhdxPUitLWdRbWtK1CxaPZEkO+S4lTbBLET98MQcEABumPrWzbaTWzNOXVNbf8EtW2g2mleH5ftTs0jMHaSILFuO7KLhflOCQOnPWtDR1vbGzC3NtFChUssMRDCFs/dz3Bznpx0pbfS0u7OBrm9a9jBjmtpAijyyo4ZcDnPXmqvhi6upY3GsXTfbCwRVdkCyAEkOir6j19D6Vk25J3ZCd1fcwNbhvrTX7GO0lkt9GhUyupQSFFPDso5yASCd3I6gVS0PTbvwqsvhyeSO+0q6YyxXDffjB65XnJJ6AevHpW3491uOxu7LThcGJ5kkmnEaB5BDjB2g8ZJP5A1vnSNMvtKtree2gu7by02tIobcAODn9atTagrrR/1cqc5KzfU8qtPC13Y/Y9Q0UXHlm63zW+sJthBRiQwYAuiA9yOeM1meNte1nUtO03xBPpVtFHYzSwvPbXZdc52kgDnjbwcnOele122iWdtY3NlF532OdNhhaQsqjGDjPIznnmsN7G10CzstLvpbe78P3BSyhtbiBSVJB2jIGGHHccdc1oq6lK7V2ti4VU3dq/+X9fkeTeC4LvVr+/fxGXuNPjhF0rXpImhTlUVAu0DO7njjAqFbbVvDuvtH4VllUw/NN552uF6/Mqggj6+1eq/FXT0fwszi0aS1tEJZYCAUUYONvQrwPpjNYniDwNZ6jo9lrmjpPEzCO5urSGZn+0xYBZVJ5DAdMYz0raNeMtXonpboXGaS1XxX/C2n9dyWx1bw/4+WLTdbEcesorLFLCxUOR1MZ6E9ypz+NS618M554oRp2riJo8D99bh9ygcAkEZrhviBpWmaeul674QkZFmYNCpJYCROdw3cqRgBgcVF4m+NVzrXhmyj8NLcW9/KBJcSxoS0JGRtA/iBIzkcbTUqnUbXsdvPoFSTg06bsmvu8jsprfVNGYWt3ohvG++j6fbw+Sqk/dAkG5TnJI6ZPHWivNND+ILfYivj+z1KTXFba0sVlHiSPA2Nzg5x7dqK1+rVeqX4/5nN7eK3pyv8zo9MxibFsumzPtaKKK485k+XYwMgxksQTjg5rsR4ivU028ulu3Ql1srO4EW+UyDbhXQ4UBjuwxxjJrjrfTfIvZb+2XyrbIZYEwUSPcCqgkk8dMjHBxwKtWTC41SFzpy3cQuNrWzjasshOPmOPU/pUzipO+56zo89KKlujr9OnhvUtdPk+0JKt/KJrhNqSGRt3IPO054256YrVtTHahCdQDXMjNp6XM0mCoUkqu3PzOeue/04qmNC3TTW07w6VdP5jQw2dx1ixnc2R13dWx0wKztehju4oba+mGmFYYIo4S4ZZG5DMhBJPBABI56denNZSdkzz1ZuxqajONH8UW87RWyzSRA3TtMVFyCQm9E/vLjv0Un1q5Y6RPNbzWJuTJp0k3n5kyHC79ylD1HTHPTAIrkr7UZNPvlttEd106yQw4H70pE2CAqsAxPbGTg96ZrcsFnocF9dtc3Vuls8UEiIzLICRtV1OSHUhgPTnk1XI2lbf+rGrpSsm+ospuk8RajHBcTX9vr0T2sc6ovmxyj92clTgxpgc8fePXNJ4t8IWnhzQbrVpb1ItSijSG2exhW2CsW+8FJILc9ucLxiuUOsLFZi6spIlut6EXDRtvi5yoDKNuWzg55OBxWveeHL3WPFOmafqniKyuLolbhpUcyb1XPy7G+UEjOPxOK2s4tNuy66b2N3Satd2tv8jj/GXiTxPFp134W1y2W/s7gGeCfULdkmkiDZypJx26dRXkl3pvha68Sww60jaZYXMHlpdWw8swTA5G9cEEYIBOM9Dnqa+hdU0y3v4tXsvEd1f311oUxCX+A0aR4zEhKjKlg21sAnIBPSvOU+F97cXVjq9/Cq6Fa3JWcSY84kkDYyHkHnBz2IrpUaM6bjJW/rocrhNyTVnr+Z2Og+FZLawCNMdRcRCNbjlBMo6EkE54xk/yrWudOXcj75GuF2q7Hlto4Chj+HvXM6NoeteFtbttN02WfUfC94xSG2JzLZSkZVAx/gJ4z/I9fQ9K0vXdRRgohgjyFXz33FmHUgRgjHuSM1zOUoq/NoeqpU4K0lY8o0SzvdL8W6tYTXCSW3nvcR/J0LKCwPtgg1y3iy4B1aO2imlis1dmZWbIGSMjH1HWvbtR8E+J9M8Tf2tDFp2qJPEY5IYCYpY8L94buGGe3XmuU8QeGIvFFw6SQGw1CB9silNhfOOD3z/hXbRrw5uZ7W/rQ4q8VXp8tF/I4X4NeJY9K8f/AG/ULVJdOZXhbfGZJQpByyj8gfbIpPFHgm+8N3CSzWdzFp07sbS4EeWaIncqNgkAgbcZxXWWfg4adIYsb5YSJ4mKgZwTnp+Fdbb/ABKutFhayv7WO/hS33LayMDI4A6K3YdT82ce1OdW0+eir6a/pYxWDlGnaotTzf4ZyX3hjx5aXOoWjLe3sRSIzyBEj34PmvxyoXJxx9a9e1zxZocl9LpwgXWbW8t/M83T4o2kmJLblcsRsAUZx3GT3rjPGHi/RvHOnaXrOjXEVhrEBEc9nKhDFMkZVsYcDpj0NXNEtvDCa34lu5Io7BLcRXdpazfMjNghowOp5wOOgNYVLVHzzTT7fMqNK8E1t/X6nQ/DzT9UXQNRs08PyrdyBoUF2BDEIHGQSMc4PRVH1PIpRpl54e1O3stJum1XVbKxW33SkqVIZGREHG4YzkHOBg5rI8IfEXxAb2x0+006CSznvGghBDM0e7kICW+4vr2ArvfCU9rq4MGuytP4htpDHcKs25VbORJGB8oXGOR908E5rnq88JNyWhnK8G2yfS5rq00651Syht7hZXYraw2rW8vms3zRljnI3Z5wPxFWvscGtakRZBLSyOXleLKyXBBbg8DBSQMSDnP4mseXVNV0TW7zTEgf+yYbqN4rmSNjhHAY4kY7Thsrz04qOyhtr/U9RNnJeRw+YWSZ8xG0bcDJkYHOXYYPYE+9c/K/iIcOqPSRuPb5v5VzGmjVD4gMOo6hC5RmbZFHsMiqPlGM9PnyevIHStfU7kWpgfzSrIGkMZPEiBfm59Rwa5PUIk1DxZb2+ky2r3DXCX908iCXy4vLCkK3bOAMfjWNON7mdON00dhfxxanp91aq8MuRsdW5APoR2rj9VubtfEGkTX1uIZlBguIFBIdequrDhlDAcEZGT61qzaZLHpF2mpLHKJ2EY8mEs0UYGMsc5bAGQTyM96zF1iwvNGSKaFtQmSf7PbrJJtkkRyMOj9TherDng5q4K22pVOPldE2vS2t75V/YXBkWSFke1hjV59uQDJEDzkHGexA6Vwbr9gnElq8d6sDPG5EDFJYm+8rAj5Tz3/OuqhuY40E12IYJZ2b7OblyPNMedjSP/AeeGH3u+c1fkhv7y1uRcz6dHbSpHHduXVboA8EM2NpPOFPQj35raD5NDog3RTTXuvQ4BZpri8gla3srO1hTy4YYnMm08gHJySTk+uOPeug8DLZWd8kuqQzRSXLeTbXke9dkmcNE4HQ/dIyMHNWdM0mea8MdhpkMf2U5TzXHl3tuBtRnHZiQ3TjuR0rMs5raPXrjTTaXeh2U8iBZ2mz5NyjAnaDkHOAMnGAfTitXLnukayqxlSdOK8/6/rY6PxT4bvbuPT72CP7fLErxyW2o3I8rlSFkDAHDZwcj17VrwaNLqvhya11XT7S2vvKNoZDGrJKmBzhSPlJ/hz2zjtV6zukvU1SzuLmK8KTtC8akAqm0ZGOuQCfxqt5sVlfaTeGSTybmNrXIcmMscFGI6ZO0j6muTnk1b+u5wczenVGXqWjDw3p0Vxo13Ha3Kxqt2Ioo1a6VPmZgu3lgMnA7ZrNttuv+JEtvsiI7vFd3UhTEdxEgBWRCBkFiU+UkY2966LX9Ksde0GSdrBzczFSGjXbMGB29TggDvntnivPrqObwb4qubua5n/swzxvIrKXUMTkqW5LY4Kjjpmrpty6+8b07Thyr4jv/FreQlrBPs+z3N7EUmlbIRy3KnpjgHac9ce1T6dql5DePpc1u91JbRK/2tpVH2iM9HVRkk8EH3HuKreMdX0mXw/NFeX6W9vchFWRkOZFYj/V9Mt9OnWs3wbFPdW1ncWUMVjfWkLWMoly6tGr4G0bs9R1z161EVeHvIyUU4czOwu7gTWzrZ3Fv9oMfmr5h+UDP3iB2zVKw1UT6lb2kqNZytbmUW7r9/n+FxwcdcDnnnFYB063spLmXUYIjcpC63EaEOJo34MqZ5U+oPXBxngnoLK2ivbCC3uZVvbV4gyO33xjjIcY9eowalxjFEe6v69B17aagk8M8UsVxFbl3EDxfvJAVICh84Bz3x7H1rl9f0m7m8GmWy1S8khRGkaBUAZomGHiGOcgZwPUYNdXFFc6VZt5t8txbRAYa5GJNvoXzgn3Iz6560+1Dz2iyWe+yMjtLslQbic9COwPU45pKTRUJuLTOV+Gmv6e1pbaDAssUsEG+ITH767jlRklsqeucVq+KLCIypfails+n2jCcBsiQScjAPTaSRwe9UdSs7zUhc3tpaQ21/aSkqkke51YKMlCp+YMDjnHbiq9vpt7capb2vidob7T0fbBFckBnO3f5hHRiPu7cnHUVq7OXOnbv/wCrRTclt2Kk6zawZml0Yl7aQXUOoNguUwdm0A8kEbSCcYBODmsfwFqt6fG8kNxrdjHpG1pUs4Z8pvZd2wBhxj5iVHSvW7aOGGILbJGkfXEYAXmvOPF50+x8SOLrQLZ7V1NzNN5a5ZgrAycAnGDgk+3pTpzUrxt0/rccJ88XCx1kni3Sjo19qNrcJPDaZL87dwBwSuRyOwI6nisPX7qC6vtL1pb2zWGCF5rSOSTaXI+8wJOMFcL0JG6uSl8OpJplkms6Q1rPaQFYVss3ElzD1VjtC/Mp6g+uah1bQItc1OyvdKtpLG4vHULZzR7ogMFiwZSVUkYJU4OTWkKMIvR9yo04JXb0f5HWXXxQ0R7WOKfT9UlkuVKGBYAwzgblLZweo/Ous8KarYaxodrcabiOJVCGDgNCw4KMB0I9K8x8KaZq914ld76DToHtN7RXEceYrmNTtJKggbugLD0zXQ6Z4rktLbWbS7sLPTtZtkNwoVQIJEIBTnILHBx61FSlHltBa+oVqKUuSH9X/pHN6rfSeOri5sdOhhkvIpphcwTs26BVJjI2uAqbhzwec5z0rhbzw9/wj13p9pYWcOqpdvHGc3TxeQAxXBCHcCM4x3IGM9K7JPETJ4lsdQisbWNr4ndfTkr55+8Y92SEAGAQexGRXVW3hePUpZ9Ug0m2W1v4y81veRr5qv1HlFR8vIzyevPFdMZ+xSvov1/rYUpLVd9v68v+HPJrb4ayakZri+12W3l8xk8t7aSQgDgfNjJ/HB9RRW/F4m02ANDqlnM95EfLkaWcxsSvy5OxgD06nn34orovV6fkhNVU/hZan0y6nuIYGVrPzFPlSTqI0ljHf19PzqhcagEuZopBIs7kv5hk5DDk85zngcjnmvXr+xXU9Suo7iFhDbhY0KoTLyn3ge68/mvIrmPFnhv+1ohJbysIdFASKGSIRuw2gtzxkYHpg81xwr30Z3wxUJySmref9fK50nheJG0SHWVto7i+uowAI2JOztGGc5x3Pvk1BoumWll4WnmV0iluD57y3LbljdWyEJOPlQjGPrWN4atLiK2sptQivluE+eV5QFWIMT+9XgYIKLleRg+5rThkezXWoZnjvoLK5NzJHcxdFI3sUJ7gknoQM4GKxaabSZxTfvOKIJ7K2utMiu7ezhupFm84XUQ2G5Qj94wU85xzgZHp3rD0+OfT/EU8NlJCJIZ4S0277kUvAIB4IOcnv2FdrcTf2gv9nWYWS0mhWZJIyUaOMkg4GO2MY4POK47WY9PfVUtY/KiaybbbmSUoJYFI3QsTyrA52k+npVQd7pmtGq2nTZneO/N0XXGtbUwYcpceWsBGZGJCsAP9zgdmOQeRWfOv2OOK38RLPp11AZblnjhG/c3+rw65+8ck7um3qK6HxTL4ej0A6nby31zfTThYh5++WIjkjkn5VAz37VneI11TUbFdQ1iy1FrOJV2yBkTKnJVnwCDw2MgY5NbwldL+maU+ZJRat07fccf4a8T3fhrXL1dNFtdQ3EPm3EFydgIZjzlc8jJ9eOPSrCXk8+szS3iZkkdpWZZnZXQH5SQRywGAMjNdH4W+Hy63dNrWpy/YGUSLZNasEKjI+YgfKVGBgd+tdNp3w505oJiNXury6WQn7UGXhxzhsdSOM05VqUZNt6lutTg7vcwiVuLAbJDGjoCGAyVYdHGOmDjmup8Lara+fJcRhVvJB/pduCN27uyjuM5OffnFcfZb1t2E0pM8bHzQF2heTVu2soZb6xluGEcKXEb5jPzZHXn8s/jWEop3izsxEY1Icx6k487y5kIIPKkHsRWL4k8NW2tSpO0klvfIhjS5i+8AT0YdGH15GTjFX9JIiDW5Y7I/wCE8YzV95V28cDHWuRNxd4niycoSsuh5LqUF5pl6LHU0WJnyYp4/mjlUdSD2OMZB6VwPiPw6NW10I8hgt3wiyMrERDuTtIb16c4PQ17b45szqWg3cVvGXuhG09u27H7xAWAz7jI59a8h0bVZNW0m3u7m3lihMW4yPgbctycf1/pXo4ebtzx9D06cvrNP2dTczvBPwPvpyZ7fxBayaRJMRM0SSMx2noisq/nW9eeHtT8NzBtTszJH8yBnYSCQHIyoz8p5HTpz1rQ8BeMl8L3l/Hrv277E5/dLEu9FbPJx24xzmr3ibxtoXirXNAs1nvINISV5bmfYE3fJ8q5zlVzjJrSdWtKdpK8fQ5qUJUKloq8Tn/ibryXmg+GRo0Ysruyd3YR4BifaACFHX1ORXo/wptjL4S0TXNcuJ7rWZYZgbidiTtkk3EAdl+RMDHFY+teBPD2t6zaRaRfW8caW5WVEcyHBYbcHOck7s59K7lLA6dYabpdth4ooxAjMypwo9O/A7Vy1asHTUIb/wDDmFWMG10G6vpumXU66rqN5Ibe1bfsaQCKNhgAnHPHpnrWJpmsxxSanFtklS5niMEcw3yOjrt3lR8zDAHvgZqp4mnOgTTalDG8Ut9JHpzb08xWRC25z6EgnBx25FbN7YR3OsaTaWhk8nTrZnM8TASqcBUQt2yNx/CskklrsNQio3fy+X/BHwW1u00VjI8i6favHcwkK5wwJJVmIO1QR0PODjpUWsSNZXgu9Ds47uS2UIbdZVjwG+Y7BjJyD9OD3rY05pbmHzJN0byYLBSGxjgYYdemfxrCk8M22i3N7qmlWksmqXYKyyLOwXaWyGIJIBHX5Rzg1KavZmEUk9TprbUEudP+12yErhjtY4PB5HHeub06GP8AsgyX1iiz20skcXnOA0kW8lSsgzzhscH1B61cP9p2d3bXElyJFazAuIo494M6gDcQPmwc4yMdBmkivdLgnstJumiuPtzOyRSRqBEwAJUrgYGTxnnJoStsCTWxp31qkOmmExJPbLgLFJghMfdAyOcHHX86wrnw3aWniCJrFZYEvEljuFiVWBQ45+YHGGxgDgZzXWBklj+YcddrDp9RWXr80ohX7K0eYpFeQsjMQue2OQCMgkdM1MJtOyM4za0RQlurbTtR02xt7piIHW1kJImmO4ZAcnlVBA+Y+oA60/XbYavpWrwSeVCR8onPHyAgtluwIGKpNo04gs7q2treWSJ8blfLBA2RvIOJD1B+uQMipdTnXWHm0aw+1xHzVF+Y2EckcZ6hd2CVPQsvTmr6ppmqa3MhL6X+z57qZGsb/TptizyAqLiJTgAg8khZB14Ofyu6FqNxeT3dlZXazGyyotLkBXcllO7I7KCV9mB7Yq9rfhSC/wBQF75sgEMO2OIEspYLt5B7Yx0wc964qCLXdItrYK0d3p8TykXEb+Y0BKk7mPXHAZl9iBjAFaLlmtP6/r9QtGadj1NJWtrW4muo0i2F5CEbIKjnP4iuV0i1i1Ky1exhdZma4R7iK83rLllVst3UkcDHAA49K6GDU7abSHnedZ1ij/0jA2lePmJXqO5xWDpAurvXhd2GrH7FLbDafIR4rvaxCuGBySBweh5FYwW5ELxTexkaDJZa2P7O1PRjdraHyJ4XPnJA2ThkDfNtYKM9hXW+GoY9M0iRJfs9vbxSyeXgeWI4y5wpB6YOR+VR2Xh8WqvO9yWvZc/aJkd08w+vUkDGB17ZGK55vDMuu2puxElrOrsLed5XfKA4y0e5lcNye3ritJSjPS9kU5Rk+yO6vbaO5tZ4ZVQpNGUYsOCCO/tzXAeHdQutJ0Kwu7uaEabEGElzH0XLYCGM8+hyPXuKwtSk8RadNeW9/rNo0UaxWx2IxSQ4yICMjZuQ5J/IjOK0NP03WPF7G7nm06GzjYRGJIWUbl6Nx98gEqAeBmnGnyrVqzOilQShzTfumjrniuyu/DktvYss10JlHlToxWZVcMx4P3SAeM1q2usHWb1YrSVLu0hj8ySO3VklRuNvzMcHv0wfy5o+IPB8iXAn0jlSQRBkjawHY9hx3pvwxiW2n1RSzrNPtlKBfkXGRwfXPUewpe5yNxNK1KiqCqUnfv8AMtyatfxf2TqVtZvdzXitBPZxuIihUFiW3dWXaV7cmsuLxxa+KTpKaNY3AeaYuEvYNjKyjhgQTgAkE9cg8V2a2lremWWUAvFMxSQHDRHAyVI6evvXF+EE1S98MWOpQWdk+oRX02yQuFE8BZxncikKTxxjHApQ5Wm7bfrc5E4uN7a7fgztZbyLSbKM3qLGzBifs8bMhbGTjjjPPWq/ia40gaZGPEMKmzmOGWVNyrxn5sdBXNeLNWuLqGC1vEtEs7gqNkVyrySEnaFyRhRk9cHoec1kjUYdHujb+J7uRW0+EzxC6bcZEfgBcd16c7snuBSjSbXN+X6FRpbPqXPCmuR2N1LbJHem1STyYDtacxxs25M8kqMEAg9gPQ122jfYLZWg060FsskkkjqkOwF8/MT7k15zpf2qLVYr5NOv1tbmALuihC77s5KTE7+VPPbAyM11ei3t7FbR3McU8llJPseKUh5oyRh+/GHB4579OKurHqFZK7t/X9f5jPF+j6Zp2my3sEMtuCVSZLWRohIrNznb79TXkWtXd3cyi/lgfUnC4MXytIuOmMkZ7jFer3msXF5FFDNBLH9oLRl5gFhRhkopzgiQnbxgg9K5bUPCk9hHJf23m6jarEBOkQJlklHUADoR78cYNXRfLpN6nXg60aban1/z/r+kQ6Ro82oaDb61pqRX1muLgW0chRo5UzlWUjhh90jr1Fek+GNcbU7SAXVk1hO0ImWMNvj8snjDYAzjGRwRn8a4n4eXn9n65Cnnx/ZdViDgFgBI46OvYnAwR149qfNbz2viuTQBJbXtq8eYUuUAKPhmVSR1+XK59MelE1ztwl6r9TDER5pyb6a37rv/AJnSa3oWg6ndrPNpsV2QgQSJLgYBPHH40UttZ+Hr6Le2bZ0JjeFZng2MDyNoIHXuOtFY6rS7/r5ihi1FKLk1b+u5vXuoPaBRJZzzM3AMWNn4kkY/GudlgtYGtb6/M8lyZntPLjj8w4ZmIiwByAp256d64mz8Z3mqXEmo6heotrbMXisI2GGcLkbuhdBgn64r0BbrTtZjsby1kcPdkwM0D7gp2klWx0+7jI/lT5HTWpM6UqLtLcr6HZzRW5HiQzXF4gM0JdVZYlzgKmP4umev1qn4jun1RILHVdPfTbYyN5ss8qllXacOpGRtJwDkj0q/qLTR6va6ajRT3Aja6tp7k7fJ2/KRgD5s56ceuaupdjxF4eXybQsLpORcJiNcdz6jI6fTOKV7NSf/AAxHmylpi6V4ds5b+GGYfaV3fumM5nYAcIcnJPYHHeuZ8YwQ6l4oh+zSrC9zbAOZwYxGyncAxPfGRipheWV6syXukyxxQTs5u4X2Qg4y2OQedrY+XrgUzUvDmo6tpK3dxcxyRzqk7tPF5ckZC4GR9PTuc45rWK5ZXk9TanaE+aTt/wAE88NlqV3NCILZrdkdnSKNS4HHzZPUrjJ/GtjTxreoeH/KtVlfSYZdkts0/ko/Q7VOdxGP4Qf511aQxaPr8d3psE629rGgvUlnwyhsjcNxyRwPbNVL2xkRtQtLbTHupbe8W4LRH5jE55yue4JwVxyM9q6HV5tLHVKqlG8TKS6toNHmsdT0uzgmmx5N79pOzdtLHc38PC5xgAcZrp9I+JPhmPTobLRYpJbtIPNFjaw4CAnH3/uYzk5zyOatWPh5otRe90fydOf7JtMM4E0TMx+YEbs4AAOQR171g+P5NPuNR08taSwrBGYlvk/cxzOfmEKt04AJzg9cDnNZe5VfK799/wCvzOV8s5JNHPX8s8l7eXsjiOS4kMjQQHAB9FPOR05781Lp9+6t5EzIkSlZJyWyUUkfKoGSx7Zqg9xHbXNxZo0qxwAEI2HcIcZAI4JBJH4VVedILtXRX82IAgRp0JBwPocjNb2TR6ysoq2x7TBrmiXNsZpJJIHQlyHjaNxz+tchp/j2+UTx3EIRmLmAsdwUZyqvnocdwceuOtZdtrcc9un2rb50Y+Yg8c+vbis+5u7AytHJsZHG7AXdk4/zxXPClFXUlc5o4SOvU7rx7rzafoUFlavAx1P9xGY2JfGNzt6fdzx1yRXm2uRWg0qa2kRTayRbfJZTj6tgjP4Vw3jjWbmzurQXU90dO2mfTJQ4UWsi8MARnd0+UN2LDpXe+DrLw94ks7RtS8STW2ryRDzYrqNYWdyB93JwVznGPWtYU/YpNvQUJQoxcd29zze61lo7O58pQkfmLhXAO9CPu8njuc10XgLQdb1O0ubqws3e3lk8sHOHfjcdobjHP+NdJqOq6dc2EmnLoNha3dhIEa4gUOzPkqcHbtBOM/MRxk16B4CTxG+u39zrqKq21qtrAmFXJyG3fKSCWXGT/sit6tflptqNvVnNJyg1Jy1RyvhjR5tO8Y6PZeINMuIpZ1aSCbeAAydMlTyQSOD613XjvwpZavpTOWuhrEf722u4Z2ikEqDggjgfTGDV3Uri8fVtOdbaBRCW2vN1G5SCyqBlvTAIPOelRwSXNjYRrrTpNEkeIZLdWLsVX5g33hyeje+D78EqspNTW5nOo5yTm9uxxS+HtTv9PgSx1zUl1COItcafeybWMjDDEOeQGyRnke+a7e11GNoIrOztJLARuLaaOXAIJQ4AHU8jg9xzWNqkuoz29rqoWC8VJV+yraNhznO6PuXGOccdDWvYwXAid5Li5vjcpvkaSJY8nGwbO6EZ5J7dqJvmWv8AX9eY60uZas2dFuYry3bycvCMGJhGUQqQMBSeuB1I4qLXJ/s+nz3X7gGBGYGY4UnGMED64rHh1W1g+x6XqMYTUwzRRrAWjQKTjcGXhcgdPY9Km16ynvrixQfZ52Rw0QkIyrxkOGD9z2wRjvWPL7xzpWkQeFbqOC+vdMhs7mNoGjJnuCB5+4ffDA8/wjHWtu7kt4YVn1E29sJXCPKVAKk9AWPT7oH5UtjJObeOS3tofsrMdkbtteMZOexHXtximWc4m0yR9XCRJLNIipchRhQSAGwcHpmlJ3dxOV3exzWk6pBdRXFuskllqKyt57pMDMvzDZlSDuLDHXgdiK3IlvNViurC8ilt2igWPz5FAZpGz86Mp9AM+9c/eaLLq00MWl3llb6jYO63V9EqnzS68Iw65PucjAPOaXwbqDW2qXdrff2jPcofK3GUzKpyd4wcEnI64PGMVrKKs2jRxuuaPQv6XHbwaRDPY3sEN7BB5Qu3UmAlSN6MMjJyvJzuzk+orO1J9agsrrxJcn7PPbMjBXU7UtQuXUID853EnJIOAMYNO0CbT9avtQt7qUGxuNR+0Wlm4cSLKnzPvzxgsN23tn3rsNdjSXSp1ljd1G1isfDcMDx69KUnyy16ivyS5WWF8q/08LIVlhuIeShIDKy9u/evPtA0m20OWO01xpVitA9uzyA/ZpVkcsj53YyRlTnvxWrpOs3OnXuoJqNolnphneKziaQGWSQNyAD8oDZyFBx6UniSGTViNStJQkEFs2xZsqvnDJ2yjBIUDP4kHmlFOLcejCKa93oYnh7VtO8o3Onwtpv9r3L2CsoJ+ZBhMgjC7cbenIPtXfafqdhLZwtbSw+W0pgVIyPvg4ZQB1wc5x9a4+3ttA8aQG3tHuFkktfOmYK6bJSVCy4IClsq3zDrz2rVl0S2gvZ/7PkMGrJGlwJc7xKqkgfLng8YLYyc8k1VRRbs7phUUXpaz/r/AIB016YBbOt2EMDjYysMhgeMGs3wp9nj0OH7DLA2mru+zCJSNkYJwCSTkj8KvXlzMmmvcafALqYoGii37RIT0G7sOetchr1nrEeuWv8AY8z2CTxyyXQXLxhtow/TnB6jb3HOKxhFtcpnCKlo3YydTDeJtf1AwL9l0sgRvdMoaOSVRiNic8H5sdMgYqXwr4hk0e6fSLuFJXVjtEbrkuR0DdDuOMZ9as6P4Xu9U1CbUtY1RZbWdDFPBZXLiKYqqqrEqRx1yuOOOoqp4n8J6dFq9jDpsws5r2RUjxD5kSkAk7/QsM7TkZIxXTeD9xs9CnVpO9Kp8NvuZp+KNQs5db067t9cv7aWxkJltII1eOXIxtfPAPuDXBeItRl1HWlPhu1vYbmabCJnLBs5Jwv8Pf8A/Xiu3tPAkXkXcVzcz+ekgEVwECIwwONvPGTgnjNbFtbQeGLC7vEgDW8I86SKIHMfHzsmfmPrgntxShKELW1KVelSi40LtvTX/I890nX76fVL+y106hIpzZFo4ZI4YYCpJeTaNwI7FuoPaux8K6rHP4Rl08NHbXtovlotq5YyqPuunHO7HbNbmnxWWswajPHdPcW99tR0CmPCAY24IzyCcnvnisRfDF/BeTXWjzRaUsDulvbmPzFaHao6A/KSQSCOeeQaJThNWascbnGT7a/1/Xkji7jwVpGmWGn6rFqV3KftZF1dGIkwSMf9YUxkKrDBDcDdmuv12BxdWMGp6bHrSxA3KSTxL5h/hckcKMZXjo2fUVwUc2o3l5qc9nPNcapcr9lkkZirQkk7VdeA2AM9OB1xUmmeKNd1vxRoNo0sMOoW0c0G9pwi3B6biVBHVfudeM8VtJVJWbe3+X9f5GsoS1u72/r/ADO10b7VZWl/pMNzE9yA9xBYykjbb44jZM7ozzwwyKv6HpB1fStSttQiv7Owe5PkW5lMZVRgkgryQWyck8g1zereGLqw0efUtX1GaXxBKskIuPOJ2pycIFAJG0HI4q34Nv7XRdCXVxql1f2MirGI3kA8uMYCsAxzwSc/WspK6covXT7/AOv1Mpp8t49zuPEOmjULACNUM0BMkIdAwLYI2kHsRkevevONU0u/0S7guITNZWxAWDdfyJCrSMGbzCOjKckA5DcjNelW2r2M9rLcW8pkCMBIgU71Y9AynkdaqeLtRt7Dw5qNxKguPJQZiUByH425HbnB/Wsac3B8rRnByfuI8w8TR3i6vLd21haRx2bpJ51hOsp8wnPmNHxt3Edh65rN1bxNd+cup/a2m1CFspI0YVV2dRtHUDJ966a1XSdZ06WS2tb6zv8AUkFxM8DZiil2nK5JGRuBO0c89Oa4aeykuYLmP7LNLJYIS9vL+7fltyvg4LRlsjg+gJFdsLXSktj16E4Ok4ta7a9n/X9M6/RviTd29nu1O0lmnmbzQYY8KAQOMHp0J/Giq3gjwTJrHhexvjeXwmlDeapnxsYORtwM9BtHXtRUzeGjJqW5xexw8/e/W34XKWnzppfhq0n1PTjIl+P9DSG6XDL/ABqVI4DY5PPb0rvbFEmeyln0y1jV7sC3iiwhhRk5dWOC2eeg+ldbqOk2GpW7QX1nDNGy7MMgyB2APb8KwxoVzp/h4wRhdWvYZMwfaTyF3YUBjypVccjuKwdaM1pozGVbnd5b3OW0+TUbbxRfy+I4lvFaEQPcblaCGEtgfL15755zk1oXGnXGkWN5c/adUgCSAxxW0Z8uONeVOwZAH3sgHp2pEGtxS/ZZYn1KeaQzzRzJHGm1V4AA67sgc9xnPFdxE4Sw2WcKkxxhVgZtuOOFPXFKc7Pp/X5BKVrNHHBdN1ea2m1nfJPIhBsoGyoIUZLJjPqR179am0i4bW7tLVVuLNbIP5LNFhbghtpbHbjHHqc9qkt7e/fUMSpb2E8WFifHzSqedm/HQHIHc+lXL3Wv9Hl3aTI7wS7ZlDKAGxztOcnkjkD3ob6L/hhXXQpwy2M9pPZ6tp0kEl1OYlj2iWaYgf6w45B4zkjAGPWuWsJtVu9WQQ2t7J9gYWd2qP5cgi5K5wRzjBq19mmv9cs76+kmint528n7QwBuI15RPKGNxDt69s9afpt5HZ6tqzQgx63PMXuDteW0dQWH8OSuACecHg+tWtE7amsZ8iaXVEGr+IVg0W406bSb23klt2htS8WRIQOQ3QKuMZOcfjjMMuvy3Vpqa63aS2yCzFtb5XcS83DDAG0EDGDnovrkU628SzXEmjasbaeCzsWaCd5JlZZxL94kDpwpYbsDoKg8aanb+KdSt4NL00T280M6C7nQqJWTDDyx/FhgBg9dxFUoK6Tj537Cd72kcNqWmXmn3MztLHFaNNOkZWQPJJGjEecQP4TtPTvVm90rVrHTDPqNs9kPNIiRs8lF5JI4zjOATzzjpXT+IftN1qGg6nqunwR2dnBF9rsra2LFYX6Bs8DlThB0BOa7Xxq0R8Ezvfg26NJGSsJUumZBkLn+Lbn9a2dZpxTW5t9Ykkkjw6ds28kafaUvRCJI5UOSOoy/+yQMc+ua0brR5NM8K2PiK4aOSC5lEcaK5WQrzjAJwec1XvbDT7f7S9heTzWsQwk0iDc6ZHB9855+lb9x4cvB4RvrzV/JSfSJIykRbKOhUMUzn7x3IDjHStXJK1mbSlor6f1/wSj4Q8Pt4j1m3OuadHNpVpeOk8UhV1SRlIAKggnOcA+pq9B8OtWlknu9Lt4JYIbh1gF05WV0U4U9MZXHQ9xWzJfNo6edb6ELfSvEMQX7HuVZVnwArptycNuHGMjGeK66zvJrLwVFqF1phmaP50gs2PIOAvX26n8e9YTrTi7xWj/ruc1SU1JSvucP8P8AS9csPEN8lvLpun7vLku7WUKwuFYtxsGCrDnr69Oa6CLT7zwh4vjOhv8AaNPuYlS8trh3diNz7HWQ/LGFB27TgEAYrq50N0tjfPbwXBkH7sQjBR3QDO49fTPGBzjis7wrDdLotpdWtr5+5Fhm+03GXKoGB2nGOGyAD2J6VjKrz3k7drGEpXvJkNnZ32tX0Wu3PmWtvFItxHa3gKhB5ZU4YHAxknfjPNbWmSbLlzZRtLGy+c+X3gK3/PJ/4hlScfy6Vj+JNMWe2MGm3BimjmASGaZ/l54CxnKsCccdMZqKy0d4vGJ1K3xHcxaeyXNlaPtjnm3Aqx7cjODwcjnpWbtJXJ0aubNy1tFfRahaTqkczqZW2go7FSqKe4JJ61g6zHa6b4imvf7O1KGAwtJcSRwGQZJwWjYH5DzvPTO0cZqS2vXjsXu7FoLycobu4gSUBlkLfMAw4yowOn8JrYh1Br/Sbp7KGOXVYozG1pMwzGxOCH9uv1xQrxf4Gqjyq/TY5q3XWrnww4tUTSGSRrgttPnzscsNvI5IIyTnqRjili1O1v5YrfTdOFjeWkpmutykSxt5e35QvJJLAc+oPIrZ+xPe2403Wr2xnWB4ljhQbXUkEYLd2xyMAdKyPGV3sudO1XRy9vfpeGwurpISVbGVKtkc4OCCeOMZ7VSd3Zf16ii1KXKya7+12OguJ9YSePUk3ol2oZoFYDkYGXbJx2HIOOtV9Kkv7m1m0aC13wQyou1iyLg7nON331IBHPIP0re8LzqfD93HNGl4kEjKUgQlZVAH3Fb7wPX0OeKydD1aC4v98M080Bu3aLzVO3ykUBWBzkKuXHPU0J7q2wtZJo19dmsUs4ntra4uJZImCwW5Ku4VcrkjoQRgE+tVNO8KjyIxqdxOt7tEytaybGglK/OQf4icdTmumupVj3SEqsWzG/OOD6GsC61g6LDI2qahZRXDRmVP3bER9dqnuQQD6His4zla0SI8yjoZOk3LLYtr9lPcvZPvSK1FqjSb8kPK23q+VAzwMdav3vjexE1rbzyCyjmiikkuJ1OA0gBEagZ+bB5JOB70+2sr2y8G6mLaC3a9n3yRGEMEuC+CG2E/KW3cj15riNG8VLNpOoWPiDQ45tJjk2xvE28qXLZVg33WU8DHYD0q3Hmbdr29DopUlWu7X1/pj/FV5Lq2nWcMMFxLJcT3REzQ5hm3FisOef3nyKBjpjjvSwW9xP8ADyabTzLf3F1dQuZVnJO8FR5Tr2AyyH3HNangTV7Jlh04hpoQ0smm2xQecgX72/HGeSVYdRmuycrZ6deoIVubF2aP9wwZgxG1t/TktnJHTqfWrlPk91L+rjqSlCSgls/8ziv7V0651bUL63vW0i4ES2t3ZXrbQkORh1XIwQx+76Zz1o0zWNWlu3gsVtzf20TmSGQsZIVVydgwvOARhScncM9q2Phha2+oeBbBdT02F72F5ILr7Qqylpo3KlixySTjINO8Z6iulahposHtopvMD3vRT5ClCwP1XPXrjA6Ck3Hm5EjJ1OaTjb+kVdc8ZWaaHFDpV/cwTC4jiF6bf93jf87cjawAByBggelCeOtunNd3No1zPbPLtuLQgW0qKSCSxY7SQuQD+Ga6ePT52062t7e5BNvIssE8q+b5ijP3sY+8CefesTTdJg07xHqmq2Glx2JSDyry3jIxcZw4dADtHA9BnJzUp07PQSdO1rFLU7zTb3UrO88PpJdT3RQyR2cqIJYzncsoJHrkZ5JGKmmEfjSeG70ma40+S1crC5yvnxBgkwMZHDKwKjPf2NXodG0+XS7m00+3u9MXUY1uoisgDlsZ2gEnBHGR75FMu7S0Ogw6zo1nLcTyLuBMhEjmRRGSzN/EPlyc9AaLpbb9P6/APaR05SmNavT4oaFCJ5RYG4iaKN49+1+UkUkqc4KggnB9KvprWnND9mlea1srpVkR75ZFG5jkqrMMcehP04rgtN12Lw34m+1tFPciWJbGe3uCons2jIJQBcKQR82QBu+tdsuoQeIX/su+zs1W1aa3hYNteIMPnDDgOuQSuc9KqcLW00NKlNR96Wi0/T+v+HLVjINB1S7hstEl/suco6XcLhlJZeM5OQgPpnGe1Z2neMdVTxNc6Tq1lp0ciqxjRbny2LDkAFh8wKlSDxzkdqfaeJT4anuNO1oXUltCQtlJ5W6WRM7RuA98AZGT1561z3iGxsviBfaSbHV7VLe4U/aLGY4miZcE+WQMhsHBB4OM9jU2V7zWnfUmNJu7mtO+5Vs73W9M1K8167iisX1uUPaxExvE7KvCSP1VtoOGBweevFZVxoeuWt/a6yLSyh06O7RZDaMZHG05RgV7fws2N3PINT6hqumNo2iWWoXUmnnTLkxXUFzB50SRLvXcV253EBevQt0IrZ8OPbabZWdx4N+3PpFgrtcR3MRVZHwCBu7ZDHnBC4Gcc10Jte8l5bPbpr/w5pNtaNavf8rHa6dr2ma5bS3n2eWO5tYAx3p8wDjOEJ+9nGAe9cDpepWOmN/Z13BHPpV/ErwvN+8ms2YnZG6DsCOoxjIGa2JxM07tIstnBcmO6YqfOjs3GdrB1HfGdvQD61Q8N21j4e1jV44tWS5u7qIyyCb95CrMSzEMASVOVO08DnmsoxUU/wAv+D6/1qZxSSdlfY6WHTNOun8vWoDDq0AaVZrglVdXI43A4cA7VwSSOPWs6PSr2SfUY7DTWWeeUxi4kd0Vkzks2eHUcgcZz7VDrNreXmm+GL/VRBdaPZMlzdOyecxb6JxtB5B5HAz613msavaadpZvLhybYbdzRHO1WON30Gc/hUSk4+d9PL+vIwTkrW16/wBfmebeNb/xGL+w0Cx0+xEc1ykfn+ZgZxkucAY6HoQc9sVieKLfUYdQRPEc9s2osvlRQCUF2h/hYHjI4Oe+evau01J9D12GWztdNll8ifz0u4wV2smD5gY9ySR71n6vqWoTx22po1tC99EkdnK1uXZfn5WQdwBuJ44zwa1pu1rI6qNd02nFJW0/H+n8jj9KvvFdnakeGF82zlYvI4tpJAZfutgg4/hFFSeK7jVvB+qnSrKeIQhTNutyYwxdmYkoAQp5xgcYAorsipzXNFJocsPSqtzlFXfqdOnjO/8AtFqL5IVuLaN/tUgLCI4I2uig5bHU9Ota9zpnibVTbajc6j9nNuUurWO0iCAKxIZHBJLELg9eeRXPWnh+x1hnaxle1ngRoLgwHzEaVG2kkY4ZxnHb61HHYeIxoZn+2SGwj3s4ifDR88q4IDLwBkDp2rjcI/ZsvU1kqUn7j5X5nQ2Ms2sa3Fq2pTokdm8tnA9tLt3ckeYydf7ox059q6W9jNvO892WY3US25a0BDO/zbcj6E4NeaeH77StImvLaWbeZI1cR3SAF1YZfZznqchsjIz+GpbQ6nc3dpaumoz6esEu15bZk8ttuRtZScj7o6chjz1FRKGvkYVaXI9XYsyXB1aS1gku7y6t4LryWgcjzOEwZVZfvFSc9emcCtywTT4PDWoC+ikOneYwd7qPa7AdXbOMr3HtVSPT9Il8ImSOygsZrON0gcZQFwoyRnBI3HGc9R1qOC7GoWN1cWss88sNs1nLa7BygH3oRn58MRzk9MZzQ9VZaGcnzGbpulpZW+oXKwPcYg8zbcEq1kGJZTHkk5C7TkdwOfQ06wFlcYFnFPcW0LeXe3JZ2aKQEsHCkAryw3Ddjmk+xXH2uwhk1A3slykEDQQsEljEZDuknBJTB56cda09R0WNtam+z6QUhW3lCx+awaQqNqNGFO0cEjBweapvu9/68vMcpa3v/X9f1Y5Lww1pDfG6Swu5ZftZMEcat5KW7kNtTdgZ56EZ5IrZu7q28/w1JbssVgjzi4ngBCxTO4kEZHf5lYH8eKq3GqSWuiW8F/bi2WN1t7qBLbbKBg+WV3EbwBjnbjIPNdL4odZNE0e+Iuktra6ikmgACsQM8vtIC9zVSfvajldtSIL6zj15ruW1vtRtb28tfOgg82NFmh7oNuejHljyN9M8KaLPHd6nDqs9tcSRyxSMEkMyvNs2hmDDjbg8evPYVl3l5Haa9ax21vDby6FGwWR9xW4iYhiYiP8AZHOe5xzV3Qnlsbx1gvPttxqh+1MEdIrmMkAfMrDB428cEYzUNSUdP6/pBq1Zbf1/XqZnjnwmsms29hoaWNs93EzOJXKmRyxyFByOBkgcVe8Qy6rpsF6un2Md7p88UEUss4CyRygsN5UDDbQqgn1A9KXxDpw0aK+1G9jnvJ57M+S1xI0rRz8AKjKvBHXPHtjFT3Mk1loB0tRt1XVIylzPcT7Sj4UM/wDtKAw+7gn061XM7Rvr/XfyKXvJJaj7O6jmmlu9HWW+n1NFvbSO4lA8qVW3NECfurxnjPfrXUreu9jDdtHPEUzvtkQBw2fuYzyf5jmuL8B/2faaLY3YJFyIRZ+XJOxETB8ZQt0Q9cgZxW1A863Mcmo26I9mNsuqHDxuR8uNueMhuvUAe9Y1I627ETi09jIt3guLKSLTNI1KDWEna7ZPKYL+8ct853AEFeOOR2p2l3+k2mvSWBuhYL9+xtIZT5bSg7WIOPncsw45HtnNdpf2t1Pc289vdtaFFKsgiDbwcd/YdPc1YFvatJHmKOWaDLI7qCyFjyQexNJ1E1qS63ZGHax3RnuoUsnguo2SZJrgF1lxzgN1yCxHXpUd+J0kkuBZrbXjw7o5Y2JVXQkANwOoY/LyOfxrf1K4W3tJPMlePeRGrqMlWY4B/Mism5V7iSWBJ7zEQVjPCRmWSNtxQDGAM4B/EdqlSvqRFvRker6RBb2zTaXA8F2XYlkfarlxgmT1GcHHqKs2mmxWctxfSAC9lRRNLuJBC9AAeAKVNRuJ7SM3FpIJxEsjxqvG4j7obJB/PtzWRa6xNq1tqUk1hdRRWYQtbGM+a5JyQR3GBnjqKfvvRm8U+TcpWjR6dDdabbafLcCW6crcvPvkM3yssrdNoG7GQeo6VrWk+nQWQ8NSyXomaBtj3cR3TnJLMC3BO4/qMVc1KbTZ7K4uLp4UtrH/AEpJjJ8kbY3K5GevcZrmbPUNT1PxFbSm5s7xRZSkQWqY2q2NrEsc7mKowHoT6VXx6/1cizabl/T/AK7mprEH2i6fWobWWA2UMlvh2MRBGGD46FRyOOufSqsdhaW0Wn6pZwXNuLlBPcGNPOTcTu27G55Jb7uAPpSeH4/EGurcf2uDYWDRSQyWzLu3sx5AzzgDIznuPStNtB+xW91aaNc3e1EZ0tmnykYP/LJR2DAtjPTg9qbfL7rZMrRfLcx9LubZLW5t7WS4vBE6vdxNKDEY3OSVWToMEcDj0qlDqZsdZl1bXIhcpa26WsM9soZJ2znaPUZYfN0BHOM1iS21lpumXsknniG4jWOOR2JaKWNgfJlToSDjnp+FSpbzWf268S3lkg1DbBayQxKqoZGG9dudqngfMpPPTPNaqC1OicI07369zuH1t7rTo7fR7aa0v/NZYknRvK3I2TuZc5RunHr2rjYprvxDH4mbS3stLvo5Yw8i4LvcJnLRnPyg/dyQecnua7jRLm50+4ePXGhgnk2AsgOx22nDM2MbiFIPPO0dK0ptI06702a2WJPIuN7b4cbgzHJZW7HJzWClGm7WOaM+ToeOeKP7S0W/0mRI7XRrz7OpLwzebNKD8rM3AUHjtn61o6NeW+lJLb3F3Lo07yRN5hZplkikTDOyMNuGYL15Gep6V3/g6JoLB9I1COKS50mTyI5WQfvYcAo4Hbg4OO6mszXPA+h3Tyq/mszW880doZOCxAG4E8jBIwM4Ga1dWHwy/rr/AFc6fbxl7kl81/X+Zztzc3WiW32OfxTawWZuQkNwkR8+JV+bdsBwVLZUg/UZrpNfns9ZtQ11aTXcLQM1td2EoVp1PDIqnq3+zyCOa4Twq1v4m0TU7bUpr83VnYxkPHbqUMUZJQJgfe7HnJ7cV6fpMFgktr5liLRrZFa2HTGUwcgcFuSOfeiolB3e4qq5XZfEv+B2OB1XxDfLa/2RaXtyZhP5Lo9r8sqg4wCCpjx/EuCOuCAa6y0h16w077J5Fq94GMcLKp8oo3DbgMlAOGGSe4rctdPFvPJcTHz5GuHlgkdRmIMOVXHTv9ao6/q8+lxyPHYX7SmWKNnih8wMrHlk67iOmDio51L3YoylLmsopI537PJreq2Wj3uool/p0DN9iMLwhwy7N4k4+YA5+Xpx15rndX1uTStHT/ia3YuLXy7W3mWN1t3UNkiRfuswwRkcnHXmtLXXPiCLU4o/ENuUgVLqyu4see0g/gIX7q5GMdTnoa2NRsjeeB9S0yedrxXJMEyoJAXwH8vCgHqDyAD/AF12tf7v6Xn6mnMoNKRX8PyQ/ETw/qNvqiW1vqCyIXa3iIJGPll55O4Ajk9BW9oNvqFlMEt1tprG0drZ/sxx5oAAyYzwHBHODzz61ydtYTeErB9RuYIkG9jHd2TuzKxUYV0bO6IkY56cH3qPWPEq+KLprPwq72syKs+pXRzbhOijJP3ip64yOMUpRbdofD+CEoud7P3T0D7NYas1rq1zp9w89nvWKKZPnjJYDOzPXgEZ7V5N4ogj1jxpara28y3M85yY7eSGW2wMbM5AJOC2ccE8mvQ9I8SpamDRNbeSC9YGBL9dohnO0EMhznJBB5HWuTj1vTdGvb/UdMiv59QQhbhZmZjI6M0bO2QcKCRkZB6Y6VNKLTel+w6DqUm3Hf8AD+v6Zr+HvB4u4luby4ngjbJjhmVWmDg4DSZypOMggcEVvztFoVs8N/IPst2W+0yPMS0e4bTIM5+UkqNv8OfSsbVfGb2PhyKSwQtLKHCSGPJhXHBZT1IJHHfj1q/4pvLDVfCN3e2rvO8IVTNCGRgTg4OOwzkr0yMGlLnbXMtNiJ+0qSTqdRvhm5vrfxfq1ld2irBKkbwzRcAouVV2H+10OOhFS+LEsNElj1SytnjvomUO8IwixkjO/IwB7cHmuRHim21TUorSHUjHLawqx1eFQZXIHzRMuPugk569Pxql4gu57u0tE1q9kmWd90F39pD2uxXI3PEFG7g9Djt6VXs25J7FRw8k7taP+v66nYaN4je213U4Lqyhg0J0jltXgBfO8ZYsoGFHc/Qk1X8V6Pb6Tot6uhQRTSEPNJbqdreU3PysOeCCQMjIJFZtvqcGhiI6JaRXVyBsE8KssDMT86yNk9gGDcfrUsUmp6voljqlsBMt4zeVhgqqGcbYm5/1bAdV5FHK07x0Xn1M1o1J7XRs6fqlqEsV052vvNskjRCvyh85+cgHbxzz0/GtPUkv7F7iC10tdSsrhQywiQL5chb5lJI+73z26Vh6DeI2oPo+qaHcWs8cxmM0Z+RM8IWYYzycAjjgGu8ACQ4bzGEa4OeScD9TWVR8r2/r5GL92XLY8lvvCOlavfT3HiFR9sUiNVikfasYUbRkEg4Bor1TTZ1uLKOWOIIr5O1O3PQjjB9R60Vf1uUfd108yJKrJ3jKyMf+zbHQ7mR9OVLMXUZVokUmNiP4sDGCM9R1z0rDgxqPiHTLeLU7+KR7IzTC3IWOTBwrsD1PDAjHPGaKKUbuLk9zWm3a/wDWzJtW8ItcW14b6WB3aYPDciANJGhIyuCQMfe4HrxXNaI+taVcX914eaKe13OWimchCiAbTg8gkHoPSiiqpzcovm1NKdaahJdDoNR1qz8QeFV1NIZgttdeVKYgoaNvuuV3cMOeO/Q9q5+C8u11fTYYIki+x3H7lxIcu8kmCDxjYVyCMdcEUUVpCKSlHs2v6+82hFXsv60PQNM06ygtZoFtTZTzTSSMVI3hyeXVhwOMfl0plhf2ms319ZXNuy3OmT7DvOQ+VyHGPUHoehoorm3Tk/61Rzwin91zLv8ATYL3x5ozarEJ/KjlkstoBBChf3kpJHILYVQD1zmqmvQRzWqagkUEGm+Y2+EqcuHGGfA4LDJIB9+aKK0g37r9PzYJtyUSHTdPF3cXGracIG0gBLc2ahoxIBs3PntgjIGOx55rQmt5dWs4dWh8mS8gu/tEQRcFVVdrISw6naMkenFFFKU2m/J2LkrXfY2tK1VNZtlktCYbjbiaCTPyOVzjI4OPUV534h0DxDNPp9vocsVnqMcccsl8z+Y4aMkMu5iSQV9uQRnkUUUJ+zlJIiU3Sa5eqX4nY6Ro6me6l1RIpruaVlt5J0DkJtG7gcAE7+PTFU73xDY6LrWqC60xkt7OCJry6VwVbIwMRjq33RnHT6UUUUlzz5Xt/wAFGtP95L3tb/52NHQ9fuWspn1qARmOR1SeLBWROGQkZyDtZc/jU2qeKdJ02Cea4nYiAqZNkbHG4ZH1ooq40YyfYKFONWb5l/V0ivd3txqemx3VjEBHtEqPJ91RwQ5XOT9OKzbu21KwvVsLe/uFudQl86NolTy4AMb2VT0U7vu8nn8aKKzWj5fX8CXKzdugyWz1Cw1qxfUtRF5byTxWrQxxeSMFGwcg89eR0OBit+/0+e1jH9hkW1wrKpkbDGVe4YtnJx0JyeKKKmU3ZMqb+Fso634Rjvrx9V082y6jLGisl5AssEoXs69R9RzmuS8OKJNevYUsFstQuZ97+TdELbtCcOVIX5lbspGMHBooq6c2+ZPov6/IVGbkpRZ6hHeq814siOi2gGZHwQ4xksAOex7V5hHdR+KPGl9eWx8uwtYkmkigBjlukVl+aQ9CAM4GQcUUUUYpc0uyX4l0YL2c59bpF3Vh4Qbw9BqJkvPIuLpzaEySkNLz1XpjjuOgroIBBpHgCZ9YgD2yRvOYkYn5S2UAbrnkc9vwooqqqcUlfd/qOpD31Ft25rfiY3gqWLVNChtPE0MxL+bcW7PcNIJI04Oeeq7sYI5GKt+DrW1s30m5jsbcC+WRbVrcMvlIADltx7gEnA60UVVTS9tv+H/yMKj0b82ZOu+IdJ0vxObrRLyaO8aURXNsYS0UxOc9SNp4PI7+tdJDdaP47tJ4ESdJ7byy+RsZcnds3Dqp2YOOooorSrRUKXOnql/kb1qagrrdf5mLoEd54c8OadqZkluZL1orae3MgCwqXIQR8fw5I5PIPXNdTqOq2VnYR6hO5njklEEJVTudydoHPTkHmiiuafvNN97E0oqck31OXXxZpMtpNqatdWupRblCyKZI9wGB8uSMZ7jBqXxDrE+u3lj4csrl7XUJRC9/hARCCN+Fz1Jx2PSiiuh0oxvLtf8ACx2YzDwoNSjvZv8AI3NCS31PVbu/gVrW7iRLcyRHAlRS2GK9CM5AyMjn2NZ99LDZ2Vze36/YrZWld7m0ldWZgf8AWFAOeRjBJPFFFcrdp8vojjo0lKo4dLnDXl3ef2Q+o3tu9yhTe5BUKkTSBwB82Ru288EjceeK7yy8H2lpfS6lpckjx3sLA2t1IzKvmAcqeewAIOeg5FFFdFaTgvd8/wBDOVWUop7b/ocJ4ksdL0SNRGXg1PTvJNxgGXfISWLBm7dDjjrjiuz8JXM95o99q9rMEmuLsvjbmNkIBwFP3SRjJ9eTmiitKq/cqb3/AOGZ0TinGLfcnk8NK+sWmsLIscZ8vfarGF5Gc8rgHJ9a5/V477UNY1nwtCLaNNamaRp41KbI0VBK2M/f+ZB780UVz05uTd+if4amTk0ubr/VvuOSMthYvpfhqG08rWLG7aGe5WJAzxHJZjg4JHBxn6elXvEVvptjYXVncxrgbI5TChj81S2dwIyQSrAZ4xnpRRXTUWkXffU9PDK9b2P2eVP5vc7nwnZaVqsVvdQ2fk2XkrbwJuwWZfvl8Yz6c8Gug1K1DWk9vDOfJWSMeQqhAnzAgKwHHOPWiiuGpJ+0t/W54tSCjKSXS/4OxnItnDp817pzXVz9qmFvMZZmdotx2naXzjDEcDiug05pJbIJdFHlX5HZc4bgYP4g0UU6mn9ehE9b3Mq71TS7K5kivS6SZ4KF/mHTJx34I/CiiitY4eMkm2z0KWFjKKd2f//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power photomicrograph shows stellate lesions (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Colby, TV, Koss, MN, Travis, WD. Tumors of the Lower Respiratory Tract. Armed Forces Institute of Pathology, Washington, DC.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pulmonary Langerhans cell histiocytosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 399px; height: 263px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power photomicrograph shows a stellate lesion that is characteristic of pulmonary Langerhans cell histiocytosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Colby, TV, Koss, MN, Travis, WD. Tumors of the Lower Respiratory Tract. Armed Forces Institute of Pathology, Washington, DC.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_54_41834=[""].join("\n");
var outline_f40_54_41834=null;
var title_f40_54_41835="Knee pain periartic causes";
var content_f40_54_41835=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F51555&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F51555&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Common periarticular knee problems in adults",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Anterior pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Injury or dysfunction of soft tissue knee extensor structures (quadriceps muscles, patellar and quadriceps tendons, retinaculum)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patellofemoral pain syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prepatellar or infrapatellar bursitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patella dislocation or fracture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Medial pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Medial collateral ligament injury",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anserine bursitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Medial meniscal injury (technically intraarticular but can present with focal medial pain and joint line tenderness)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Medial plica syndrome or capsular injury (less common)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Lateral pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lateral collateral ligament injury",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Iliotibial band syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lateral meniscal injury (technically intraarticular but can present with focal lateral pain and joint line tenderness)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lateral plica syndrome or capsular injury (less common)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Popliteal tendinopathy (less common)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Posterior pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Popliteal (Baker's) cyst",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Deep vein thrombosis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_54_41835=[""].join("\n");
var outline_f40_54_41835=null;
var title_f40_54_41836="Patient history vulvar lesions";
var content_f40_54_41836=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F59050&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F59050&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Detailed history in patients with vulvar lesions",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Chief complaint",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            <p>",
"             Onset",
"            </p>",
"            <p>",
"             Duration",
"            </p>",
"            <p>",
"             Timing",
"            </p>",
"            <p>",
"             Pattern",
"            </p>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            <p>",
"             What makes it better",
"            </p>",
"            <p>",
"             What makes it worse",
"            </p>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            <p>",
"             Treatment, nonprescription",
"            </p>",
"            <p>",
"             Treatment, prescription",
"            </p>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            <p>",
"             Impact on quality of life",
"            </p>",
"            <p>",
"             Impact on sexual activity",
"            </p>",
"            <p>",
"             Limitations of activities of daily living",
"            </p>",
"            <p>",
"             Psychological distress",
"            </p>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Extra-genital rash",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Previous diagnoses",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            <p>",
"             Hygiene",
"            </p>",
"            <p>",
"             Urinary habits",
"            </p>",
"            <p>",
"             Ano-rectal habits",
"            </p>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            <p>",
"             Exposures",
"            </p>",
"            <p>",
"             Travel",
"            </p>",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Associated symptoms",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            <p>",
"             Itch",
"            </p>",
"            <p>",
"             Pain",
"            </p>",
"            <p>",
"             Burning",
"            </p>",
"            <p>",
"             Sting",
"            </p>",
"            <p>",
"             Feeling of rawness",
"            </p>",
"            <p>",
"             Dampness",
"            </p>",
"            <p>",
"             Bleeding",
"            </p>",
"            <p>",
"             Vaginal discharge",
"            </p>",
"            <p>",
"             Dyspareunia",
"            </p>",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Other",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            <p>",
"             Allergies",
"            </p>",
"            <p>",
"             Medications",
"            </p>",
"            <p>",
"             Past medical history",
"            </p>",
"            <p>",
"             Past surgical history",
"            </p>",
"            <p>",
"             Family history",
"            </p>",
"            <p>",
"             Social history",
"            </p>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            <p>",
"             Hormonal status",
"            </p>",
"            <p>",
"             Menstrual history",
"            </p>",
"            <p>",
"             Pregnancy",
"            </p>",
"            <p>",
"             Sexual history",
"            </p>",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_54_41836=[""].join("\n");
var outline_f40_54_41836=null;
var title_f40_54_41837="Labor curve";
var content_f40_54_41837=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F53413&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F53413&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 521px\">",
"   <div class=\"ttl\">",
"    Progress of labor curve",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 501px; height: 401px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     First stage = A + B + C + D where A=latent phase; B=acceleration phase; C=phase of maximum slope; D=deceleration phase",
"     <br>",
"      Second stage = E",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Friedman. Labor: Clinical evaluation and managment, 2nd ed, Appleton, New York 1978.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_54_41837=[""].join("\n");
var outline_f40_54_41837=null;
var title_f40_54_41838="Calculation of frontal plane axis";
var content_f40_54_41838=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F85682&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F85682&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 566px\">",
"   <div class=\"ttl\">",
"    Calculation of frontal plane axis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 546px; height: 472px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    If the QRS complex is positive in leads I and II, it falls between -30 and 90&deg; and is normal, as indicated by the yellow area. If the QRS complex is negative in I and positive in aVF, there is right axis deviation. If the QRS complex is positive in I and negative in II, there is left axis deviation. If the QRS complex is negative in I and aVF, there is extreme axis deviation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_54_41838=[""].join("\n");
var outline_f40_54_41838=null;
var title_f40_54_41839="Interstitial brachytherapy";
var content_f40_54_41839=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F68329&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F68329&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    Interstitial brachytherapy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 471px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    For interstitial brachytherapy several small hollow catheters are placed into the breast surrounding the partial mastectomy site. The number of catheters used is dependent on the size and shape of the target. Radioactive seeds are inserted into the catheters for a short time period of time each day and then removed. The catheters are removed after five days, when treatment is completed.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_54_41839=[""].join("\n");
var outline_f40_54_41839=null;
